PROGRAM GUIDE

Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available
NO MORE NEEDLESS INJECTIONS

(Actual size, 100 µl)

One and done

ALZET® Osmotic Pumps are small infusion pumps inserted at the beginning of your study and then, that's it. There's no dosing schedule. No repeated injections. Just a continuous, predictable release of your test agent for the entire study. Days. Nights. Even weekends. Anywhere from one day to six weeks. With no external connections to monitor and less need for handling, it's less stress for you and your lab animals. Learn more about ALZET Osmotic Pumps and just how needless injections can be at alzet.com/NoMoreNeedles.

VISIT US AT EXHIBIT #2411
# TABLE OF CONTENTS

1  **WELCOME LETTER**

2-23  **COMMITTEES**

2  Annual Meeting Program Committee
2  Scientific Program Subcommittee Members
6  Clinical Trials, Education, and Satellite Educational Symposia Committees
7  AACR Officers, Directors, and Foundation
8  Standing Committees
11  Specialty Award Committee
11  Scientific Achievement Awards Committees
15  Scientific Grant Review Committees
19  Scientific Task Forces
20  Scientific Working Group Steering Committees
22  Constituency Groups
23  AACR 50-Year Members and Honorary Members

24-28  **SUPPORTERS**

24  Annual Meeting 2019 Supporters
25  The Scientific Program
25  AACR Awards and Lectureships
26  AACR Runners for Research 5K Run/Walk
26  AACR Travel Grants and Scholar Awards
26  Key Meeting Elements
27  Research Grants and Fellowships
28  Special Conference Supporters for 2018-2019
28  Sustaining Members

29-45  **GENERAL INFORMATION**

46-57  **MAPS**

46  Georgia World Congress Center • Exhibit Hall Floor Plan
    Bldg. B • Level 1
48  Georgia World Congress Center • Bldg. B • Level 2
50  Georgia World Congress Center • Bldg. B • Level 3
52  Georgia World Congress Center • Bldg. B • Level 4
53  Georgia World Congress Center • Bldg. A • Level 1
54  Georgia World Congress Center • Bldg. A • Level 3
56  Georgia World Congress Center • Bldg. A • Level 4
Visit the Merck Booth and Learn More About KEYTRUDA

• Approved indications
• Resources for health care professionals
• The Merck Access Program
• KEY+YOU Patient Support Program
<table>
<thead>
<tr>
<th>Page</th>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>58-63</td>
<td>FRIDAY, MARCH 29</td>
<td>AACR-MICR Distinguished Lectureship Series</td>
</tr>
<tr>
<td></td>
<td>61</td>
<td>AACR-WICR Charlotte Friend Memorial Lectureship</td>
</tr>
<tr>
<td>64-83</td>
<td>SATURDAY, MARCH 30</td>
<td>AACR-MICR Jane Cooke Wright Memorial Lectureship</td>
</tr>
<tr>
<td>84-115</td>
<td>SUNDAY, MARCH 31</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td></td>
<td>86</td>
<td>Opening Plenary Session</td>
</tr>
<tr>
<td></td>
<td>87</td>
<td>Pezcoller Foundation-AACR International Award for Extraordinary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Achievement in Cancer Research</td>
</tr>
<tr>
<td></td>
<td>111</td>
<td>AACR-Irving Weinstein Foundation Distinguished Lecture</td>
</tr>
<tr>
<td></td>
<td>112</td>
<td>AACR-MICR Jane Cooke Wright Memorial Lectureship</td>
</tr>
<tr>
<td>116-153</td>
<td>MONDAY, APRIL 1</td>
<td>AACR Margaret Foti Award for Leadership and Extraordinary</td>
</tr>
<tr>
<td></td>
<td>116</td>
<td>Achievements in Cancer Research</td>
</tr>
<tr>
<td></td>
<td>116</td>
<td>Distinguished Public Service Award Lecture</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>Plenary Session</td>
</tr>
<tr>
<td></td>
<td>147</td>
<td>AACR-Waun Ki Hong Award for Outstanding Achievement in Translational</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and Clinical Cancer Research</td>
</tr>
<tr>
<td></td>
<td>148</td>
<td>AACR G.H.A. Clowes Memorial Award</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>AACR Princess Takamatsu Memorial Lectureship</td>
</tr>
<tr>
<td>154-187</td>
<td>TUESDAY, APRIL 2</td>
<td>Distinguished Public Service Award Lecture</td>
</tr>
<tr>
<td></td>
<td>154</td>
<td>Plenary Session</td>
</tr>
<tr>
<td></td>
<td>166</td>
<td>Gertrude B. Elion Cancer Research Award Lecture</td>
</tr>
<tr>
<td></td>
<td>173</td>
<td>AACR Award for Outstanding Achievement in Chemistry in Cancer</td>
</tr>
<tr>
<td></td>
<td>183</td>
<td>AACR-CRI Lloyd J. Old Award in Cancer Immunology</td>
</tr>
<tr>
<td></td>
<td>184</td>
<td>AACR-American Cancer Society Award for Research Excellence in Cancer</td>
</tr>
<tr>
<td></td>
<td>184</td>
<td>Epidemiology and Prevention</td>
</tr>
<tr>
<td></td>
<td>184</td>
<td>AACR-Joseph H. Burchenal Memorial Award for Outstanding</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Achievement in Clinical Cancer Research</td>
</tr>
<tr>
<td>188-197</td>
<td>WEDNESDAY, APRIL 3</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>198-215</td>
<td>TRAVEL AWARDS</td>
<td>Scholar-in-Training Awards</td>
</tr>
<tr>
<td></td>
<td>198</td>
<td>Global Scholar-in-Training Awards</td>
</tr>
<tr>
<td></td>
<td>209</td>
<td>AACR Minority and Minority-Serving Institution Faculty Scholars in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer Research Awards</td>
</tr>
<tr>
<td></td>
<td>210</td>
<td>AACR Minority Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td></td>
<td>213</td>
<td>AACR Women in Cancer Research Scholar Awards</td>
</tr>
<tr>
<td></td>
<td>214</td>
<td>AACR-Undergraduate Scholar Awards</td>
</tr>
</tbody>
</table>
One-stop Integrated Service to Accelerate Drug Development

Gene Editing

Animal Facility

Animal & Cell Models

Preclinical Services

CDMO/CMC (in progress)

Regulatory Affairs (IND)

\[ \text{RenMab Mice} \rightarrow \text{Antibody Discovery} \]

Single Humanized Immune Checkpoint Mice

- B-hPD-1
- B-hBTLA
- B-hCD28
- B-hCD40
- B-hCD47
- B-hCD47 (C)
- B-hCTLA4
- B-hGITR
- B-hOX40

Double Humanized Immune Checkpoint Mice

- B-hPD-1/h4-1BB
- B-hPD-1/hBTLA
- B-hPD-1/hCD27
- B-hPD-1/hCTLA4
- B-hPD-1/hLAG3
- B-hPD-1/hOX40
- B-hPD-1/hCD40
- B-hPD-1/hCD27
- B-hPD-1/hCTLA4
- B-hPD-1/hTIM3

Triple Humanized Immune Checkpoint Mice

- B-hCD274 (PD-L1)/hSIRPA/hCD47
- B-hPD-1/hSIRPA/hCD47

- B-hPD-1/hLAG3
- B-hPD-1/hOX40
- B-hPD-1/hCD27
- B-hCD40
- B-hOX40/h4-1BB

Visit our booth at 1613
10 posters will be presented at the exhibit hall
Raffle at 1613 to win Amazon gift cards

www.biocytogen.com | info@biocytogen.com
XOSPATA Now Approved

To learn more, see abstract #7506 and visit booth #4916

XospataHCP.com
Bio X Cell is the leading manufacturer of ultra-pure monoclonal antibodies for *in vivo* pre-clinical research. Discover More at AACR booth 1842
Striving to outsmart cancer. Together.


Cytek Bio’s Aurora and Northern Lights flow cytometry solutions are where your vision begins. Our unique combination of patent-pending, innovative technologies that offer next-level performance and flexibility take what was once hidden and place it in full view.

It's all in how you see it.

The new reality is at work in labs around the world. See it for yourself at the AACR Annual Meeting booth #1949!

We can’t wait to see where your vision takes you.
Give More Patients the OPDIVO® Opportunity.

OPDIVO® (nivolumab) INJECTION FOR INTRAVENOUS USE 10 mg/mL

While attending this meeting, please visit us at Booth 2229
Cancer is complex.
That’s why your patients deserve a dedicated team, personalized treatment plan, and access to clinical trials.

Partner with Winship at Emory.
Georgia’s only National Cancer Institute-Designated Comprehensive Cancer Center, providing the state’s highest level of care. Our researchers and oncologists provide breakthrough treatments years before others can, helping more patients thrive than any other cancer institute in Georgia.

For cancer patients, the right partner can make all the difference.

See us at the AACR Conference, booth 4160, or visit emoryhealthcare.org/referwinship.
Innovating antibodies, improving lives, 20 years and counting

Genmab, creator of DARZALEX® (daratumumab) and ARZERRA® (ofatumumab)

To learn more about our next-generation antibody technologies and ongoing clinical trials, visit Booth 2125.

© Genmab A/S 1/2019
Q² Solutions has a global network of laboratories with specialized services in immuno-oncology, biomarker discovery and development, bioinformatics, and companion diagnostics (CDx).

Testing services for:

**Anatomic Pathology**
- IHC (single & multiplex)
- Tumor Infiltrating Lymphocytes (TILs)
- Digital Pathology
- FISH

**Flow Cytometry and Immunoassays**
- Immuno-Phenotyping
- Receptor Occupancy
- TILs
- Intracellular Cytokine Survey
- Minimal Residual Disease (MRD)
- Circulating Soluble Proteins

**Genomics**
- Tumor Mutational Burden (TMB)
- TCR Immune Sequencing
- Immune Gene Signature / Epigenetic Signatures
- MMR Deficiency & MSI
- Whole Exome Sequencing
- Whole Genome Sequencing
- Microbiome

To learn more, visit www.Q2LabSolutions.com
THE PATH TO DRUG DISCOVERY

IDENTIFY YOUR TARGET
Utilize our publicly available tumor database — which includes genomic data, tumor frequency, SOC response, and much more!
Validate your tumor of interest against your target profile using FFPE slides — available for over 400 PDX models.

VALIDATE YOUR TARGET WITH PILOT STUDIES
Characterize the expression of human immune cell protein, tumor proteins, or antigens in your custom in vivo mouse-tumor model system.
Assess aspects of drug absorption, distribution, metabolism, and excretion over time. Our PK study options include therapeutic antibody half-life evaluation using our FcRN platform.

CHOOSE YOUR IN VIVO PLATFORM
Choose from over 11,000 mouse models, including aged, immunodeficient, and humanized.
Can’t find the model you need? JAX Model Generation Services can design your model using the most advantageous background.

PRECLINICAL EFFICACY TESTING
Our study directors determine key facets for a successful study design to evaluate individual human immune variability as it relates to therapeutic response, as well as execute your study to obtain translationally-relevant biomarkers and readouts.

CALL FOR YOUR CONSULTATION
Speak with a Ph.D.-level Technical Information Scientist
micetech@jax.org
1.800.422.6423 (US, Canada, & Puerto Rico)
1.207.288.5845 (from any location)
jax.org
Check us out in booth #3330

Learn more about the Science family of journals (Science, Science Advances, Science Immunology, Science Robotics, Science Signaling, & Science Translational Medicine), AAAS Membership, Science Careers, Science Webinars, & our numerous programs & custom projects.

» Submit your research: sciencemag.org/journals

» Search for a job: sciencecareers.org

» Become a member: aaas.org/join

» Get webinar alerts: scim.ag/2RibX2N

Stop by booth #3330 to sign up for email alerts for free Science webinars
Discoveries in immuno-oncology (IO) have expanded the horizon of cancer therapy. But there is still much to uncover in how tumors evade the immune system and how we can harness the human body’s cancer-fighting capabilities. Through an alliance between Merck KGaA, Darmstadt, Germany and Pfizer, our combined talent and resources are pioneering the exploration of this innovative approach. Standing together with the physicians and patients who have participated in our clinical studies and trials, we continue to move closer to revealing the full potential of IO therapies in our pursuit for a brighter future.

Join us in our commitment to every patient, doctor, and researcher who inspire us to push forward in our fight against cancer.
JOIN THE AMERICAN ASSOCIATION FOR CANCER RESEARCH IN THE GLOBAL CONQUEST OF CANCER

THE ESSENTIAL ASSOCIATION FOR YOU. JOIN TODAY!

KEY BENEFITS OF AACR MEMBERSHIP
- Substantially Reduced Registration Rates for AACR Annual Meetings and Special Conferences throughout the year
- Privilege of Sponsoring an Abstract for AACR Annual Meetings
- Early Access to Housing Reservations for AACR Annual Meetings
- Exclusive Discounts on Subscriptions to our eight-renowned peer-reviewed scientific journals
- Free Online Access to AACR’s Cancer Today Magazine, the authoritative resource for cancer patients, survivors, and their family members and friends
- Collaboration and Resources through our Survivor and Patient Advocacy initiatives
- Funding and Award Opportunities, including career development resources, research fellowships, scholar-in-training, and travel grants
- Professional Development for early-career investigators and professionals including educational workshops, special symposia and professional advancement sessions (no charge to member)
- Opportunities to network and join any of our Association and Scientific Working groups
- Representation in Congress to ensure the continued support of cancer and biomedical research funding
- AACR Alerts and Newsletters to stay up to date on AACR’s programs and activities
- Membership Directory that provides online access to over 40,000 members internationally
- New Opportunities to interact with colleagues globally through an expanding portfolio of international programs

ABOUT THE AACR

The AACR was founded over 110 years ago with the goal of preventing and curing cancer. AACR’s programs and services foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

With over 40,000 members in 120 countries and territories around the world, we firmly believe each member plays an integral role in achieving that mission.

JOIN OUR MISSION.

Already a member?
Be sure to visit myAACR to pay your member dues, register for future AACR conferences, or update your Membership Profile.

For additional details, contact AACR Membership:
Telephone: 215-440-9300 | Fax: 267-765-1078
Email: membership@aacr.org

AACR.org/Membership

1802071A
UPGRADE YOUR HUMAN CELL CULTURE

WE OFFER COMPLETE SOLUTIONS FOR CULTURING AND ASSAYING PRIMARY HUMAN CELLS, CANCER CELLS, AND STEM & BLOOD CELLS.

- PERSONALIZED SUPPORT BY PHD SCIENTISTS
- NEW CANCER CELL CULTURE PORTFOLIO FOR 2D AND 3D CULTURE OF CELL LINES AS WELL AS PRIMARY TUMOR ISOLATION
- COMPLETE PORTFOLIO OF HUMAN CELL TYPES, CELL CULTURE MEDIA AND CELL-BASED ASSAYS
- PRODUCT CUSTOMIZATION BASED ON YOUR NEEDS

TEST YOUR CELL CULTURE KNOWLEDGE AT OUR BOOTH AND WIN A FREE GIANT MICROBE™

MEET US
AACR BOOTH #1624

FOR IN VITRO RESEARCH ONLY AND NOT FOR DIAGNOSTIC OR THERAPEUTIC PROCEDURES
Follow the AACR Journals on Twitter to keep abreast of the latest breaking research.

@CD_AACR
@CEBP_AACR
@CIR_AACR
@CAPR_AACR
@CR_AACR
@CCR_AACR
@MCR_AACR
@MCT_AACR

For more information and to learn more about AACR Publications, visit AACRJournals.org

American Association for Cancer Research
Finding Cures Together
JOIN US IN SAN DIEGO!

AACR ANNUAL MEETING 2020

THE SAN DIEGO CONVENTION CENTER

APRIL 25-29

SAVE THE DATE!

For more information as it becomes available, visit

AACR.org

American Association for Cancer Research

FINDING CURES TOGETHER®
2019 SCIENTIFIC CONFERENCES
Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment

AACR Annual Meeting 2019
Program Committee Chair: John D. Carpten
March 29-April 3, 2019 | Atlanta, GA

AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research
Conference Cochairs: Christine H. Chung, Robert L. Ferris, David Raben, and James W. Rocco
April 29-30, 2019 | Austin, TX

AACR International Conference New Horizons in Cancer Research
Program Committee Cochairs: Elizabeth M. Jaffee and Hong Wu
May 3-5, 2019 | Shenzhen, China

The Hippo Pathway: Signaling, Cancer, and Beyond
Conference Cochairs: Fernando Camargo, Anwesha Dey, and Kun-Liang Guan
May 8-11, 2019 | San Diego, CA

Bladder Cancer: Transforming the Field
Conference Cochairs: Charles G. Drake, Jason A. Efstathiou, Donna E. Hansel, Dan Theodorescu, and Ellen C. Zwarthoff
May 18-21, 2019 | Denver, CO

International Conference on Malignant Lymphoma (ICML)
June 18-22, 2019 | Lugano, Switzerland

Environmental Carcinogenesis: Potential Pathway to Cancer Prevention
Conference Cochairs: Margaret L. Kripke, Ernest T. Hawk, and Timothy R. Rebbeck
June 22-24, 2019 | Charlotte, NC

Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy
Conference Cochairs: Crystal L. Mackall and Patrick Hwu
July 19-22, 2019 | San Francisco, CA

Pancreatic Cancer: Advances in Science and Clinical Care
Conference Cochairs: Dafna Bar-Sagi, Luis A. Diaz, Elizabeth M. Jaffee, Ben Z. Stanger, and Brian M. Wolpin
September 6-9, 2019 | Boston, MA

Advances in Ovarian Cancer Research
Conference Cochairs: Carol Aghajanian, David D. L. Bowtell, George Coukos, Alan D. D’Andrea, and Karen H. Lu
September 13-16, 2019 | Atlanta, GA

Advances in Pediatric Cancer Research
Conference Cochairs: Crystal Mackall, David Malkin, Stefan Pfister, and Kimberly Stegmaier
September 17-20, 2019 | Montreal, Quebec, Canada

12th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Conference Chair: Laura Fejerman
September 20-23, 2019 | San Francisco, CA

Learn more and register at AACR.org/Calendar
Dear Members, Colleagues, and Friends of the AACR,

We are delighted to welcome you to Atlanta, Georgia, for the 110th Annual Meeting of the American Association for Cancer Research (AACR). For this special anniversary year, we have a spectacular program planned. We are excited to have such a diverse and global audience of laboratory researchers, physician-scientists, population scientists, and other health care professionals, cancer survivors, patients, and advocates, to benefit from the stimulating presentations and discussions that will take place over the next few days.

Through the hard work and expert guidance from members of our Annual Meeting Program Committee, Education Committee, and Clinical Trials Committee, we have developed a multidisciplinary program that embodies the theme of this year’s meeting—“Integrative Cancer Science • Global Impact • Individualized Patient Care.”

Basic science provides the foundation for progress in the field, and half of the meeting is devoted to strong basic science discoveries. We will also cover the full breadth and depth of cancer science and medicine—including translational, clinical, and prevention research. This year, two special sessions on “Making Science Count for Patients” will emphasize the critical role of discovery science in solving the cancer problem by informing translational research that leads to clinical application. We will also celebrate special anniversaries of the discoveries of the Li-Fraumeni syndrome and the p53 gene, which now serve as paradigm models of cancer predisposition and tumor suppression.

Improving the lives of cancer patients is at the heart of the AACR’s mission, and patients are a critical focus of the Annual Meeting program. Sessions throughout the program—including a plenary session—will focus on diverse populations and cancer health disparities, outlining the challenges that must be overcome to ensure that everyone, regardless of ethnic or socioeconomic background, benefits from breakthroughs in cancer treatment. The issues of survivorship and survivorship research will also be highlighted throughout the program in a new Survivorship Track.

Exciting progress has been made since last year’s meeting, and sessions will cover hot areas in immuno-oncology, drug discovery and development, and convergence science. Additionally, nearly 220 oncology clinical trials and trials in progress will be presented. During the Clinical Trials Plenary Sessions, trials are paired with a presentation focusing on the science behind the trial and its implications for delivering improved care to patients. Clinical trials will also be presented in other formats, including minisymposia and poster sessions.

We deeply appreciate the work done by members of the Scientific Program Committee who reviewed the nearly 6,000 proffered papers that were submitted to the Annual Meeting and organized them into poster sessions and minisymposia. We are also excited to have a record number of NextGen Stars presenting their work in major sessions and in two special spotlight sessions this year. Sixteen young investigators were selected for this honor through a highly competitive application process.

We want to extend our gratitude to the corporations, organizations, and foundations that have provided generous financial support for the AACR Annual Meeting 2019. These valued contributions allow us to host this critically important forum that lays the groundwork for fruitful collaborations and advances in cancer research. Their commitment also enables the professional advancement of the next generation of leaders in cancer research through their support of a variety of sessions, research grants, scholar-in-training awards, and scientific merit awards.

Thank you for joining us! We look forward to an exciting few days of great science, stimulating discussions, and inspiring new ideas. Please plan to attend the Wrap-Up Plenary Session on Wednesday, April 3, to hear some of the highlights from the week.

Sincerely,

John D. Carpten
Chair, 2019 Program Committee

Elizabeth M. Jaffee, MD
President, 2018-2019

Margaret Foti, PhD, MD (hc)
Chief Executive Officer, AACR

PROGRAM GUIDE
ANNUAL MEETING
PROGRAM COMMITTEE

Chair
John D. Carpten

Vice Chairs
Kenneth C. Anderson
Marcia R. Cruz-Correa
Todd R. Golub
Stephen D. Hursting
Patricia M. LoRusso
Richard M. Marais
Aviv Regev
Antoni Ribas
Brian M. Rivers
David A. Tuveson

Cochairs
Nilofer S. Azad
Anna D. Barker
Julian Blagg
John M. Carethers
Louis Chesler
David C. Christiani
Mario Colombo
Joseph N. Contessa
Lisa M. Coussens
David Craig
Christina Curtis
Riccardo Dalla-Favera
Caroline Dive
Laura Fejerman
Kevin L. Gardner
David R. Gius
Mithat Gönen
Jennifer Rubin Grandis
John D. Groopman
Susan E. Hankinson
Jamie Holloway
Catriona H.M. Jamieson
Peter Kuhn
Sherene Loi
Thomas J. Lynch, Jr.
Crystal L. Mackall
Tak W. Mak
Hiroyuki Mano
Gordon B. Mills
Lisa A. Newman
Kunle Odunsì
Moshe Oren

Klaus Pantel
William Pao
Luis F. Parada
Electra D. Paskett
Edith A. Perez
Eric H. Rubin
Anil K. Rustgi
Patty Spears
Victor E. Velculescu
Jennifer A. Wargo
Louis M. Weiner
E. John Wherry III

SCIENTIFIC PROGRAM
SUBCOMMITTEE MEMBERS

Molecular and Cellular Biology/Genetics

Cell Growth Signaling Pathways
Joseph N. Contessa, Chair
Amy H. Bouton
Jennifer Rubin Grandis
Amit C. Maity

Cell Death
Albert C. Koong, Chair
Jerry E. Chipuk
Samuel R. Denmeade

Oncogenes and Tumor Suppressor Genes
David R. Gius, Chair
Michelle C. Barton
Erik S. Knudsen
David S. Yu

Gene Regulation and Transcription Factors
Charles Lin, Chair
Andrea Califano
Nicole L. Simone

Epigenetics
Bodour Salhia, Chair
Scott Bultman
Manel Esteller
Steven A. Johnsen
Cell Cycle
Gustave W. Leone, Chair
J. Alan Diehl
Helen M. Piwnica-Worms

DNA Damage and Repair
Alan Ashworth, Chair
Christopher Lord
Pamela N. Munster

Metabolism and Cancer
George Poulogiannis, Chair
Ralph J. DeBerardinis
Douglas R. Spitz, Jr.

Genomics
Stephan M. Pfister, Chair
William P. Hendricks
Franklin Huang
Willy Hugo
Akinyemi Ojesina

microRNAs and Other Noncoding RNAs
Lin He, Chair
Doren Ginsberg
Ashish Lal
Blair B. Madison

Cellular Stress Responses
James M. Larner, Chair
Christine Chio
Andrei V. Gudkov
Fen Xia

Tumor Biology
Nonclinical Models of Cancer
Dean W. Felsher, Chair
Jos Jonkers
Michael M. Shen
Thea D. Tlsty

Stem Cell Biology
Brigitte N. Gomberts, Chair
Leslie Crews
Steven Pollard

Tumor Adhesion
Joan S. Brugge, Chair
Valerie M. Weaver

Invasion and Metastasis
Marisol S. Soengas, Chair
Claudia D. Andi
Arniban Maitra
Lloyd C. Trotman
Danny R. Welch
Lei Zheng

Angiogenesis
Michele De Palma, Chair
Adriana Albini
Luisa Iruela-Arispe

Tumor Microenvironment
Ashani T. Weeraratna, Chair
Robert A. Anders
Douglas T. Fearon
Troy A. McEachron
Miriam Merad

In Vivo Imaging
Julie K. Schwarz, Chair
Mukund Seshadri
Anna M. Wu

Pediatric Cancer—Basic Science
William A. Weiss, Chair
Oliver Delattre
Rani E. George

Radiation Science
Simon N. Powell, Chair
Joshua Walker
Gayle E. Woloschak

Bioinformatics and Systems Biology
Bioinformatics and Computational Biology
John Quackenbush, Chair
John Castle
Catherine S. Grasso
Enrique V. Villareal

Convergence Science and Systems Biology
Elana J. Fertig, Chair
Benjamin D. Greenbaum
Tumor Evolution and Heterogeneity
Christine A. Iacobuzio-Donahue, Chair
Jonathan J. Keats
Andrea Sottoriva

Carcinogenesis
Frank G. Ondrey, Chair
Chu-Xia Deng
Margaret L. Kripke

Cancer Chemistry
Drug Discovery, Design, and Delivery
Michael Brands, Chair
Rajesh Chopra
Michelle L. Lamb

Structural and Chemical Biology
Ashok R. Venkitaraman, Chair
Sara J. Buhrlage

Proteomics and Mass Spectrometry
Bernhard Küster, Chair
Brian B. Haab

Clinical Research
Translational Research: Molecular Biology in the Clinic
Javed Khan, Chair
Johann S. de Bono
Todd R. Golub
Filip Janku

Pediatric Cancer—Clinical Investigations
Julie R. Park, Chair
Stacey L. Berg

Clinical Research in the Elderly
Amina Jatoi, Chair

Clinical Research in Minorities and Medically Underserved Populations
Chani Hughes-Halbert, Chair
Melissa A. Troester
Robert A. Winn

Biostatistics in Clinical Trials
Meredith M. Regan, Chair

Immuno-oncology
Patrick Hwu, Chair
Gregory L. Beatty
Dung T. Le
Michal Lotem
Naiyer A. Rizvi

Radiation Oncology
Julia R. White, Chair

Surgical Oncology
Nita Ahuja, Chair
Lisa A. Newman

Clinical Endocrinology
Lauren Fishbein, Chair
Theresa A. Guise
Richard J. Pietras

Survivorship Research and Supportive Care
Kimlin Tam Ashing, Chair

Biomarkers
Kurt A. Schalper, Chair
Amir Goldkorn
Priti Hegde
Alison P. Klein

Outcomes Research
Dawn L. Hershman, Chair

Endocrinology
Molecular and Preclinical Endocrinology
Lauren Fishbein, Chair
Theresa A. Guise
Richard J. Pietras

Clinical Endocrinology
Lauren Fishbein, Chair
Theresa A. Guise
Richard J. Pietras
**Epidemiology**

Epidemiology
Christine B. Ambrosone, Chair
Melissa B. Davis
Lawrence S. Engel
Anirban Maitra
Lorelei A. Mucci
Mariana C. Stern

**Experimental and Molecular Therapeutics**

Drug Discovery
Peter S. Dragovich, Chair
Paul A. Clarke
Melissa M. Vasbinder

Mechanisms of Drug Action
Jennifer R. Diamond, Chair
James C. Barrow
Stephen Leong
Todd M. Pitts

Drug Resistance
Roger S. Lo, Chair
Shridar Ganesan
Anthony G. Letai

Molecular Targets
William C. Hahn, Chair
Ross L. Cagan
Dean G. Tang

Pharmacology, Pharmacogenetics, and Pharmacogenomics
Michelle A. Rudek, Chair
Houda Alachkar
Duncan I. Jodrell

Small Molecule Therapeutic Agents
S. Percy Ivy, Chair
James E. Audia
Jim Bischoff
Dirk Brockstedt
David S. Hong
Gary K. Schwartz

Biologic Therapeutic Agents
Daniel S. Chen, Chair
Julie R. Brahmer
Parkash S. Gill

Gene- and Vector-Based Therapy
Yvonne Y. Chen, Chair

Preclinical Radiotherapeutics
Jason S. Lewis, Chair

Immunology

Tumor Immunobiology
Charles G. Drake, Chair
Christina Puig Saus
Daniel E. Speiser

Immunotherapy: Preclinical and Clinical
Patrick Hwu, Chair
Gregory L. Beatty
Dung T. Le
Michal Lotem
Naiyer A. Rizvi

Prevention, Early Detection Research, and Interception

Preclinical Prevention, Early Detection, and Interception
Zvi Livneh, Chair
Sam M. Hanash
Kimberly A. Kelly

Clinical Prevention, Early Detection, and Interception
Victoria L. Seewaldt, Chair
Nickolas Papadopolous

Implementation Science
Maria E. Fernandez, Chair
Jamie S. Ostroff
CLINICAL TRIALS, EDUCATION, AND SATELLITE EDUCATIONAL SYMPOSIA COMMITTEES

Clinical Trials Committee

Cochairs
Nilofer S. Azad
Louis M. Weiner

Members
Peter C. Adamson
Philippe L. Bedard
Julie R. Brahmer
Fatima Cardoso
Ryan B. Corcoran
Susan M. Domchek
Alexander M.M. Eggermont
Keith T. Flaherty
Silvia C. Formenti
Irene M. Gobrial
Roy S. Herbst
Waun Ki Hong
David M. Hyman
Razelle Kurzrock
Marc Ladanyi
Worta McCaskill-Stevens
Rosemarie Mick
Steven Plantadosi
Raphael E. Pollock
Timothy A. Yap

Education Committee

Chair
Lisa M. Coussens

Cochairs
Christina Curtis
Riccardo Dalla-Favera
Lisa A. Newman
David A. Tuveson

Members
Melissa L. Bondy
Carol L. Brown
Andrea Califano
Heike E. Daldrup-Link
Chi Van Dang
Kimberly E. Davis
Melissa B. Davis
Michele De Palma
Jayanta Debnath
John E. Dick
Chyke A. Doubeni
Charles G. Drake
Mikala Egeblad
Isla P. Garraway
Scarlet Gomez
Gregory J. Hannon
Andrea A. Hayes-Jordan
Cimona Hinton
Roy A. Jensen
Yibin Kang
Celina G. Kleer
Christopher I. Li
Edison T. Liu
Mignon L. Loh
Patricia M. LoRusso
Erica E. Marsh
Cornelius J.M. Melief
Edith P. Mitchell
Motomi Mori
Mohammed Murtaza
Akinyemi Ojesina
Dana Pe’er
Raul Rabadan
Ann Richmond
Michel Sadelain
Margaret A. Shipp
Diane Simeone
David L. Spector
Sheila A. Stewart
Eleanor M. Walker
Jedd D. Wolchok
Jun Yang
Satellite Educational Symposia Committee

Chair
George D. Demetri

Members
Lisa M. Coussens
Patricia M. LoRusso

AACR OFFICERS, DIRECTORS, AND FOUNDATION

AACR Officers and Directors

President
Elizabeth M. Jaffee

President-Elect
Elaine R. Mardis

Treasurer
William N. Hait

Immediate Past President
Michael A. Caligiuri

Chief Executive Officer
Margaret Foti

Directors
Cory Abate-Shen
Adriana Albini
Alan Ashworth
Dafna Bar-Sagi
René Bernards
Karen M. Cichowski
Levi A. Garraway
Philip D. Greenberg
Carl H. June
Edison T. Liu
Gordon B. Mills
Martine J. Piccart
Antoni Ribas
Lillian L. Siu
David A. Tuveson

AACR Foundation

Officers
Raymond N. DuBois, Chair and President
William H. Mears, Jr., Vice Chair
Margaret Foti, Secretary-Treasurer and CEO
Bayard D. Clarkson, Founding Chair of the Board and President Emeritus

Trustees
Beverly W. Aisenbrey
Carlos L. Arteaga
Christian Bardon
James V. Buzzitta
Michael A. Caligiuri
Nancy E. Davidson
Faye Florence
Cathy Fraser
Judy E. Garber
Nance Guilmartin
William N. Hait
Richard A. Heyman
Wen-Jen Hwu
Tyler Jacks
Elizabeth M. Jaffee
V. Craig Jordan
Eleanor D. Kress
Sherry Lansing
John E. Leonard
Lindy Li
Elaine R. Mardis
Laurence J. Marton
Gladys H. Monroy
John E. Oxendine
Anil K. Rustgi
Stephen D. Ryan
Anil Sethi
Ellen V. Sigal
Ajit Singh
Nancy Staisey
Geoffrey M. Wahl
STANDING COMMITTEES

**Continuing Medical Education Committee**

**Chair**
A. William Blackstock, Jr.

**Members**
Antonio T. Fojo
Steven Grant
Mignon L. Loh
Patricia M. LoRusso
Mark E. Robson
Steven T. Rosen
Edward A. Sausville

*Additional appointments pending*

**Executive Committee**

Elizabeth M. Jaffee, President
Elaine R. Mardis, President-Elect
Michael A. Caligiuri, Immediate Past President
William N. Hait, Treasurer
Margaret Foti, CEO

**Exhibits Committee**

**Chair**
Edward Chu

**Members**
Craig J. Burd
Maximilian Diehn
Ajay Goel
Tari A. King
Amanda W. Lund
Gordon B. Mills
Meredith A. Morgan
Andrea L. Richardson
Janis M. Taube
Jeffrey A. Toretsky
Danny R. Welch
Douglas Yee

**Finance and Audit Committee**

**Chair**
Thomas J. Lynch, Jr.

**Members**
Walter J. Curran, Jr.
Susan M. Galbraith
Richard B. Gaynor
Mary J.C. Hendrix
Hervé J. Hoppenot
Candace S. Johnson
Michelle M. Le Beau
Bernard K. Levy
David B. McFadden
William H. Mears, Jr.
Beverly S. Mitchell
Edith A. Perez
David M. Reese
Steven T. Rosen
Stephen D. Ryan
John H. Stewart IV
Cheryl L. Willman
William N. Hait, *ex officio*
Elizabeth M. Jaffee, *ex officio*
Elaine R. Mardis, *ex officio*

**Nominating Committee**

**Chair**
Judy E. Garber

**Members**
Carlos L. Arteaga
Nina Bhardwaj
Suzanne Cory
Olivera J. Finn
Tak W. Mak
Karen H. Vousden
Owen N. Witte

**Publications Committee**

**Chair**
Victor E. Velculescu

**Members**
Dafna Bar-Sagi
Mary Helen Barcellos-Hoff
Michael E. Berens
John D. Carpten
Maura L. Gillison
Rakesh K. Jain
Pasi A. Jänne
Gerrit A. Meijer
Gordon B. Mills
Steffi Oesterreich
Gloria M. Petersen
David R. Piwnica-Worms
William Pao
Charles W.M. Roberts
Alice T. Shaw
Lillian L. Siu
Saraswati Sukumar
Toshikazu Ushijima
William N. Hait, ex officio

Science Education and Career Advancement Committee

Chair
Kathleen W. Scotto

Members
Lucile L. Adams-Campbell
Adriana Albini
Fabrice André
Dafna Bar-Sagi
Allison S. Betof-Warner
Oliver Bögler
John M. Carethers
Angelo M. DeMarzo
Caroline Dive
Sinisa Dovat
Steven M. Dubinett
Irene M. Ghabrial
Ernest T. Hawk
Susan Band Horwitz
Tari A. King
Ming Lei
Roger S. Lo
Beverly D. Lyn-Cook
Kim L. O’Neill
Timothy R. Rebbeck
Victoria M. Richon
Brian M. Rivers
Paul A. Scheet
Yu Shyr
Sanya A. Springfield
José G. Treviño II
Danny R. Welch
Jedd D. Wolchok

Science Policy and Government Affairs Committee

Chair
George D. Demetri

Members
Lucile L. Adams-Campbell
Frederick R. Appelbaum
Alan Ashworth
Steven D. Averbuch
Anna D. Barker
Lisa H. Butterfield
John D. Carpten
Kenneth H. Cowan
John F. DiPersio
H. Shelton Earp III
Peter D. Emanuel
B. Mark Evers
Judy E. Garber
Stanton L. Gerson
Joe W. Gray
Lee M. Greenberger
Roy S. Herbst
Chanita Hughes-Halbert
Roy A. Jensen
Thomas W. Kensler
Steven K. Libutti
Patricia M. LoRusso
Christine M. Lovly
Sean J. Mulvihill
Augusto C. Ochoa
Gilbert S. Omenn
Edith A. Perez
David R. Piwnica-Worms
Brian M. Rivers
Eric H. Rubin
Ellen V. Sigal
Robert W. Sobol
Eduardo M. Sotomayor
Roger Stupp
Dan Theodorescu
Laura J. van’t Veer
Victor E. Velculescu
Robert H. Vonderheide
**Health Policy Subcommittee**

**Chair**
Gilbert S. Omenn

**Members**
Karen H. Antman
William S. Dalton
Mark A. Israel
Richard E. Kouri
Thomas J. Lynch, Jr.
Peter J. Neumann
Steven R. Paterino
Scott D. Ramsey
Mark E. Robson
Deborah Schrag
Ellen V. Sigal
Sean R. Tunis

**Tobacco and Cancer Subcommittee**

**Chair**
Roy S. Herbst

**Members**
Denise R. Aberle
Thomas H. Brandon
Geoffrey T. Fong
Jennifer Rubin Grandis
Ellen R. Gritz
Dorothy K. Hatuskami
Ernest T. Hawk
Fadlo R. Khuri
Scott J. Leischow
Peter G. Shields
Benjamin Toll
Kasisomayajula Viswanath
Graham Warren
Stephanie R. Land, *ex officio*

**Regulatory Science and Policy Subcommittee**

**Chair**
Kenneth C. Anderson

**Members**
James Abbruzzese
William S. Dalton
Raymond N. DuBois
Susan M. Galbraith
Judy E. Garber
Levi A. Garraway
Richard B. Gaynor
Roy S. Herbst
Sandra J. Horning
Pasi A. Jänne
Chitkala Kalidas
Peter F. Lebowitz

**Special Conferences Committee**

**Chair**
William C. Hahn

**Members**
Cory Abate-Shen
Scott A. Armstrong
René Bernards
Andrea Califano
Lewis C. Cantley
Lisa M. Coussens
Luis A. Diaz
Robert J. Gillies
Joe W. Gray

**Standing Committees (cont’d)**
Joanna L. Groden
Chanita Hughes-Halbert
David M. Hyman
Trey Ideker
Catriona H.M. Jamieson
Peter A. Jones
Philip W. Kantoff
Michael B. Kastan
Quynh-Thu Le
Massimo Loda
Scott Manalis
Elaine R. Mardis
Ira Mellman
Lisa A. Newman
Timothy R. Rebbeck
Charles M. Rudin
David A. Sabatini
Louis M. Staudt
Kimberly Stegmaier
Charles Swanton
Alejandro Sweet-Cordero
Giorgio Trinchieri
Nicholas C. Turner
Miguel A. Villalona-Calero
Jane E. Visvader
Anna M. Wu
Michael B. Yoffe
Lin Zhang

Tellers Committee

Chair
Nancy E. Davidson

Members
Susan Band-Horwitz
V. Craig Jordan
Bruce A.J. Ponder

SPECIALTY AWARD COMMITTEE

AACR June L. Biedler Prize for Cancer Journalism Judging Panel

Chair
Clifton Leaf

Members
Lecia Bushak
Damon Dahlen
Carey Goldberg
Stefanie Joho
Esther Landhuis
Patricia M. LoRusso
Erin Schumaker
Maiken Scott
Mary Jackson Scroggins
David Wahlberg
Swagata Yadavar

SCIENTIFIC ACHIEVEMENT AWARDS COMMITTEES

AACR Award for Lifetime Achievement in Cancer Research Committee

Chair
Benjamin G. Neel

Members
Frederick W. Alt
J. Carl Barrett
René Bernards
Suzanne Cory
Nancy E. Davidson
Vishva M. Dixit
Elaine Fuchs
Michael Karin
Lawrence A. Loeb
George C. Prendergast
Carol L. Prives
AACR Award for Outstanding Achievement in Chemistry in Cancer Research Committee

Chair
Ruth Nussinov

Members
Natalie G. Ahn
Rima S. Al-Awar
Julian Blagg
Gabriela Chiosis
Craig M. Crews
Philip Jones
Sunil Sharma
Joanne Stubbe

AACR Cancer Epidemiology and Prevention Award Committee

Chair
Adriana Albini

Members
Paolo Boffetta
Pamela J. Goodwin
Susan E. Hankinson
Curtis C. Harris
Peter Kraft
Lawrence H. Kushi
Marian L. Neuhouser
Elizabeth A. Platz
Thomas A. Sellers
Melissa A. Simon
Kenneth Kenji Tanabe
Cornelia M. Ulrich

AACR Clinical Cancer Research Awards Committee

Chair
Michael A. Carducci

Members
Susan E. Bates
Marcia R. Cruz-Correa
Sandra Demaria
John F. DiPersio
Martin E. Gleave
Michael V. Knopp
Patrick J. Loehrer, Sr.
Giovanni Melillo
Stephen J. Schuster
Elizabeth M. Swisher
Heather A. Wakelee

AACR Distinguished Lectureship in Breast Cancer Research Committee

Chair
Vered Stearns

Members
Alexander D. Borowsky
Matthew P. Goetz
Jos Jonkers
Geoffrey J. Lindeman
Timothy R. Rebbeck
Laura J. van’t Veer
Valerie M. Weaver
Douglas Yee
Carlos L. Arteaga, ex officio

AACR Distinguished Lectureship on the Science of Cancer Health Disparities Committee

Chair
Smita Bhatia

Members
Gerardo Colón-Otero
Ethan Dmitrovsky
Elena Martinez
Augusto C. Ochoa
Gloria M. Petersen
Brian M. Rivers
Beti Thompson
Jeffrey N. Weitzel
Cheryl L. Willman
Robert A. Winn
**AACR Laboratory Research Award Committee**

**Chair**
Anna M. Wu

**Members**
Mariano Barbacid  
Dafna Bar-Sagi  
Mary Helen Barcellos-Hoff  
James R. Heath  
Marcelo G. Kazanietz  
Klaus Pantel  
John H.J. Petrini  
Thomas M. Roberts  
Kala Visvanathan  
Emile E. Voest

**AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Committee**

**Chair**
Michael A. Caligiuri

**Members**
Kenneth C. Anderson  
Anna D. Barker  
Patrick Hwu  
Peter A. Jones  
Michael B. Kastan  
Richard D. Kolodner  
Richard M. Marais  
Yusuke Nakamura  
Lisa A. Newman  
Edith A. Perez  
Elizabeth A. Platz

**AACR Outstanding Investigator Award for Breast Cancer Research Committee**

**Chair**
Lajos Pusztai

**Members**
Fabrice André  
Cathrin Briskén  
Myles A. Brown  
Powel H. Brown  
Angela M. DeMichele  
Susan M. Domchek  
Leisha A. Emens  
Charlotte Kuperwasser  
Cynthia X. Ma  
Ruth M. O’Regan  
Martine J. Piccart  
Jean J. Zhao  
Carlos L. Arteaga, ex officio

**AACR Team Science Award Committee**

**Chair**
Luis A. Diaz

**Members**
Christopher H. Contag  
Steven M. Dubinett  
Matthew J. Ellis  
Douglas T. Fearon  
Karen A. Gelmon  
Ramaswamy Govindan  
Joe W. Gray  
John V. Heymach  
Norbert Kraut  
Rong Li  
Sanford D. Markowitz  
Katherine L. Nathanson  
Nickolas Papadopoulos  
Ulrike Peters  
Kenneth J. Pienta  
Uri Tabori  
Manon van Engeland
AACR-Minorities in Cancer Research
Jane Cooke Wright Memorial Lectureship Committee

Chair
Brian M. Rivers

Members
Lucile L. Adams-Campbell
Smita Bhatia
Carol L. Brown
Nathan A. Ellis
Christopher S. Lathan
Gloria M. Petersen
Amelie G. Ramirez
Luz Maria Rodriguez
Javier F. Torres-Roca
Claire F. Verschraegen

AACR-Princess Takamatsu Memorial Lectureship Committee

Chair
Lewis C. Cantley

Members
Cory Abate-Shen
Shelley L. Berger
Thierry Boon
Karen Cichowski
Harold L. Moses
Michael N. Pollak
Toshikazu Ushijima
Susumu Nishimura, ex officio
Takao Sekiya, ex officio

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology Committee

Chair
Ellen Puré

Members
Carl H. June
Lewis L. Lanier
Melinda S. Merchant
Alexander Rudensky
Robert D. Schreiber

Manuel Alejandro Sepulveda
Julianne Smith
Jedd D. Wolchok

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Committee

Chair
Kornelia Polyak

Members
Mary C. Beckerle
Powel H. Brown
Albert de la Chapelle
Dwight Gary Gilliland
Sandra J. Horning
Pasi A. Jänne
Daniel D. Karp
Edison T. Liu
William G. Nelson
Lillian L. Siu
Eric J. Small
Sanya A. Springfield

AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship Committee

Chair
Caroline Dive

Members
Nita Ahuja
Rakesh K. Jain
Kenneth W. Kinzler
Elizabeth R. Lawlor
Brigette B. Ma
David Malkin
Sumithra J. Mandrekar
Julie R. Palmer
Jennifer A. Pietenpol
Peter K. Vogt
Cassian Yee
Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research Committee

Chair
Michael B. Kastan

Members
Mariano Barbacid
Nina Bhardwaj
Carlos M. Caldas
Elisabetta Dejana
Joe W. Gray
Lorenzo Moretta
David A. Tuveson
Jennifer A. Wargo

AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training (START) Grants Scientific Review Committee

Chair
Yves G. Pommier

Members
Dyeison Antonow
Jill Bargonetti
J. Carl Barrett
Timothy Eisen
Stephen E. Fawell
Abby M. Green
Susan P. Lees-Miller
Mark J. O’Connor
David Raben

SCIENTIFIC GRANT REVIEW COMMITTEES

AACR Basic Cancer Research Fellowships Scientific Review Committee

Chair
Timothy A. Chan

Members
David A. Boothman
Christin E. Burd
Navdeep S. Chandel
Selina Chen-Kiang
James V. DeGregori
Nicholas C. Denko
Connie J. Eaves
Leisha A. Emens
Ajay Goel
Michael J. Gough
William B. Isaacs
Christopher Kemp
Chuan-Yuan Li
David Liebner
Steven B. McMahon
Maureen E. Murphy
Senthil K. Muthuswamy
Shyam Nyati
COMMITTEES

AACR-Bayer Research Grants Scientific Review Committee

Chair
Judith A. Varner

Members
Fernanda I. Arnaldez
Malcolm V. Brock
William G. Cancé
Emmanuelle Di Tomaso
Scott Z. Fields
Virginia G. Kaklamani
Balveen Kaur
Eleni Lagkadinou
Daniel Laheru
Linda J.Z. Penn
Vinay Puduvalli
Harry Raftopoulos
W. Kimryn Rathmell
Neelesh Sharma
Toshiyasu Taniguchi

The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Scientific Review Committee

Chair
Daniel D. Karp

Members
Cedric Blanpain
Andrew P. McMahon
Tannishtha Reya
Joan Seoane
Viviane Tabar
Fiona M. Watt

AACR Breast Cancer Research Grants Scientific Review Committee

Chair
Susan M. Domchek

Members
Foluso O. Ademuyiwa
Kimlin T. Ashing
Lisa L. Baumbach-Reardon
Fergus J. Couch
Laura Fejerman
William D. Foulkes
Ramesh K. Ganju
Kevin L. Gardner
Lori J. Goldstein
Brandy Heckman-Stoddard
Mien-Chie Hung
Karen T. Liby
Geoffrey J. Lindeman
Noralane M. Lindor
Sherene Loi
Ingrid A. Mayer
Ruth M. O’Regan
Vered Stearns
Saraswati Sukumar
Melinda L. Telli
Amanda E. Toland
Stephen T. Wong
Xiaoting Zhang
Qun Zhou

AACR Cancer Health Disparities Research Grants Scientific Review Committee

Chair
Kala Visvanathan

Members
Daniel J. George
Michael G. Goggins
Norman H. Lee
Beverly D. Lyn-Cook
Lorna Haughton McNeill
Edith P. Mitchell
Joseph D. Rosenblatt
Ann G. Schwartz
Melissa A. Simon
Rachel M. Syme
Jun J. Yang
AACR Gastric Cancer Research Grants Scientific Review Committee

Chair
Duane T. Smoot

Members
Afsaneh Barzi
Jordan D. Berlin
Daniel V.T. Catenacci
Ryan B. Corcoran
Daniel G. Haller
Haejin In
Fabian McCartney Johnston
Steven K. Libutti
Bruce D. Minsky
Manish A. Shah
Patrick Tan
Lei Zheng

AACR Gertrude B. Elion Cancer Research Award Scientific Review Committee

Chair
Pierre P. Massion

Members
Alfonso Bellacosa
Michael A. Carducci
John Doench
Robert A. Gatenby
Alison P. Klein
David N. Louis
Kenneth J. Pienta
Ravi Salgia
Sheila K. Singh
Clayton C. Yates
Jinghui Zhang

AACR Hematologic Malignancies Research Grants Scientific Review Committee

Chair
Eduardo M. Sotomayor

Members
P. Leif Bergsagel
James R. Cerhan
Rajesh Chopra
Carol A. Huff
Anthony G. Letai
Michael P. Link
Ruben A. Mesa
Lindsay M. Morton
Bertrand Nadel
Robert Z. Orlowksi
Laura Pasqualucci
Miguel-Angel Perales
Feyruz V. Rassool

AACR Immuno-oncology Research Grants Scientific Review Committee

Chair
Julie R. Brahmer

Members
Yinon Ben-Neriah
Malcolm K. Brenner
Donald J. Buchsbaum
William E. Carson, III
José R. Conejo-Garcia
Juan R. Cubillos-Ruiz
Andrea Facciabene
Tim F. Greten
Zhiwei Hu
Darrell J. Irvine
James W. Lillard, Jr.
Aung Naing
Jeffrey C. Rathmell
Elizabeth A. Repasky
Michele W.L. Teng
Cornelia Liu Trimble
Fernando Vidal-Vanaclocha
Weiping Zou
### AACR-Johnson & Johnson Lung Cancer Innovation Science Grants Scientific Review Committee

**Chair**
Charles M. Rudin  

**Members**
Alex A. Adjei  
Trever Bivona  
Kristin M. Dittmar  
Daniel M. Gomez  
Curtis C. Harris  
Stephen S. Hecht  
J. Jack Lee  
Vassiliki Papadimitrakopoulou  
Suresh S. Ramalingam  
LeCia V. Sequist  
Eva Szabo  
Miguel A. Villalona-Calero  
Robert A. Winn

### AACR Lung Cancer Research Grants Scientific Review Committee

**Chair**
Vassiliki Papadimitrakopoulou  

**Members**
Ruggero De Maria  
Anna Farago  
Apar K. Ganti  
Bonnie S. Glisson  
Ramaswamy Govindan  
Hatim Husain  
Karen L. Kelly  
Christine M. Lovly  
Patrick C. Ma  
Erminia Massarelli  
Patrick Nana-Sinkam  
Sai-Hong Ignatius Ou  
Roman Perez-Soler  
Katerina A. Politi  
Karen L. Reckamp  
Julien Sage  
LeCia V. Sequist  
David Sidransky  
Victoria M. Villaflor  
Seiji Yano

### AACR-MPM Transformative Cancer Research Grants Scientific Advisory Board

**Chair**
H. Robert Horvitz  

**Members**
Joan S. Brugge  
John D. Carpten  
William C. Hahn  
Helen E. Heslop  
David P. Ryan  
Robert H. Vonderheide

### AACR NextGen Grants for Transformative Cancer Research Scientific Review Committee

**Chair**
John M. Carethers  

**Members**
Fernanda I. Arnaldez  
Bruce A. Chabner  
Dmitry I. Gabrilovich  
David R. Gius  
Leslie I. Gold  
Gloria S. Huang  
Tomoo Iwakuma  
Kevin Sean Kimbro  
Peter Kuhn  
Zhenkun Lou  
Peter J. O'Dwyer  
Jeff Patrick  
Stefan M. Pfister  
Leonidas C. Platanias  
Sylvia K. Plevritis  
Raphael E. Pollock  
Patricia M. Price  
Barrett J. Rollins  
M. Celeste Simon  
Nicole L. Simone  
Pramod K. Srivastava  
Mehmet Toner  
Phuoc T. Tran  
Ashani Weeraratna  
Zeng-Jie Yang  
Leonard I. Zon
AACR-Novocure Tumor Treating Fields Research Grants Scientific Review Committee

Chair
Sanjiv Sam Gambhir

Members
Manish K. Aghi
Denise M. Damek
Anders Rosendal Korshøj
Rimas V. Lukas
Maciej M. Mrugala
Yazmin Odia
Erik P. Sulman
Ilan Volovitz
Eric T. Wong
Myonggeun Yoon

AACR Ovarian Cancer Research Grants Scientific Review Committee

Chair
Kathleen R. Cho

Members
Neil Johnson
Stuart M. Lichtman
Ursula A. Matulonis
Erinn Bruno Rankin
Stephen C. Rubin
Goli Samimi

AACR Pediatric Cancer Research Grants Scientific Review Committee

Chair
James F. Amatruda

Members
Maryam Fouladi
Abha Gupta
Pooja Hingorani
Michael D. Hogarty
Edward Anders Kolb
Corinne M. Linardic
Leo Mascarenhas
Ryan D. Roberts
Steve X. Skapek
Elizabeth A. Stewart
Lisa L. Wang
Brenda Weigel

SCIENTIFIC TASK FORCES

Hematologic Malignancies

Chair
Jonathan D. Licht

Members
Kenneth C. Anderson
Scott A. Armstrong
P. Leif Bergsagel
Michael A. Caligiuri
Rajesh Chopra
Riccardo Dalla-Favera
Faith E. Davies
John E. Dick
Yusri Elsayed
Maria E. Figueroa
Steven D. Gore
Ricky W. Johnstone
Carl H. June
Thomas J. Kipps
Toshio Kitamura
Michelle M. Le Beau
Ronald Levy
Mignon Loh
Kyle J. Macbeth
Ravindra Majeti
Ari M. Melnick
Ruben A. Mesa
Charles G. Mullighan
Bertrand Nadel
Dirk Nagorsen
Lilli Petruzzelli
Stephen J. Schuster
Eduardo M. Sotomayor
Louis M. Staudt
Kimberly Stegmaier
Jeffrey W. Tyner
COMMITTEES

Pathology

Chair
Massimo F. Loda

Members
Andrew H. Beck
Angelo M. De Marzo
Jayanta Debnath
Kojo Elenitoba-Johnson
Michelangelo Fiorentino
Christopher D.M. Fletcher
Chris A. French
Thomas J. Fuchs
Felice Giangaspero
Jiaoti Huang
A. John Iafrate
Michael M. Ittmann
Roy A. Jensen
Annette S. Kim
Michael Kluk
Janina A. Longtine
Robin G. Lorenz
Tamara Lotan
Anirban Maitra
Gerrit A. Meijer
Richard N. Mitchell
Anil Parwani
Francesco Pezzella
Eli Pikarsky
Jorge S. Reis-Filho
Andrea L. Richardson
Mark A. Rubin
Lawrence D. True
Ignacio I. Wistuba

SCIENTIFIC WORKING GROUP STEERING COMMITTEES

Cancer Immunology (CIMM)

Chair
Dmitry I. Gabrilovich

Chair-Elect
Weiping Zou

Past Chair
Jedd D. Wolchok

Members
Gregory L. Beatty
José R. Conejo-Garcia
Douglas T. Fearon
Tim F. Greten
Ronald Levy
Hiroyoshi Nishikawa
Kunle Odunsi
Laurence Zitvogel

Chemistry in Cancer Research (CICR)

Chair
Julian Blagg

Chair-Elect
Andrew J. Phillips

Past Chair
Melissa M. Vasbinder

Members
Julian Adams
Jim Bischoff
Michael Brands
Sara J. Buhrlage
Stephen V. Frye
Philip Jones
Vinod F. Patel
Ian P. Street
Molecular Epidemiology (MEG)

Chair
Ellen L. Goode

Chair-Elect
Shelley S. Tworoger

Past Chair
Melissa L. Bondy

Members
Jenny Chang-Claude
Jennifer A. Doherty
Peter Kraft
Julie R. Palmer

Pediatric Cancer (PCWG)

Chair
Crystal L. Mackall

Chair-Elect
Kimberly Stegmaier

Members
Smita Bhatia
Patricia Blanc
Hubert N. Caron
Adolfo Ferrando
Richard J. Gilbertson
Lia Gore
Nada Jabado
Katherine A. Janeway
Andrew L. King
David Malkin
Stefan M. Pfister
Gregory H. Reaman
Patrick J. Sullivan
Gilles Vassal

Tumor Microenvironment (TME)

Chair
Yibin Kang

Chair-Elect
Sheila A. Stewart

Past Chair
Valerie M. Weaver

Members
David A. Cheresh
Theresa A. Guise
Amanda W. Lund
Senthil K. Muthuswamy
Drew C. Radisky
Xiang (Shawn) Zhang
Dihua Yu (MRS Representative)
Michael R. Shurin (ICMS Representative)

Radiation Science and Medicine (RSM)

Chair
David R. Gius

Chair-Elect
Mary Helen Barcellos-Hoff

Members
Susan M. Bailey
CONSTITUENCY GROUPS

Associate Member Council (AMC)

Chair
Allison S. Betof Warner

Chair-Elect
Robert T. Jones

Past Chair
Kenneth Dutton-Regester

Members
Brian J. Abraham
Kristin G. Anderson
Renée de Leeuw
Andreana N. Holowatyj
Francis W. Hunter
Faruk Mohammed
Maeve Mullooly
Chirag B. Patel
Neil Vasan

Minorities in Cancer Research (MICR)

Chair
Brian M. Rivers

Chair-Elect
Laura Fejerman

Chair-Elect Designate
John M. Carethers

Members
Kimlin Tam Ashing
John D. Carpten
Luis G. Carvajal-Carmona
Gerardo Colón-Otero
Margaret Foti
Beverly D. Lyn-Cook
Mary Jackson Scroggins
Mariana C. Stern
Robert A. Winn
Clayton C. Yates
Sanya A. Springfield, ex officio

Women in Cancer Research (WICR)

Chair
Lucile L. Adams-Campbell

Chair-Elect
Marcia R. Cruz-Correa

Past Chair
Judith S. Sebolt-Leopold

Members
Cathrin Brisken
Sara A. Courtneidge
Margaret Foti
Bahija Jallal
Brigette B. Ma
Edith P. Mitchell
Morag Park
Kornelia Polyak
Shelia K. Singh
AACR 50-YEAR MEMBERS AND HONORARY MEMBERS

AACR 50-Year Members

It is the AACR’s privilege to honor those scientists who have reached the milestone of 50 years of AACR membership. The AACR Board of Directors would like to extend their sincere thanks and appreciation to these members for their dedication to cancer research and continued participation in and support of the AACR’s activities and programs. Special recognition of these distinguished members will be given during the Annual Business Meeting of Members, to be held on Monday, April 1, in Room B408.

Abdul Al Saadi
Ettore Appella
Leonard D. Berman
Tapas K. Das Gupta
Dincer Firat
Salman Gailani
Robert C. Gallo
David M. Goldenberg
Stanley Goldfarb
Melvin Greenblatt
Shuichi Karasaki
William B. Kremer
Harvey J. Lerner
Paul H. Levine
Lawrence A. Loeb
Jorge E. Maldonado
John C. Marsh
Sami A. Mayyasi
Takao Ohnuma
Ryoichi Oyasu
Carlos A. Perez
Walter J. Pories
Kedar N. Prasad
Chitta R. Raha
Johng Sik Rhim
Gabriel Seman
Richard A. Steeves
Leo L. Stolbach
David C. Stolinsky
Takashi Sugimura
Alton I. Sutnick

AACR Honorary Members

The AACR is extremely pleased to recognize AACR’s Honorary Members. The Board of Directors wish to convey their heartfelt thanks to the following individuals who have made extraordinary contributions to the advancement of cancer research, either through outstanding personal scientific activity or exceptional leadership in cancer research.

Joseph R. Biden, Jr.
HRH Princess Chulabhorn
Bernard Fisher
Joseph F. Fraumeni, Jr.
Susan Band Horwitz
Hon. Connie Mack
Hon. John Edward Porter
Takashi Sugimura
James D. Watson
Harald zur Hausen
ANNUAL MEETING 2019 SUPPORTERS

AACR gratefully acknowledges the generous support of individuals and organizations whose funding has made Annual Meeting 2019 possible.

Special Thanks to Distinguished Supporters of AACR Annual Meeting 2019

Cure Level

AstraZeneca

Bristol-Myers Squibb

Progress Level

Genentech, A Member of the Roche Group

Lilly Oncology

Merck & Co., Inc.

Novartis

Promise Level

AbbVie, Inc.

American Brain Tumor Association

Breast Cancer Research Foundation

Cancer Research Institute

Celgene Corporation

Get Your Rear in Gear

Gilead Sciences, Inc.

Incyte Corporation

Irving Weinstein Foundation

Novocure

Pezcoller Foundation

Pfizer Oncology

Pharmacyclics, LLC

Prostate Cancer Foundation

Seattle Genetics

Società Italiana di Cancerologia
THE SCIENTIFIC PROGRAM

Major Symposia
AstraZeneca
Dharma Master Jiantai Symposium in Targeted Therapy
Dharma Master Jiantai Symposium in Biomarkers

Opening Plenary: Achieving Equitable Patient Care through Precision and Convergent Cancer Science
AstraZeneca

Recent Advances in Organ Site Research
AstraZeneca
Dharma Master Jiantai Symposium in Recent Advances in Lung Cancer Research

Regulatory Science and Policy Track
AstraZeneca
Bristol-Myers Squibb
Genentech, A Member of the Roche Group

AACR AWARDS AND LECTURESHIPS

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
American Cancer Society

AACR Award for Lifetime Achievement in Cancer Research
American Association for Cancer Research

AACR Award for Outstanding Achievement in Chemistry in Cancer Research
American Association for Cancer Research

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Cancer Research Institute

AACR Distinguished Lectureship in Breast Cancer Research
Aflac, Inc.

AACR Distinguished Lectureship on the Science of Cancer Health Disparities
Susan G. Komen

AACR-G.H.A. Clowes Memorial Award
Lilly Oncology

AACR-Irving Weinstein Foundation Distinguished Lectureship
The Irving Weinstein Foundation

AACR Joseph H. Burchenal Clinical Cancer Research Award
Bristol-Myers Squibb

AACR June L. Biedler Prize for Cancer Journalism
Dr. June L. Biedler Estate

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
American Association for Cancer Research

AACR-Minorities in Cancer Research Jane Cooke Wright Memorial Lectureship
American Association for Cancer Research

AACR Princess Takamatsu Memorial Lectureship
Princess Takamatsu Cancer Research Fund

AACR Team Science Award
Lilly Oncology

AACR Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
Waun Ki Hong Endowment Fund
SUPPORTERS

AACR-Women in Cancer Research
Charlotte Friend Memorial Lectureship
American Association for Cancer Research

Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
Pezcoller Foundation

AACR RUNNERS FOR RESEARCH 5K RUN/WALK
Visionary Sponsor
Miltenyi Biotech

Elite Sponsor
Sidney Kimmel Cancer Center at Jefferson NCI-designated

Innovator Sponsors
Bristol-Myers Squibb
GlaxoSmithKline
Merck & Co., Inc.
Novick Group, Inc.

AACR TRAVEL GRANTS AND SCHOLAR AWARDS

AACR Margaret Foti Undergraduate Prizes in Cancer Research
The Margaret Foti Foundation
Kathleen Scotto
José G. Treviño

AACR Undergraduate Scholar Awards
The Margaret Foti Foundation

AACR Women in Cancer Research Scholar Awards
John and Nancy Cargile
Kelly Golat Memorial Fund for Cancer Research

AACR Travel Grants and Scholar-in-Training Awards
American Brain Tumor Association
The Estate of Dr. June L. Biedler
Breast Cancer Research Foundation
Breast Cancer Research Foundation in Memory of Arti Hurria, MD
Bristol-Myers Squibb Oncology
James V. Buzzitta, MD Family Fund
Dr. Charles Chalfant Club R-K
The Margaret Foti Foundation
Get Your Rear in Gear Philadelphia supported by the Colon Cancer Coalition
Gerald B. Grindey Memorial Fund
Molecular Epidemiology Working Group of the AACR
The Pezcoller Foundation
Prostate Cancer Foundation
Società Italiana di Cancerologia (the Italian Cancer Society)
The John W. Warner Fund
Donations in Honor of Cathy Whalen

AACR Scientific Working Groups

AACR Cancer Immunology Working Group
Bristol-Myers Squibb
Incyte Corporation
Merck & Co., Inc.

AACR Pediatric Cancer Working Group
Aflac, Inc.

KEY MEETING ELEMENTS

AACR-G.H.A. Clowes Memorial Reception
Lilly Oncology

Fellows of the AACR Academy Induction Ceremony and Celebration Dinner
Gilead Sciences, Inc.

Headshot Lounge
Bristol-Myers Squibb
High School Science Education Programs  
Aflac, Inc.

Late-Breaking Poster Sessions  
Bristol-Myers Squibb

Online Program, Proceedings, and Itinerary Planner  
Novartis

President’s Reception  
Bristol-Myers Squibb

Professional Advancement Series  
AbbVie, Inc.

Professional Educational Grants  
AbbVie, Inc.
Astellas
AstraZeneca
Daiichi-Sankyo
Eisai Inc.
Genentech, A Member of the Roche Group
Incyte Corporation
Ipsen Biopharmaceuticals, Inc.
Janssen Research & Development, LLC
Lilly Oncology
Merck & Co., Inc.
Novartis
Pfizer Oncology
Prometheus Laboratories, Inc.
Regeneron
Seattle Genetics
Taiho Oncology
Takeda Oncology
TESARO

Progress and Promise Against Cancer Community Event  
Pharmacyclics, LLC

Scientist ↔ Survivor Program  
Canadian Institutes of Health Research
Celgene Corporation
Daiichi-Sankyo
Gilead Sciences, Inc.
Lilly Oncology
Merck & Co., Inc.

Novartis
Novo cure
Pfizer Oncology
Seattle Genetics

Women in Cancer Research Resource Center  
Bristol-Myers Squibb

RESEARCH GRANTS AND FELLOWSHIPS

Amgen, Inc.
AstraZeneca
Bayer
The Bosarge Family Foundation
Bristol-Myers Squibb
Breast Cancer Research Foundation
Cancer Research UK
Debbie’s Dream Foundation
Genentech, A Member of the Roche Group
GlaxoSmithKline
Incyte Corporation
Johnson & Johnson
The John and Elizabeth Leonard Family Foundation
Loxo Oncology
MPM Oncology Charitable Foundation
Neuroendocrine Tumor Research Foundation
Novocure
Pfizer Oncology
The QuadW Foundation and the QuadW Fund of Communities
Foundation of Texas
Takeda Oncology
SUPPORTERS

SPECIAL CONFERENCE SUPPORTERS FOR 2018-2019

AbbVie, Inc.
Amgen, Inc.
Astellas
AstraZeneca
Bristol-Myers Squibb
Celgene Corporation
Daiichi-Sankyo
Ferring Pharmaceuticals
Genentech, A Member of the Roche Group
Gilead Sciences, Inc.
Icyte Corporation
Ipsen Biopharmaceuticals, Inc.
Janssen Research & Development, LLC
Juno Therapeutics
Lilly Oncology
Lustgarten Foundation
Merck & Co., Inc.
Mirati Therapeutics
Novartis
Novocure
Pancreatic Cancer Action Network
Pentax
Pfizer Oncology
Pharmacyclics, LLC
Prometheus Laboratories Inc.
Rivkin Center for Ovarian Cancer
Seattle Genetics
Shire Pharmaceuticals
Susan G. Komen
TESARO
The Leukemia & Lymphoma Society

SUSTAINING MEMBERS

Leadership Sustaining Members
Amgen, Inc.
AstraZeneca
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Genentech, A Member of the Roche Group
Merck & Co., Inc.
Novocure
Pfizer Oncology
Takeda Oncology

Strategic Sustaining Members
Gilead Sciences, Inc.
GlaxoSmithKline
Icyte Corporation
Novartis
Pharmacyclics, LLC

Major Sustaining Members
Astex Pharmaceuticals, Inc.
Celgene Corporation
Daiichi-Sankyo
Eisai Inc.
EMD Serono
Janssen Research & Development, LLC
Lilly Oncology
Loxo Oncology
Pezcroller Foundation
SANOFI GENZYME
Servier
TESARO
Theradex Oncology

Associate Sustaining Member
Asana BioSciences, LLC

Confirmed Supporters as of March 5, 2019.
## GENERAL INFORMATION

<table>
<thead>
<tr>
<th>Room Name</th>
<th>Location</th>
<th>Opens</th>
<th>Phone #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACR Office</td>
<td>B311</td>
<td>Thursday, 6:00 a.m.</td>
<td>404-222-5302</td>
</tr>
<tr>
<td>AACR Exhibit Booth (AACR Central)</td>
<td>Exhibit Hall B</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Amphitheater</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Member Resource and Career Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minorities in Cancer Research (MICR) Networking and Resource Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACR Electronic Privacy Center</td>
<td>International Blvd. Entrance</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Foundation</td>
<td>International Blvd. Entrance</td>
<td>Saturday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Publications Booth</td>
<td>Exhibit Hall B, Booth 3226</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Session Central</td>
<td>Exhibit Hall B</td>
<td>Friday, 3:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>CancerCareers.org Center</td>
<td>International Blvd. Entrance</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>CME Booth</td>
<td>Registration Hall</td>
<td>Friday, 3:00 p.m.</td>
<td>404-222-5300</td>
</tr>
<tr>
<td>Information Booth</td>
<td>International Blvd. Entrance</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Coat, Package, and Luggage Check</td>
<td>Building C Lobby</td>
<td>Friday, 2:00 p.m.</td>
<td>404-222-5303</td>
</tr>
<tr>
<td>Child Care</td>
<td>A410</td>
<td>Friday, 2:30 p.m.</td>
<td>404-222-5303</td>
</tr>
<tr>
<td>Exhibit Management Office</td>
<td>Exhibit Hall B</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
<tr>
<td>Exhibitor Lounge</td>
<td>Exhibit Hall B</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
<tr>
<td>Housing Booth (CMR)</td>
<td>Registration Hall</td>
<td>Friday, 12:00 p.m</td>
<td>404-222-5301</td>
</tr>
<tr>
<td>First Aid Station</td>
<td>B410</td>
<td>Thursday, 7:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Membership Booth</td>
<td>Registration Hall</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
<tr>
<td>Membership Hub</td>
<td>International Blvd. Entrance</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
<tr>
<td>NCI/NIH Meeting Room</td>
<td>A408</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Nursing Suite</td>
<td>A409</td>
<td>Friday, 2:30 p.m.</td>
<td></td>
</tr>
<tr>
<td>Press Office</td>
<td>B308</td>
<td>Saturday, 12:00 p.m.</td>
<td>404-222-5315</td>
</tr>
<tr>
<td>Registration</td>
<td>Registration Hall</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
<tr>
<td>Scientist↔Survivor Program Room</td>
<td>B214</td>
<td>Sunday, 6:30 a.m.</td>
<td></td>
</tr>
<tr>
<td>Speaker Preparation Room</td>
<td>A301</td>
<td>Friday, 12:00 p.m</td>
<td></td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

REGISTRATION

Registration will be located in the Registration Hall on the following schedule:

- **Friday, March 29**: 12:00 p.m.-7:00 p.m.
- **Saturday, March 30**: 7:00 a.m.-6:00 p.m.
- **Sunday, March 31**: 6:30 a.m.-6:00 p.m.
- **Monday, April 1**: 6:30 a.m.-6:00 p.m.
- **Tuesday, April 2**: 6:30 a.m.-6:00 p.m.
- **Wednesday, April 3**: 6:30 a.m.-12:00 p.m.

Spouse registration may only be purchased on-site beginning Sunday, March 31. All spouse registrations must be tied to an existing attendee record and are not available to individuals working in the cancer research field. Spouse fee includes only social activities provided during the conference and access to the Poster and Exhibit Hall; it does NOT admit individuals to lecture sessions. The fee for spouse registration is $75.

To enhance the Annual Meeting experience, the AACR is using smart badges to gather information trends on session attendance, poster and exhibit activity, and convention center traffic. This technology will assist the AACR staff in anticipating overflow sessions and in developing programs for future Annual Meetings.

HOUSING

The AACR Housing Desk (CMR) will be available in the Registration Hall for individuals who need assistance with their accommodations. The Housing Desk will be open during the following hours:

- **Friday, March 29**: 12:00 p.m.-7:00 p.m.
- **Saturday, March 30**: 7:00 a.m.-6:00 p.m.
- **Sunday, March 31**: 6:30 a.m.-6:00 p.m.
- **Monday, April 1**: 6:30 a.m.-6:00 p.m.
- **Tuesday, April 2**: 6:30 a.m.-6:00 p.m.
- **Wednesday, April 3**: 6:30 a.m.-10:00 a.m.

EXHIBIT HALL

The Exhibit Hall is located in Hall B. Exhibit hours are:

- **Sunday, March 31**: 1:00 p.m.-5:00 p.m.
- **Monday, April 1**: 9:00 a.m.-5:00 p.m.
- **Tuesday, April 2**: 9:00 a.m.-5:00 p.m.
- **Wednesday, April 3**: 9:00 a.m.-12:00 p.m.

AACR ELECTRONIC PRIVACY CENTER

The AACR is committed to protecting your privacy while ensuring that you receive important communications about cancer-related events, products, and services focused on your career and interests. Stop by one of the Electronic Privacy Centers, located at the International Blvd. entrance and at the Membership Center in AACR Central, to find out more and pick up a special gift. From Communications to Cookies, thank you for entrusting us with your valuable information as we keep you at the center of AACR activities.

MEMBERSHIP

With over 42,000 members in over 120 countries, the AACR comprises leaders and future leaders focused on every aspect of high-quality innovative cancer research. We firmly believe that our members play an integral part in achieving our mission.

Annual Meeting participants are invited to visit the Membership Hub (Registration/
International Blvd. Entrance), the Membership Center (located in AACR Central), and the Membership Booth (Registration) to learn more about membership and the exclusive benefits available to members, join one or more Association groups within the AACR, update contact information, pay membership dues, and more. AACR Dedicated Member mementos are also available on a first-come, first-served basis.

Membership for Early-Career Trainees and Students

The AACR is committed to the education, training, and professional development of early-career researchers, trainees, and students. Membership is FREE for graduate students, medical students, residents, postdoctoral or clinical fellows, undergraduate students, and high school students who are enrolled in education or training programs that could lead to a career in cancer research. Visit the Membership Hub, Membership Center at AACR Central, or Membership Booth (Registration) to learn more about this amazing opportunity to join our esteemed association.

AACR New Member Networking Mixer

The AACR is extremely pleased to host a New Member Networking Mixer each year to welcome newly elected members into the association and provide them with an opportunity to meet and interact with the AACR leadership, network with colleagues and forge new relationships, and learn more about exclusive member benefits and how to get involved in the association. Visit the Membership Hub, located at the International Blvd. Entrance, for more information.

Member Appreciation Breakfast: Celebrating AACR Long-Term Members

The AACR is extremely pleased to recognize those scientists who have been long-term members. The AACR board of directors extends its sincere and heartfelt thanks to these members for their devotion to cancer research and long participation in and support of the AACR.

Meet the 2019-2020 AACR President, Elaine R. Mardis

The Meet the 2019-2020 AACR President event provides an opportunity for AACR members and annual meeting attendees to meet informally with the 2019-2020 AACR President, Dr. Elaine R. Mardis, to congratulate her on her presidency and ask general questions.
PROFESSIONAL ADVANCEMENT SERIES

Professional Advancement Series of sessions is organized to provide important skills to investigators at all levels, from junior faculty to high school students. These sessions are an exclusive benefit for AACR members. For all Professional Advancement Sessions, attendance is free for members with your Annual Meeting registration.

In 2019, the Professional Advancement Series of sessions has been organized in a collaborative effort between the Associate Member Council (AMC), Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, and the AACR Science Education and Career Advancement Committee.

Participation by AACR members for all sessions—except Personalized Career Conversations, which require advance registration—is on a first-come, first-served basis, as space is limited. As an additional member benefit, webcasts of selected Professional Advancement Session presentations will be available free to AACR members in good standing. (Note: Participation in the Annual Meeting Webcast is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides.)

Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

Friday, March 29, 2019; 9:00 a.m.-2:00 p.m.
Regency VI-VII, Hyatt Regency Atlanta

This interactive program is designed to inspire students to pursue careers in cancer research and biomedical sciences by providing an opportunity for students to learn about cancer from cancer research experts while interacting with their peers. The program includes lectures, tours of the exhibits and poster areas, student presentations, and a networking lunch. AACR members are encouraged to volunteer as judges. The AACR Special Program for High School Students is supported by a generous grant from Aflac.

14th Annual Undergraduate Student Caucus and Poster Competition
Special presentation of Margaret Foti Foundation Undergraduate Prizes for Cancer Research

Saturday, March 30, 2019; 9:00 a.m.-4:00 p.m.
Grand Ballroom, Omni Atlanta Hotel at CNN Center

With over 200 undergraduate student participants every year, the Undergraduate Student Caucus Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 14th year, this session gives undergraduates the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for monetary prizes while presenting research. Undergraduate students at all levels are welcome to participate in this exciting and free event. AACR members are encouraged to volunteer as judges. Winners of this competition will be presented with Margaret Foti Foundation Undergraduate Prizes for Cancer Research, which reward excellence in research conducted and presented by undergraduate students.
Careers in Clinical and Translational Cancer Research Roundtable
Saturday, March 30, 2019; 5:30 p.m.-7:30 p.m.
Atrium Ballroom A, Atlanta Marriott Marquis

Celebrating its 10-year anniversary, this Professional Advancement session is designed for investigators at all levels to further their knowledge about their own, as well as peripheral, clinical and translational cancer research fields. Participants will meet with small-group roundtable mentors who represent a variety of roles in academia, industry, and government sectors, to discuss professional experiences, successes, and lessons learned that have helped establish his/her clinical, translational, or physician-scientist career path.

The Critical Role of Physician-Scientists in Advancing Cancer Science—Suggestions for Continued Success
Sunday, March 31, 2019; 5:00 p.m.-7:00 p.m.
Regency VII, Hyatt Regency Atlanta

Through panel discussion and Q&A, this Professional Advancement session will explore the critical roles of physician-scientists and provide strategies for success in scientific discoveries in cancer, the clinical care of patients and/or the health of populations, the advancement of education/mentoring, and opportunities for administrative leadership. Funding opportunities and the unique aspects of the grant review process for physician-scientist awards will also be discussed.

Personalized Career Conversations: Pathways to Academia, Industry, and Government
Sunday, March 31, 2019; 5:00 p.m.-7:00 p.m.
International Ballroom N and S, Hyatt Regency Atlanta

The AACR Annual Meeting has always offered a variety of unique opportunities for individuals to meet other cancer research experts, but it can be intimidating for early-career scientists to walk up to a senior scientist at a conference and try to start a conversation. This Professional Advancement session, offered as a benefit exclusively for Associate members, will provide a chance for early-career researchers to meet a world-renowned cancer research expert in a one-on-one setting to discuss science, professional experiences, and career advice. Preregistration for this session was required, but limited space may be available on a first-come, first-served basis on-site.

Workforce Development: Professional Enhancement and Career Advancement Reception and Roundtable
Monday, April 1, 2019; 6:30 p.m.-8:30 p.m.
Centennial III and IV, Hyatt Regency Atlanta

This session is designed to assist with the professional and career development of investigators at all career levels. The session will consist of informal small-group conversations at roundtables with representatives from varying roles in the academic, industry, and government sectors. Approximately 10 participants per table will have the opportunity to informally speak with a roundtable mentor about his/her experiences, successes, and lessons learned that have helped establish the mentor’s career path. Dinner and beverages will be available.
GENERAL INFORMATION

ANNUAL MEETING INFORMATION BOOTH

The Annual Meeting Information Booth is located in the International Blvd. Entrance. It will be open during session hours to provide information about the AACR, the Annual Meeting, and the city of Atlanta, GA. Staff members will be available to assist you with city and convention center maps, shuttle bus schedules, and information on AACR’s programs.

PRESS RELATIONS

The AACR Press Office is located in Room B308 of the Convention Center. It will be open from 12:00 p.m. to 6:00 p.m., Saturday, March 30; 7:30 a.m. to 6:00 p.m., Sunday, March 31 through Tuesday, April 2; and 7:30 a.m. to 12 p.m., Wednesday, April 3. The AACR’s press contacts are Julia Gunther, Assistant Director of Public Relations, 770-403-7690, julia.gunther@aacr.org; Rachel Salis-Silverman, Director of Public Relations, 267-970-3685, rachel.silverman@aacr.org; Sarah Cohn, Manager of Public Relations, 856-397-0314, sarah.cohn@aacr.org; Charmaine Riley, Senior Coordinator of Public Relations, 360-789-5147, charmaine.riley@aacr.org; and Rick Buck, Senior Director of Communications and Public Relations, 856-562-5668, rick.buck@aacr.org.

SPEAKER PREPARATION ROOM

Speakers should visit the Speaker Preparation Room (Room A301 in the Georgia World Congress Center, Building A) at least four hours before their sessions begin to test their presentations. The Speaker Preparation Room will be open on Friday, March 29, from 12:00 p.m. to 6:30 p.m., daily during the meeting from 6:00 a.m. to 6:30 p.m., and close on Wednesday, April 3, at 12:00 p.m. Please note: Speakers in sessions located in hotels should not check in at the Speaker Preparation Room. Speakers in hotel sessions should arrive at the session room 30 minutes prior to the start of the session and check in with the AV technician to upload and test presentations. Speakers cannot use personal laptops in any session rooms.

CHILD CARE

Professional child care services are offered at a nominal cost in Room A410 on the following schedule:

- Friday, March 29: 2:30 p.m.-7:00 p.m.
- Saturday, March 30: 7:30 a.m.-7:00 p.m.
- Sunday, March 31: 6:30 a.m.-7:00 p.m.
- Monday, April 1: 6:30 a.m.-7:00 p.m.
- Tuesday, April 2: 6:30 a.m.-7:00 p.m.
- Wednesday, April 3: 6:30 a.m.-1:30 p.m.

As a convenience for registrants, the AACR subsidizes the cost of this service. The cost for this service to the user is $12 per hour for each child age 6 months-12 years (2-hour minimum required). Snacks and beverages are included in the fee, but meals must be provided by parents. Medication will NOT be administered by KiddieCorp. To ensure a safe and fun-filled environment, any child who...
is ill will not be admitted to the children’s program. Advance registration was strongly encouraged. On-site registration will be permitted as space allows.

NURSING MOTHERS SUITE
Annual Meeting participants who are also nursing mothers will find the Nursing Mothers Suite to be a private, comfortable, and secure environment in which to nourish and nurture their babies. AACR-Women in Cancer Research (WICR) is pleased to sponsor this important service again in 2019. The Nursing Mothers Suite will be available in Room A409 on the following schedule:

- Friday, March 29: 2:30 p.m.-7:00 p.m.
- Saturday, March 30: 2:30 p.m.-7:00 p.m.
- Sunday, March 31: 6:30 a.m.-7:00 p.m.
- Monday, April 1: 6:30 a.m.-7:00 p.m.
- Tuesday, April 2: 6:30 a.m.-7:00 p.m.
- Wednesday, April 3: 6:30 a.m.-1:30 p.m.

To view more information or register for any of these symposia, visit www.AACR.org/Satellite19.

SATellite educational symposia
The Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information can be found at the specially marked counter located in the Registration area in the Registration Hall.

Saturday, March 30 • 6:30 p.m.-9:00 p.m. Advances in Biomarker-Guided Cancer Immunotherapy: Experts Discuss Clinical Utility and Future Directions
Regency VI, Hyatt Regency Atlanta

Saturday, March 30 • 6:30 p.m.-9:00 p.m. Immune Checkpoint Inhibitor Combinations for Lung Cancers: Experts Discuss the Challenges and Opportunities of Rapidly Evolving Treatments
Regency VII, Hyatt Regency Atlanta

Saturday, March 30 • 6:30 p.m.-9:00 p.m. BTK Inhibition as an Anticancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond
Embassy Hall, Hyatt Regency Atlanta

Sunday, March 31 • 6:30 p.m.-9:00 p.m. Leveraging the Immune System for Therapeutic Benefit in Non-small Cell Lung Cancer—Scientific Insights, Clinical Applications, and Future Directions
Centennial I-II, Hyatt Regency Atlanta

Sunday, March 31 • 6:30 p.m.-9:00 p.m. Exploring New Treatment Windows for Immune Checkpoint Blockade in Melanoma
Centennial III-IV, Hyatt Regency Atlanta
Monday, April 1 • 6:30 p.m.-9:00 p.m.
Exploring the Underlying Biology and Current Research Database Supporting the Use of PARP Inhibition as a Therapeutic Strategy for Patients with Inherited and Sporadic Cancers
Centennial I-II, Hyatt Regency Atlanta

Monday, April 1 • 6:30 p.m.-9:00 p.m.
Molecular Tumor Board in EGFR-Mutant Lung Cancers: Integrating Clinical Data into Patient Care
International North and South, Hyatt Regency Atlanta

GUIDE TO POSTER SESSIONS AND EXHIBITS
Limited quantities of the Guide to Poster Sessions and Exhibits will be distributed at the entrances to the Poster and Exhibit Hall. Pick up a copy to locate posters, browse poster session topics, and learn about exhibiting companies and the products and services they offer.

EXHIBITOR SPOTLIGHT THEATERS
Located in the Exhibit Hall, the Exhibitor Spotlight Theaters have been reserved by exhibiting companies to present special one-hour sessions during exhibit hours. For a full list of presentations taking place in Spotlight Theaters A, B, and C, please refer to the Guide to Poster Sessions and Exhibits and the Annual Meeting App.

EXPLORE!
Explore! is a fun way attendees can interact with exhibitors while entering a drawing for $250 Amazon gift cards. Download the AACR Annual Meeting App. Scan the QR codes when visiting participating exhibitors and special locations for a chance to win, courtesy of the AACR. Get out there, visit the exhibitors, and Explore! Winners will be notified after the meeting and prizes will be mailed shortly thereafter.

DIGITAL PRODUCT SHOWCASE
Visit one of the AACR Digital Product Showcase kiosks to learn more about exhibiting companies. Attendees will be able to scan their badges to gain access to an interactive digital product gallery. In addition to being able to search the gallery, when a product is chosen it will direct the attendee to the company’s exhibit booth. Kiosks will be placed in several high-traffic locations—registration area, exhibit entrance, and throughout the Exhibit Hall—so that attendees have multiple opportunities to interact with products and brands.

HEADSHOT LOUNGE
Need a new headshot? Don’t forget to stop by the BMS Headshot Lounge, located in the Exhibit Hall. Professional photographers will be available to provide you with the perfect headshot for your next business card, resume, etc. Kiosks will be set up, which will display your photos and allow you to choose at least three that will be emailed directly to you.
EXHIBITOR-HOSTED REFRESHMENT BREAKS

Don’t miss the Exhibitor-Hosted Refreshment Breaks in the Exhibit Hall on Monday, April 1 and Tuesday, April 2, starting at 1:30 p.m. Light snacks will be available, compliments of the AACR exhibitors. Strategically located food and beverage stations are the ideal platform for interaction between attendees and exhibitors.

FOOD COURT

The AACR will provide an area on the show floor for all conference attendees to purchase lunch during poster and exhibit hours. The Food Court will be located in the back of the Exhibit Hall and will serve a variety of food and beverages.

AACR CENTRAL

AACR Central serves as a hub for information and services for attendees and also as an event space for various programs. Open during Exhibit Hall hours, AACR Central is located centrally in the Exhibit Hall and is home to the Amphitheater, Associate Member Resource and Career Center, Membership Center, MICR Networking and Resource Center, and WICR Networking and Resource Center.

At AACR Central, attendees can:

• Apply for AACR membership, learn more about AACR member benefits, and check on the status of membership.

• Participate in events organized by the Associate Member Council (AMC), Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), the Science Education and Career Advancement Committee, the Molecular Epidemiology Working Group (MEG), and others.

• Find additional information on AACR’s conferences, award programs, advocacy efforts, and the AACR Foundation.

• Pick up copies of Cancer Today, AACR’s peer-reviewed journals, and Proceedings from other AACR conferences.

• Purchase tickets for the AMC and AMC Fundraising Committee “Flavor of the City Networking and Fundraising Event.”

MINORITIES IN CANCER RESEARCH (MICR)

AACR-MICR Distinguished Lectureship Series: The Impact of Global Health Research on Advancing Cancer Health Equity in the U.S.

Friday, March 29, 2019; 3:00 p.m.-6:00 p.m. National Center for Primary Care, Morehouse School of Medicine, Atlanta, GA

Global health research presents a tremendous opportunity to better understand the role of epigenetics in health outcomes. Epigenetics is the study of how environmental and social experiences across the lifespan affect gene function, ultimately influencing health trajectories or modifying disease risk. In this session, participants will engage in scientific discourse relative to epigenomic investigations in racial/ethnic minority and health disparity populations. Faculty, students, and community members are invited to engage in bidirectional conversations to increase awareness and understanding of how global efforts...
to eradicate the burden of cancer can contribute to the advancement of cancer health equity in the United States. Hosted in partnership with Morehouse School of Medicine.

**WOMEN IN CANCER RESEARCH (WICR)**

**AACR-WICR: 20th Anniversary: Celebrating Women in Cancer Research**

**Saturday, March 30, 2019; 5:15 p.m.-6:15 p.m.**

Room A311, Georgia World Congress Center

This celebration will highlight the achievements of Women in Cancer Research as an AACR membership group and the achievement of women scientists and their contributions to the field.

**CANCER AND BIOMEDICAL CAREER FAIR**

The 2019 Cancer and Biomedical Research Career Fair is coming to Atlanta, GA, on Saturday, March 30, from 9:00 a.m. to 3:00 p.m. in Rooms B401-B403. Building upon the success of AACR’s previous Career Fairs, the 2019 Career Fair will provide many opportunities for both job seekers and employers. The Career Fair will once again bring job seekers with highly specialized scientific skills (basic and translational researchers, clinicians, and epidemiologists) together with recruiters and potential employers representing academia, cancer centers, government, and industry. Employers will be able to speak with early-career scientists as well as more experienced scientists during the Career Fair and throughout the Annual Meeting inside the CancerCareers.org Center in the Registration area. Registration for the Career Fair is free to job seekers.

**ANNUAL RECEPTION**

All Annual Meeting registrants are invited to attend the Annual Reception on Sunday evening, March 31, from 8:30 p.m. to 11:30 p.m. in the Atrium Ballroom of the Atlanta Marriott Marquis. Complimentary light refreshments will be served, and a live band will provide music for dancing. On Sunday evening, shuttle buses will run between all AACR hotels where busing is provided during the day and the Georgia World Congress Center. Shuttle schedules will be posted in each hotel. Each registrant will receive a voucher for a complimentary beverage at the Annual Reception with his/her registration materials.

**ASSOCIATE MEMBER MEET AND GREET**

**Sunday, March 31, 2019; 8:00 p.m.-9:30 p.m.**

Room A601, Atlanta Marriott Marquis

Hosted by the Associate Member Council (AMC), join members for an informal meet and greet and network with other early-career attendees; obtain information about programs, events, and initiatives specifically for Associate members both at the conference and throughout the year; and meet with those representatives who are advocating to the AACR on behalf of the needs and concerns of graduate students, medical students and residents, and clinical and postdoctoral fellows. Take advantage of some exciting promotions that will be available only for those who stop by this informal pop-up space and connect with...
other early-career attendees throughout the reception!

NCI/NIH MEETING ROOM

The NCI Meeting Room, located in Room A408 of the Convention Center, provides researchers with the opportunity to interact with NCI and NIH Program Staff. Program and Review staff from the NCI as well as Review staff from CSR attend the Annual Meeting and can be available at the Meeting Room for discussions and consultation throughout the conference.

Researchers interested in speaking with their Program Directors should contact them ahead of the AACR Annual Meeting to arrange a time to meet at the NCI Meeting Room. Conferences can be scheduled to discuss individual grant/review questions. New investigators are especially encouraged to meet with Program staff handling grant portfolios in their area of scientific interest.

The Meeting Room will be open from 9:00 a.m. to 5:00 p.m. Sunday through Tuesday and from 9:00 a.m. until 12:00 p.m. on Wednesday.

SCIENTIST↔SURVIVOR PROGRAM

The AACR Scientist↔Survivor Program (SSP) builds partnerships among the scientific and cancer survivor and patient advocacy communities worldwide. Launched in 1998 at the AACR Annual Meeting, the program was designed to meet the needs of both groups and offers them an unparalleled opportunity to meet and interact over several days in a stimulating and engaging atmosphere.

The program exposes advocates to special lay-language lectures, small group discussions, and other interactions that provide a solid background in cancer research. Survivor and patient advocates are able to keep abreast of recent advances in drug development and basic, clinical, and translational cancer research and be exposed to the knowledge and dedication of cancer scientists. Scientists who participate in the program gain a more personal understanding of cancer’s impact on patients and their loved ones, are exposed to the key concerns of survivor and patient advocates, and become more cognizant of the vital role that advocates play in supporting cancer research.

Promoting the exchange of information on key aspects of cancer research, survivorship, advocacy, and public policy strengthens communication and enhances efforts to accelerate progress in the fight against cancer. Feel free to visit the Scientist↔Survivor Advocate Poster Sessions on Sunday, March 31, from 1:00 p.m. to 5:00 p.m. and Monday, April 1, from 8:00 a.m. to 12:00 p.m. in the Poster and Exhibit Hall. For more information on the Scientist↔Survivor Program, visit the Survivor and Advocate Lounge located in Room B214 of the Georgia World Congress Center, or email ssprogram@aacr.org.

AACR ADVOCACY PARTNERS’ PAVILION

Visit the Advocacy Pavilion in the Poster and Exhibit Hall to learn about resources and services of nonprofit cancer patient advocacy organizations. The pavilion is the ideal location to promote networking and the exchange of ideas among groups, patients, and health care professionals.
AACR FOUNDATION

Join us for the AACR Runners for Research 5k Run/Walk on Saturday, March 30, 7:30 a.m. at Centennial Park! If you can’t make the event, you can still raise critical funds for cancer research through April 30 as a Virtual Runner at AACR.org/Research5k. To learn about all the AACR Foundation activities and how you can get involved, stop by their booth in Registration/International Blvd. Entrance.

ONLINE ITINERARY PLANNER AND ANNUAL MEETING APP

The Annual Meeting program is subject to change. Updates will be available in the online Itinerary Planner and the Annual Meeting App, along with full session details, including complete titles, author listings, and text for abstracts in poster sessions and minisymposia. To access the Itinerary Planner and download the Annual Meeting App, visit www.AACR.org/AACR2019.

AACR ENGAGE: SECOND-SCREEN PRESENTATION ACCESS

The AACR is introducing access to presentations on personal devices for a limited number of sessions at the Annual Meeting. Attendees in these selected sessions will be able to view the session slides on their smartphones, tablets, or laptops and make notes on the slides. At the presenter’s discretion, attendees will also be able to respond to poll questions or submit questions to the presenter.

AACR Engage sessions will be identified in the Annual Meeting App, and users can access the application through a URL that will be posted to the app and displayed to attendees at the beginning of each session. (Please note: Participation is at the discretion of each speaker. Slides can be viewed on personal devices but cannot be saved; user notes will be delivered via e-mail at the end of the session.)

NEW FOR 2019: AACR SESSION CENTRAL

This new feature will offer attendees a place to view many in-demand sessions from a central location. AACR Session Central, conveniently located in Hall B of the Georgia World Congress Center, will show up to 10 sessions in real time from around the entire conference. Simply stop by, grab a headset, and tune in to any of the sessions being shown as they occur throughout each day.

ANNUAL MEETING WEBCASTS

Exclusive online streaming access to the audio and slides of scientific sessions presented at the AACR Annual Meeting 2019 is available free to all paid attendees. Webcasts will be available on April 24, 2019 and will include:

- Presentation slides synchronized with recorded audio presentations
- Speakers’ mouse movements captured and included in playback
• Availability on compatible mobile devices and smartphones such as iPad, iPod Touch, iPhone, and Android devices
• Presentations searchable by session title, presentation title, and speaker name
• Exclusive access to online content for 15 months after the Annual Meeting

Participation in the AACR Annual Meeting Webcast is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Access is granted via individual username and password.

As in previous years, the AACR will make the Opening Ceremony, the plenary sessions, and the award lectures available free as streaming video to all interested users. To view a demo of previous webcasts, visit webcast.aacr.org.

COAT AND LUGGAGE CHECK

Coat, package, and luggage check service will be available in the Building C Lobby on the following schedule:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, March 29</td>
<td>2:00 p.m.-7:00 p.m.</td>
</tr>
<tr>
<td>Saturday, March 30</td>
<td>6:30 a.m.-7:00 p.m.</td>
</tr>
<tr>
<td>Sunday, March 31</td>
<td>6:30 a.m.-8:30 p.m.</td>
</tr>
<tr>
<td>Monday, April 1</td>
<td>6:30 a.m.-8:30 p.m.</td>
</tr>
<tr>
<td>Tuesday, April 2</td>
<td>6:30 a.m.-8:30 p.m.</td>
</tr>
<tr>
<td>Wednesday, April 3</td>
<td>6:30 a.m.-4:00 p.m.</td>
</tr>
</tbody>
</table>

SPECIAL ACCOMMODATIONS FOR ATTENDEES

The American Association for Cancer Research recognizes the importance of making its educational activities available to all interested participants of the professional medical community. This AACR educational activity is designed to accommodate all attendees and fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Registrants in need of auxiliary learning aids or special requirements for hotel accommodations, transportation, or other facilities connected with this meeting should contact the AACR Office in Room B311 of the Georgia World Congress Center.

CODE OF CONDUCT, POLICIES, AND PROCEDURES

The AACR Annual Meeting 2019 will bring together over 22,000 academics, scientists, pharmaceutical industry representatives, and others from across the globe. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following policies and procedures for conference participants. By registering for the AACR Annual Meeting 2019, you agree to the following terms:

• The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants—attendees, presenters, exhibitors, staff, vendors, etc.
• The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.
• The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.

• Children under 12 years of age are not permitted in any scientific session, poster session, the Exhibit Hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the Convention Center.

• Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls or send emails or texts as the back lighting on electronic devices is distracting to other participants.

• The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.

• Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.

• If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshal has the authority to delay or terminate the conference.

• The AACR encourages responsible drinking for those drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.

LOST AND FOUND

Anything left in any area of the Center will be taken to the AACR Security Office, Room B310. Any item not picked up from this office by the end of the meeting will be handed over to the Georgia World Congress Center, Public Safety. You can contact Public Safety at 404-223-3538.

EMERGENCY RESPONSE PROCEDURES

If an emergency occurs, immediately call Georgia World Congress Center Security at 404-223-4911 (or 4911 from a house phone). They will contact the Atlanta Police Department at 9-1-1 Center via their direct line. GWCC Public Safety and Police Officers are trained to handle emergencies and will also respond to the incident. If you choose to call 9-1-1 yourself, be sure to call GWCC Public Safety at the above number immediately thereafter.

NO SMOKING REGULATION

Smoking is prohibited in all areas of the Georgia World Congress Center and at sessions and social events held in other venues.
PHOTOGRAPHY AND SOCIAL MEDIA POLICIES

Photography. Conference attendees may take photographs during oral or poster presentations provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience.

Social Media. Conference attendees may share information from presentations on social media provided that they respect the wishes of presenters. Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.” Attendees must respect the presenters’ requests in these instances and refrain from posting any images from these designated slides or posters on social media.

NOTICE OF PHOTOGRAPHER AND VIDEOGRAPHER ON PREMISES

A professional photographer and videographer may be on-site to document AACR Annual Meeting events and activities between March 29 and April 3, 2019. Photographs and video footage are the sole property of AACR. By registering for and attending these events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on-site.

CONTINUING MEDICAL EDUCATION (CME)

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 47.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by May 15, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR website at www.aacr.org/am19cme and via email. Your CME certificate will be sent to you via email after the completion of the activity.
ABIM MOC Statement

Successful completion of this CME activity enables the participant to earn up to 47.0 MOC points in the American Board of Internal Medicine. It is the CME activity providers’ responsibility to submit participant completion information to the ACCME for the purpose of granting MOC credit.

To receive ABIM MOC, participants must submit the MOC request form available on the website, as well as the CME Request for Credit Evaluation. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

The fight against cancer is rapidly progressing with the accelerating pace of discoveries in the basic, translational, and clinical sciences. This is due in large part to the advent of new technologies, such as advanced live imaging techniques and liquid biopsies, and our increased understanding of the importance of harnessing the power of the immune system to develop new immunotherapies. However, understanding and combating the processes of cancer initiation, progression, and response to treatment require a multidisciplinary approach. The AACR Annual Meeting brings together cancer biologists, clinical oncologists, and population scientists with engineers, computational biologists, and physical scientists to develop quantitative approaches and ask new questions to develop better strategies for curing cancer. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists increases the contributions of laboratory research to drug development as well as patient care, transforms the design and conduct of clinical research protocols, and creates an avenue for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes. This meeting also acts as a forum to discuss cancer health disparities and help ensure that all patients benefit from emerging breakthroughs in research and cancer treatment.

Despite the tremendous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States (U.S.) alone, it is predicted that 609,640 people will die from some form of cancer in 2018, making it the second most common cause of death after heart disease. One of the challenges we face is that cancer comprises more than 200 different diseases. For many of the most commonly diagnosed cancers in the U.S.—including lung, prostate, ovarian, urinary bladder, and colorectal cancer—incidence has been declining for more than a decade. However, incidence of other forms of cancer—including endometrial, liver, thyroid, skin, childhood cancer, and leukemia—has been on the rise. Incidence, diagnosis, access to treatment, and survival rates are also impacted by the cancer health disparities that exist in certain segments of the U.S. population, with older and underprivileged populations often witnessing higher incidences of cancer and mortality.
This conference will bring together over 23,000 investigators from the basic, translational, and clinical disciplines and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. To provide the most advanced technologies and treatments, it is critical to bridge the gap between physicians who are answering fundamental questions about cancer biology and clinicians who are applying the latest diagnostic and treatment advances to patient care. As the incidence of cancer continues to increase, the fields of cancer prevention and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.

After participating in this CME activity, physicians should be able to:

1. Assess the technological advances and tools, such as liquid biopsies, being used to accelerate progress in cancer research and improve early detection and early interception, with the ultimate goal of extending patients' lives and improving their quality of life

2. Articulate how advances in precision cancer medicine are leading to improved patient outcomes

3. Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy and combination therapies, in a variety of cancer types to improve patient outcomes

4. Formulate new strategies integrating multidisciplinary scientific and clinical research efforts towards the prevention, early detection, and interception of cancer

5. Identify factors that impact the diagnosis, treatment, and prevention of various forms of cancers in patients from diverse populations

6. Develop collaborations among physicians, researchers, and clinician-scientists to advance approaches for cancer treatment and prevention

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the meeting app, itinerary planner, and website of this conference.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants and will be disclosed at the activity.

Questions about CME?

Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
GEORGIA WORLD CONGRESS CENTER
Exhibit Hall Floor Plan
Bldg. B • Level 1
GEORGIA WORLD CONGRESS CENTER
Bldg. B • Level 2
GEORGIA WORLD CONGRESS CENTER
Bldg. A • Level 1

HALL A
PLENARY SESSIONS
OPENING CEREMONY
PLENARY SESSIONS
SELECTED MAJOR SYMPOSIA
SELECTED FORUMS
DOWN TO HALL A (PLENARY SESSIONS)
GEORGIA WORLD CONGRESS CENTER
Bldg. A • Level 4
FRIDAY, MARCH 29**

EDUCATIONAL SESSIONS • 3:00 p.m.–5:00 p.m.
Sydney Marcus Auditorium, Building A, Georgia World Congress Center

**Immune-Targeted Biomarker Incorporation into Therapeutic Decision Making**

**Chair:** David A. Barbie, Boston, MA

3:00 p.m.  The evolving landscape of biomarker selection in immunotherapy treatment decisions. Leena Gandhi, Boston, MA

3:30 p.m.  Predicting immunotherapy response with protein-based tools: PD-L1 and beyond. David L. Rimm, New Haven, CT

4:00 p.m.  Cancer immunoediting: Framing response and resistance in immunotherapy. Gavin P. Dunn, Saint Louis, MO

4:30 p.m.  Improving precision immuno-oncology using novel technologies. David A. Barbie, Boston, MA

**Room A313-314, Georgia World Congress Center**

**Modulating the Gut Microbiome to Treat Dysbiosis and Cancer**

**Chair:** Jonathan Braun, Los Angeles, CA

3:00 p.m.  Cancer therapeutics: A view from the microbiota. Christian Jobin, Gainesville, FL

3:30 p.m.  Dynamic monitoring of the dysbiotic microbiome. Jonathan Braun, Los Angeles, CA

4:00 p.m.  Identification and targeting of microbial vulnerabilities. Ami S. Bhatt, Stanford, CA

4:30 p.m.  Encapsulated fecal transplant: It’s not just for *Clostridium difficile* any more. Elizabeth L. Hohmann, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Room A411-412, Georgia World Congress Center

**Molecular Pathology for Cancer Researchers: Present and Future**

**Chair:** Angelo M. De Marzo, Baltimore, MD

- **3:00 p.m.** **Introduction.** Massimo F. Loda, New York, NY
- **3:10 p.m.** **Pathology for cancer researchers: An overview.** Jiaoti Huang, Durham, NC
- **3:35 p.m.** **Antibody validation of immunohistochemistry (IHC) and in situ hybridization assays in tissue: Pitfalls, tips, and techniques.** Angelo M. De Marzo, Baltimore, MD
- **4:00 p.m.** **Molecular pathology and diagnostics.** Andrea L. Richardson, Baltimore, MD
- **4:25 p.m.** **Computational pathology, imaging, and artificial intelligence.** Andrew H. Beck, Boston, MA

Room A305, Georgia World Congress Center

**Quantitative Approaches to Study Cancer Evolution and Heterogeneity**

**Chair:** John E. Dick, Toronto, ON, Canada

- **3:00 p.m.** **Tracking the arc of leukemia development from the beginning to the end.** John E. Dick, Toronto, ON, Canada
- **3:30 p.m.** **Quantifying clonal dynamics through treatment and metastasis.** Christina Curtis, Stanford, CA
- **4:00 p.m.** **Reconstructing the life history of cancers.** Moritz Gerstung, Hinxton, Cambridgeshire, United Kingdom
- **4:30 p.m.** **Evolution and heterogeneity in glioblastomas.** Raul Rabadan, New York, NY
FRIDAY, MARCH 29**

METHODS WORKSHOPS • 3:00 p.m.–5:00 p.m.
Room A302, Georgia World Congress Center

Controversies in Replication cfDNA Measurements

Chair: Paul T. Spellman, Portland, OR

3:00 p.m.  Key questions for ctDNA analysis. Paul T. Spellman, Portland, OR
3:30 p.m.  Title to be announced. Jamie Platt, Research Triangle Park, NC
4:00 p.m.  The dual roles of analytical and clinical data in ctDNA test validation. Justin Odegard, Redwood City, CA
4:30 p.m.  Title to be announced. Mark Sausen, Baltimore, MD

Room A311-312, Georgia World Congress Center

Game-Changing Technologies for High-Throughput Functional Characterization of Cancer Gene Variants

Chair: Rachel Karchin, Baltimore, MD

3:00 p.m.  Using large-scale mutagenesis to define cancer risk and understand inhibitor resistance. Douglas Fowler, Seattle, WA
3:30 p.m.  Escaping the confines of clinical genomics through massively parallel variant phenotyping. Cory Matthew Johannessen, Cambridge, MA
4:00 p.m.  Multiplexed functional assays to assess BRCA1 variants. Lea Starita, Seattle, WA
4:30 p.m.  CHASM plus reveals the scope of somatic missense mutations driving human cancers. Rachel Karchin, Baltimore, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
AWARDS AND LECTURES • 3:00 p.m.–6:30 p.m.
Off-site: Morehouse School of Medicine, National Center for Primary Care
AACR-MICR Distinguished Lectureship Series
The Impact of Global Health Research on Advancing Cancer Health Equity in the U.S.
Chair: Brian M. Rivers, Atlanta, GA
Speakers: Rick A. Kittles, Duarte, CA
Melissa B. Davis, Detroit, MI
Camille Ragin, Philadelphia, PA
Anna R. Giuliano, Tampa, FL

EDUCATIONAL SESSIONS • 5:15 p.m.–7:15 p.m.
Room A313-314, Georgia World Congress Center
Biomarker Studies: Study Design and Statistical Considerations
Chair: Shilin Zhao, Nashville, TN
5:15 p.m.  From discovery to clinics: Design considerations in biomarker studies. Yingye Zheng, Seattle, WA
5:45 p.m.  Needle in a haystack: Biomarker discovery in high-dimensional data. Shilin Zhao, Nashville, TN
6:15 p.m.  Precision oncology: Integrating biomarkers in phase III clinical trial designs. Antje Hoering, Seattle, WA
6:45 p.m.  Population risk stratification: Integrating biomarkers in cancer risk assessment. Ruth Pfeiffer, Bethesda, MD
**FRIDAY, MARCH 29**

**Educational Sessions (cont’d)**

Room A302, Georgia World Congress Center

**Genetic Predispositions to Childhood Leukemias: Implications for Pathogenesis and Screening**

**Chair:** Mignon L. Loh, San Francisco, CA

- **5:15 p.m.**  The inherited susceptibility to acute lymphoblastic leukemia: 10 years of genomic discovery. Jun J. Yang, Memphis, TN
- **5:45 p.m.**  Juvenile myelomonocytic leukemia: Learning from patients in a world without walls. Mignon L. Loh, San Francisco, CA
- **6:15 p.m.**  SAMD9 and SAMD9L: A new class of genetic predispositions to myeloid diseases in children. Jeffery Klco, Memphis, TN
- **6:45 p.m.**  Now what? Clinical implications of identifying a germline cancer predisposition. Junne Kamihara, Boston, MA

Room A311-312, Georgia World Congress Center

**Host versus Tumor Autophagy in Cancer**

**Chair:** Jayanta Debnath, San Francisco, CA

- **5:15 p.m.**  Autophagy and secretion in cancer. Jayanta Debnath, San Francisco, CA
- **5:45 p.m.**  Autophagy and pancreatic cancer. Alec C. Kimmelman, New York, NY
- **6:15 p.m.**  Autophagy in host and tumor metabolism. Eileen P. White, New Brunswick, NJ
- **6:45 p.m.**  Tumor cell-intrinsic roles of autophagy. Andrew M. Thorburn, Aurora, CO

Room A411-412, Georgia World Congress Center

**Intersection of Radiation and Immune Therapy**

**Chair:** Sandra Demaria, New York, NY

- **5:15 p.m.**  Clinical experience with radiotherapy in the context of immune checkpoint blockade. Michael A. Postow, New York, NY
- **5:45 p.m.**  Effects of radiation on tumor antigenicity and adjuvanticity: From mouse to human. Sandra Demaria, New York, NY
- **6:15 p.m.**  Interplay of DDR-targeting agents and oncolytic viruses with radiotherapy. Kevin J. Harrington, London, United Kingdom
- **6:45 p.m.**  Using smart materials to enhance in situ vaccination by radiation. Wilfred Ngwa, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
METHODS WORKSHOPS • 5:15 p.m.–7:15 p.m.
Sydney Marcus Auditorium, Building A, Georgia World Congress Center
Decoding Tumor Organ Systems with Single-Cell Transcriptomics

Chair: Nicholas E. Navin, Bellaire, TX

5:15 p.m.  Delineating human breast tissue architecture with single-cell genomics. Nicholas E. Navin, Bellaire, TX

5:45 p.m.  Single-cell lineage tracing dissects cellular states and plasticity in glioblastoma. Mario L. Suvà, Charlestown, MA

6:15 p.m.  Multidimensional single-cell analysis of the tumor microenvironment. Alexander Swarbrick, Darlinghurst, Australia

6:45 p.m.  Single-cell and spatial gene expression analysis of tumorigenesis. Itai Yanai, New York, NY
SATURDAY, MARCH 30**

EDUCATIONAL SESSIONS • 8:00 a.m.–10:00 a.m.
Room A313-314, Georgia World Congress Center
Characterizing Cancer Disparities Nationally and Internationally Using Publicly Available Data: Recent Advances
Chair: Folakemi T. Odedina, Orlando, FL
8:00 a.m. Introduction. Folakemi T. Odedina, Orlando, FL
8:05 a.m. The Surveillance, Epidemiology, and End Results (SEER) program. Kathy Cronin, Bethesda, MD
8:38 a.m. Integrating spatial science with SEER data. Trang M. VoPham, Boston, MA
9:08 a.m. Use of prospective approaches to characterize cancer registry data. Folakemi T. Odedina, Orlando, FL
9:38 a.m. Discussion

Room A311-312, Georgia World Congress Center
Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
Co-Chairs: Philip Jones, Houston, TX; Jim Bischoff, Basel, Switzerland
8:00 a.m. Discovery of BLU-667 for RET-driven cancers. Jason Brubaker, Cambridge, MA (not eligible for CME credit)
8:30 a.m. Discovery and development of USP7 inhibitors. Tim Harrison, Belfast, United Kingdom
9:00 a.m. Identification and optimization of chemical series that lead to discovery of erdafitinib: A potent pan-fibroblast growth factor receptor (FGFR) inhibitor. Patrick Angibaud, Val-de-Reuil, France
9:30 a.m. Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680. Jenna Jeffrey, Hayward, CA

Sydney Marcus Auditorium, Building A, Georgia World Congress Center
Coevolution of Tumor and Microenvironment in Cancer Metastasis
Chair: Kornelia Polyak, Boston, MA
8:00 a.m. Systems immunology and tumor microenvironment: Novel perspectives. Jérôme Galon, Paris, France
8:30 a.m. Blocking the heterotypic interactions of tumor and TME to control late-stage cancer. Dihua Yu, Houston, TX
9:00 a.m. Exploring the metastatic niche. Ilaria Malanchi, London, United Kingdom
9:30 a.m. Mechanisms underlying polyclonal metastases. Kornelia Polyak, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B312-314, Georgia World Congress Center

**The Evolution of the Art and Science of Go/No Go Decisions in Cancer Drug Development**

**Chair:** David S. Hong, Houston, TX

- **8:00 a.m.** The changing landscape of oncology drug development. David S. Hong, Houston, TX
- **8:15 a.m.** GO/NO GO decisions in cancer drug discovery: Has the decision-making process evolved? Nancy E. Kohl, Wellesley, MA
- **8:30 a.m.** Insights from a clinical development prediction algorithm: What we measure matters. David Feltquate, New York, NY (not eligible for CME credit)
- **8:45 a.m.** Pivotal decision making in oncology drug development: A perspective. Sandra J. Horning, San Francisco, CA

Room B405-407, Georgia World Congress Center

**Integrating Tools for Machine Learning in Cancer Image Analysis**

**Co-Chairs:** Christos Davatzikos, Philadelphia, PA; Saima Rathore, Philadelphia, PA

- **8:00 a.m.** Machine learning in imaging: Seeing the invisible. Christos Davatzikos, Philadelphia, PA; Saima Rathore, Philadelphia, PA
- **8:30 a.m.** Deep learning: Promises and challenges. Jayashree Kalpathy-Cramer, Charlestown, MA
- **9:00 a.m.** Deep learning for reading mammograms: State of the art and clinical implementation. Regina Barzilay, Cambridge, MA
- **9:30 a.m.** AI tools for computational pathology. Lee Cooper, Atlanta, GA

Georgia Ballroom 2, Building C, Georgia World Congress Center

**Metabolic Drivers of Cancer**

**Chair:** Karen H. Vousden, London, United Kingdom

- **8:00 a.m.** Regulation of ROS and cancer progression. Karen H. Vousden, London, United Kingdom
- **8:30 a.m.** The interplay between cancer metabolism and NRF2. Gina M. Denicola, Tampa, FL
- **9:00 a.m.** Metabolic control of tumor initiation. Jared Rutter, Salt Lake City, UT
- **9:30 a.m.** Mitophagy in tumor cell growth control and metastasis. Kay F. Mcleod, Chicago, IL
SATURDAY, MARCH 30**

Room B302-303, Georgia World Congress Center
**Stromal Niches for Organ-Tropic Metastasis**

Chair: Yibin Kang, Princeton, NJ

8:00 a.m.  Systemic consequences of the tumor-bone microenvironment: Implications for therapy. Theresa A. Guise, Indianapolis, IN

8:30 a.m.  A stromal gene program drives metastasis and immune evasion in colorectal cancer. Eduard Batlle Gomez, Barcelona, Spain

9:00 a.m.  Reactive neutrophils in the immunosuppressive metastatic microenvironment. Xin Lu, Notre Dame, IN

9:30 a.m.  Stromal niches for bone metastasis. Yibin Kang, Princeton, NJ

Thomas Murphy Ballroom, Building B, Georgia World Congress Center
**Tumor Immunology and Immunotherapy for Nonimmunologists: Standard Cancer Therapies Are Ultimately Immunotherapies**

Chair: Olivera J. Finn, Pittsburgh, PA

8:00 a.m.  Chemotherapy converting to immunotherapy. Laurence Zitvogel, Villejuif, France

8:30 a.m.  Radiotherapy as inducer of tumor immunity. Silvia C. Formenti, New York, NY

9:00 a.m.  Virotherapy as inducer of antitumor immunity. Michael C. Brown, Durham, NC

9:30 a.m.  Targeted therapy as ultimately immunotherapy. Ryan J. Sullivan, Boston, MA

Room A411-412, Georgia World Congress Center
**Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy**

Chair: Gabriele Bergers, Leuven, Belgium

8:00 a.m.  Improving immunotherapy of cancer by normalizing tumor vessels. Rakesh K. Jain, Boston, MA

8:30 a.m.  Inducing high-endothelial venules in cancer to improve immunotherapy. Gabriele Bergers, Leuven, Belgium

9:00 a.m.  Targeting the tumor microenvironment for treatment of chemoresistant desmoplastic colon cancer. Tatiana Petrova, Lausanne, Switzerland

9:30 a.m.  Clinical development of antiangiogenic and immune checkpoint blockade combinations. F. Stephen Hodi, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

66  AACR ANNUAL MEETING 2019
METHODS WORKSHOPS • 8:00 a.m.–10:00 a.m.

Room B206, Georgia World Congress Center

Clinical Trial Design: Part 1: The ABCs of Doing Cancer Clinical Trials

Cochairs: Patricia M. LoRusso, New Haven, CT; Mithat Gonen, New York, NY

8:00 a.m. How to develop trial objectives: Translation of science from bench to bedside to bench. Patricia M. LoRusso, New Haven, CT

8:30 a.m. Modernizing eligibility criteria for oncology clinical trials. Tatiana Prowell, Silver Spring, MD

9:00 a.m. Title to be announced. Mithat Gonen, New York, NY

9:30 a.m. Designing meaningful and impactful clinical trials. Jyoti D. Patel, Chicago, IL

Georgia Ballroom 1, Building C, Georgia World Congress Center

Designing Biomarker Studies to Achieve Desired Clinical Applications

Chair: Christopher I. Li, Seattle, WA

8:00 a.m. Introduction. Christopher I. Li, Seattle, WA

8:05 a.m. Intended clinical application drives your study design: Principles and operational considerations. Ziding Feng, Seattle, WA

8:40 a.m. Evaluating biomarkers for prognostic enrichment of clinical trials. Kathleen Kerr, Seattle, WA

9:20 a.m. Deriving early detection biomarker performance goals by setting a minimum benefit-to-harm ratio. Steven J. Skates, Boston, MA

CANCER AND BIOMEDICAL RESEARCH CAREER FAIR

9:00 a.m.–3:00 p.m.

Room B401, Georgia World Congress Center

Registration: 8:00 a.m.-2:00 p.m.
SATURDAY, MARCH 30**

PROFESSIONAL ADVANCEMENT SESSION • 9:00 a.m.–4:00 p.m.
Grand Ballroom, Omni Hotel
Fourteenth Annual AACR Undergraduate Student Caucus and Poster Competition
(not eligible for CME credit)
Chair: Kathleen W. Scotto, New Brunswick, NJ

9:40 a.m. Special remarks from the AACR President. Elizabeth M. Jaffee, Baltimore, MD
9:55 a.m. Navigating the Annual Meeting. John D. Carpten, Los Angeles, CA
10:10 a.m. Understanding cancer. Ernest T. Hawk, Houston, TX
10:30 a.m. Message from an advocate. Speaker to be announced
10:45 a.m. Remarks from lead judge and introduction of judges. Beverly Lyn-Cook, Jefferson, AR
11:00 a.m. Poster session
1:30 p.m. Break and lunch
2:00 p.m. Professional development panel and Q&A. Moderator: Jose G. Trevino, Gainesville, FL
3:00 p.m. Remarks from 2018 First Place Miller Prize Winner. Jane Pearce, Chapel Hill, NC
3:05 p.m. Presentation of Margaret Foti Foundation Undergraduate Prizes for Cancer Research. Margaret Foti, Philadelphia, PA
3:50 p.m. Closing remarks and evaluation

EDUCATIONAL SESSIONS • 10:15 a.m.–12:15 p.m.
Room A311-312, Georgia World Congress Center
Chemistry to the Clinic: Part 2: Novel Chemical Tools and Leads for Unprecedented Targets
Co-chairs: Sara J. Buhrlage, Boston, MA; John Yuan Wang, Andover, MA

10:15 a.m. Introduction. Sara Buhrlage, Boston, MA
10:20 a.m. Covalent inhibitors on demand—computational and empirical covalent ligand discovery. Nir London, Rehovot, Israel
10:50 a.m. Targeting the spliceosome: Perspectives from structural biology. Nicholas Larsen, Cambridge, MA
11:20 a.m. The dTAG system: Engineering immediate and selective protein degradation. Behnam Nabet, Boston, MA
11:50 a.m. Enabling in vivo studies with ADME-challenged tool compounds. Joachim Rudolph, South San Francisco, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B312-314, Georgia World Congress Center

Diverse Functions of Neutrophils in Cancer

Chair: Mikala Egeblad, Cold Spring Harbor, NY

10:15 a.m. Neutrophil adaptation to the cancer niche. Daniel W. McVicar, Frederick, MD
10:45 a.m. Neutrophils direct tumor cell fate in squamous lung cancer. Trudy G. Oliver, Salt Lake City, UT
11:15 a.m. Neutrophils contribute to anti-PD1 treatment failures in NSCLC. McGarry Houghton, Seattle, WA
11:45 a.m. Epithelial-to-mesenchymal transition renders tumor cells susceptible to neutrophil cytotoxicity. Zvika Granot, Jerusalem, Israel

Room B405-407, Georgia World Congress Center

The Endothelium and Fluid Flows: Linking Metastasis and Immunity

Chair: Amanda Waite Lund, Portland, OR

10:15 a.m. Introduction. Amanda Waite Lund, Portland, OR
10:20 a.m. The endothelial niche in metastasis and hematopoiesis. Shahin Rafii, New York, NY
10:50 a.m. The hemodynamics of metastasis. Sébastien Harlepp, Strasbourg Cedex, France
11:20 a.m. Tumor lymphatic drug delivery and bioengineering. Susan N. Thomas, Atlanta, GA
11:50 a.m. Lymphatic transport and antitumor immunity. Amanda Waite Lund, Portland, OR

Room A305, Georgia World Congress Center

Extracellular Vesicles and Intercellular Communication in Cancer

Chair: Alissa M. Weaver, Nashville, TN

10:15 a.m. EV cargo selection and its regulation by oncogenic signaling. Alissa M. Weaver, Nashville, TN
10:45 a.m. Large oncosomes in cancer intercellular communication. Dolores Di Vizio, Los Angeles, CA
11:15 a.m. Genome-wide interrogation of extracellular vesicle biology using artificial barcoded microRNAs. Suzanne Pfeffer, Stanford, CA
11:45 a.m. The exosomes in immune suppression and tumor progression. Wei Guo, Philadelphia, PA
SATURDAY, MARCH 30**

Educational Sessions (cont’d)

Room B302-303, Georgia World Congress Center
**Fibroblasts in the Driver’s Seat: Impact on Tumor Progression and Therapy Resistance**

**Chair:** Sheila A. Stewart, St. Louis, MO

10:15 a.m.  **The stromagenic switch and establishment of a tumor hospitable environment.** Ellen Puré, Philadelphia, PA

10:45 a.m.  **Role of fibroblast heterogeneity in immunosuppression in breast cancer.** Fatima Mechta-Grigoriou, Paris, France

11:15 a.m.  **Shaping the inflammatory niche: Cancer-associated fibroblasts facilitate breast cancer metastasis.** Neta Erez, Tel Aviv, Israel

11:45 a.m.  **The stromal p38-MK2 pathway supports tumor progression.** Sheila A. Stewart, St. Louis, MO

Room B304-305, Georgia World Congress Center
**Fluorescence Image-Guided Surgery for Improved Clinical Outcomes**

**Chair:** Summer L. Gibbs, Portland, OR

10:15 a.m.  **Title to be announced.** Summer L. Gibbs, Portland, OR

10:45 a.m.  **Microdose clinical trials update with fluorescent anti-EGFR Affibody ABY-029.** Brian W. Pogue, Hanover, NH

11:15 a.m.  **Optical and optoacoustic imaging: A hyperloop mechanism for drug development and optical tracer evaluation.** Gooitzen M. Van Dam, Groningen, Netherlands

11:45 a.m.  **Title to be announced.** Jason M. Warram, Birmingham, AL

Georgia Ballroom 2, Building C, Georgia World Congress Center
**From Cancer Genomics to the 3D Organization of the Genome**

**Chair:** Elisa Oricchio, Lausanne, Switzerland

10:15 a.m.  **Cancer genetic and epigenetic alterations modify the genome topology.** Elisa Oricchio, Lausanne, Switzerland

10:55 a.m.  **STAG2 mutations alter cohesin complex structure and function and provide therapeutic vulnerabilities in leukemia.** Zuzana Tothova, Boston, MA

11:35 a.m.  **Structural variants in the cancer genome: A 3D analysis.** Jesse Dixon, La Jolla, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Room A313, Georgia World Congress Center
**Integrating Tumor Immunology and Molecular Epidemiology**

**Chair:** Melissa L. Bondy, Houston, TX

**10:15 a.m.**  **Introduction.** Melissa L. Bondy, Houston, TX

**10:20 a.m.**  **“Integration of immunology (+ microbiology and genomics) into epidemiology” 101.** Shuji Ogino, Boston, MA

**10:55 a.m.**  **Immune analysis of ovarian cancer: Multiple datasets, multiple datatypes.** Ellen L. Goode, Rochester, MN

**11:30 a.m.**  **Computational modeling of tumor immunology from bulk RNA-seq data.** X. Shirley Liu, Boston, MA

Room A404-405, Georgia World Congress Center
**Regulatory Science and Policy Session**
**Impact of a Brexit on Oncology Drug Development and Regulation**

**Chair:** C. Simone Fishburn, Redwood City, CA

**Speakers:** Susan M. Galbraith, Cambridge, United Kingdom  
Joanna M. Hackett, London, United Kingdom  
John S. Haurum, Cambridge, United Kingdom  
Richard M. Marais, Manchester, United Kingdom

Room A402-403, Georgia World Congress Center
**Science Policy Session**
**Making Your Voice Heard: How to Effectively Advocate for Cancer Research and Science-Based Policy**

**Chair:** George J. Weiner, Iowa City, IA

**Panelists:** Brittany A. Avin, Baltimore, MD  
Billy Foster, Gary, IN  
Andreana N. Holowatyj, Salt Lake City, UT  
Jon G. Retzlaff, Washington, DC

Georgia Ballroom 3, Building C, Georgia World Congress Center
**Oncolytic Virus Therapy**

**Chair:** Smita K. Nair, Durham, NC

**10:15 a.m.**  **Exploiting virus biology to create anticancer therapeutics.** Smita K. Nair, Durham, NC

**10:45 a.m.**  **Title to be announced.** John C. Bell, Ottawa, ON, Canada

**11:15 a.m.**  **Title to be announced.** Donald M. McDonald, San Francisco, CA
SATURDAY, MARCH 30**

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

Sydney Marcus Auditorium, Building A, Georgia World Congress Center

**Personalized Circulating Tumor DNA Analysis for Minimal Residual Disease Detection**

**Chair:** Muhammed Murtaza, Phoenix, AZ

10:15 a.m. High-accuracy personalized detection of residual disease using circulating tumor DNA analysis. Muhammed Murtaza, Phoenix, AZ

10:45 a.m. Genome-wide mutational integration for ultra-sensitive circulating tumor DNA detection. Daniel Landau, New York, NY

11:15 a.m. Exploiting ctDNA biology and personalized sequencing for sensitive detection of residual disease. Christopher G. Smith, Cambridge, United Kingdom

11:45 a.m. Application of circulating tumor DNA analysis as a biomarker in resectable non-small cell lung cancer. Christopher Abbosh, London, United Kingdom

Room A411-412, Georgia World Congress Center

**Precision Medicine in 2019**

**Chair:** Shivaani Kummar, Palo Alto, CA

10:15 a.m. Immune-based therapies: Predictors of benefit. Mario Sznol, New Haven, CT

10:40 a.m. Genomic profiling—identifying drivers. Funda Meric-Bernstam, Houston, TX

11:05 a.m. Companion and complementary diagnostics to inform drug development and approval. Gideon Blumenthal, Silver Spring, MD

11:30 a.m. Practicing precision medicine: One patient at a time. Shivaani Kummar, Palo Alto, CA

11:55 a.m. Panel discussion

Thomas Murphy Ballroom, Building B, Georgia World Congress Center

**Tumor Immunology and Immunotherapy for Nonimmunologists: Roundtable Discussions**

**Chair:** Thomas F. Gajewski, Chicago, IL

**Table 1:** Turning cold tumors hot. Thomas F. Gajewski, Chicago, IL

**Table 2:** Cancer vaccines: Cancer immunoprevention. Olivera J. Finn, Pittsburgh, PA

**Table 3:** The microbiome in cancer. Laurence Zitvogel, Villejuif, France

**Table 4:** Combinations of radiotherapy with immunotherapy. Silvia C. Formenti, New York, NY

**Table 5:** Oncolytic viruses. Michael C. Brown, Durham, NC

**Table 6:** Immunotherapy toxicity. Ryan J. Sullivan, Boston, MA

**Table 7:** Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures. James P. Allison, Houston, TX

**Table 8:** Engineering T cells for tumor therapy. Philip D. Greenberg, Seattle, WA

**Table 9:** T-cell therapy. Patrick Hwu, Houston, TX

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Table 10: CAR T cells. Carl H. June, Philadelphia, PA
Table 11: Biomarkers for response versus resistance. Jason J. Luke, Chicago, IL
Table 12: Advanced immunophenotyping of clinical samples. Alexander Swarbrick, Darlinghurst, Australia
Table 13: Translational biomarkers for cancer immunotherapy. Cornelia L. Trimble, Baltimore, MD
Table 14: Topic to be announced. Marc S. Ernstoff, Buffalo, NY
Table 15: Tumor-derived exosomes as biomarkers of cancer progression and reprogramming of the host immune system. Theresa L. Whiteside, Pittsburgh, PA
Table 16: Immune checkpoint therapy. Padmanee Sharma, Houston, TX
Table 17: Topic to be announced. Faculty to be announced.
Table 18: Intratumoral immunotherapies: Bringing the fight to the tumor. Joshua D. Brody, New York, NY
Table 19: Topic to be announced. Scott J. Antonia, Durham, NC
Table 20: Myeloid-derived suppressor cells. Dmitry I. Gabrilovich, Philadelphia, PA

METHODS WORKSHOPS • 10:15 a.m.–12:15 p.m.
Room B206, Georgia World Congress Center
Clinical Trial Design: Part 2: Novel Trial Designs
Cochairs: Patricia M. LoRusso, New Haven, CT; Mithat Gonen, New York, NY
10:15 a.m.  Title to be announced. Michael A. Carducci, Baltimore, MD
10:40 a.m.  Title to be announced. Marc Theoret, Silver Spring, MD
11:10 a.m.  Title to be announced. Alexia Iasonos, New York, NY
11:40 a.m.  Title to be announced. Lorenzo Trippa, Boston, MA

Georgia Ballroom 1, Building C, Georgia World Congress Center
Methods to Study Metabolism for Cancer Research
Chair: Matthew G. Vander Heiden, Cambridge, MA
10:15 a.m.  Importance of tissue context in understanding metabolic vulnerabilities. Matthew G. Vander Heiden, Cambridge, MA
10:40 a.m.  Title to be announced. Joshua D. Rabinowitz, Princeton, NJ
10:55 a.m.  Title to be announced. Thales Papagiannakopoulos, New York, NY
11:40 a.m.  Quantifying lipogenesis in tumors, tissues, and cells. Christian Metallo, La Jolla, CA
**EDUCATIONAL SESSIONS • 1:00 p.m.–3:00 p.m.**

Thomas Murphy Ballroom, Building B, Georgia World Congress Center
**CAR-T, TCR, and Beyond: A Rapidly Evolving Revolution in Cancer Cellular Immunotherapeutics**

Chair: Joseph McGuirk, Westwood, IL

1:00 p.m. **CAR T: A brief historical perspective.** Joseph McGuirk, Westwood, IL

1:05 p.m. **CAR-T cells in the clinic: Strategies to enhance efficacy and reduce toxicity.** Saad J. Kenderian, Rochester, MN

1:30 p.m. **Boutique to global regulatory approval: Constantly enhancing and improving engineered T cells.** Bruce Levine, Philadelphia, PA

2:00 p.m. **Lessons learned from comparing CD28 and 4-1BB-based CD19 CARs.** Michel Sadelain, New York, NY

2:30 p.m. **The future of CAR T: Allogeneic approach.** Ewelina Morawa, Cambridge, MA (not eligible for CME credit)

Room A311-312, Georgia World Congress Center
**Chemistry to the Clinic: Part 3: Unconventional Modalities to Extend the Antitumor Target Space**

Cochairs: Michael Brands, Berlin, Germany; Zhao-Kui Wan, Hangzhou, China

1:00 p.m. **Expanding and integrating the chemical modality space for challenging therapeutic targets.** Eric Valeur, Mondal, Sweden

1:30 p.m. **Macrocyclic peptide model system: Permeability screening tools and predictive design rules.** Tomi Sawyer, Boston, MA

2:00 p.m. **Macrocyclic natural product-based therapeutics.** Frank Fang, Andover, MA

2:30 p.m. **Structural principle of small molecule–mediated ubiquitin ligase targeting.** Eric Sebastian Fischer, Boston, MA

Room A404-405, Georgia World Congress Center
**Regulatory Science and Policy Session**
**East Looks West: Chinese Pharma Explores Western Markets**

Chair: Joshua L. Berlin, Redwood City, CA

Speakers: Frank Jiang, Shanghai, China
Joan Shen, Shanghai, China
Dan Zhang, Beijing, China

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Room A402-403, Georgia World Congress Center  
**Regulatory Science and Policy Session**  
**FDA 201—Topics in Oncology Regulation**

**Cochairs:** Lola A. Fashoyin-Aje, Silver Spring, MD; Harpreet Singh, Silver Spring, MD  
**Speakers:** R. Angelo de Claro, Silver Spring, MD  
Nicole J. Gormley, Silver Spring, MD  
Ke Liu, Silver Spring, MD  
Pallavi Mishra-Kalyani, Silver Spring, MD  
Rajeshwari Sridhara, Silver Spring, MD

Room B405, Georgia World Congress Center  
**Features and Functions of the Pancreatic Tumor Microenvironment**

**Chair:** Mara H. Sherman, Portland, OR

1:00 p.m.  **Origins and roles of pancreatic cancer fibroblasts.** Mara H. Sherman, Portland, OR

1:30 p.m.  **Metabolic regulation of the tumor microenvironment.** Cosimo Commissio, La Jolla, CA

2:00 p.m.  **Title to be announced.** Marina Pasca Di Magliano, Ann Arbor, MI

2:30 p.m.  **Title to be announced.** Florencia Mcallister, Houston, TX

Room A411-412, Georgia World Congress Center  
**Obesity: The Effects of Local and Systemic Inflammation on Cancer**

**Chair:** Ernst R. Lengyel, Chicago, IL

1:00 p.m.  **Introduction: A brief overview of adipose tissue metabolism.** Ernst R. Lengyel, Chicago, IL

1:05 p.m.  **Paracrine role of mammary adipocytes in breast cancer progression and drug resistance.** Catherine Muller, Toulouse, France

1:30 p.m.  **The contribution of adipose fatty acid binding protein in cancer progression.** Bing Li, Louisville, KY

2:00 p.m.  **Adipose stromal cell role in EMT and chemoresistance.** Mikhail Kolonin, Houston, TX

2:30 p.m.  **Cancer and obesity: Stromal contributions of adipocytes to cancer progression.** Philipp E. Scherer, Dallas, TX
Georgia Ballroom 1, Building C, Georgia World Congress Center

**Preleukemia and Clonal Hematopoiesis**

**Chair:** Benjamin L. Ebert, Boston, MA

1:00 p.m. **The genetics and biology of clonal hematopoiesis.** Benjamin L. Ebert, Boston, MA

1:40 p.m. **Prediction of AML evolution from age-related clonal hematopoiesis.** Liran Shlush, Rehovot, Israel

2:20 p.m. **Clonal hematopoiesis in human aging and disease.** Siddhartha Jaiswal, Stanford, CA

Georgia Ballroom 2, Building C, Georgia World Congress Center

**Resistance to Therapies and Cancer Cell Dormancy**

**Chair:** Douglas T. Fearon, Cold Spring Harbor, NY

1:00 p.m. **Drug tolerance and lineage plasticity in colorectal cancer.** Livio Trusolino, Candiolo, Italy

1:30 p.m. **Evolution of acquired resistance to targeted therapies in lung cancer.** Aaron N. Hata, Charlestown, MA

2:00 p.m. **From residual disease to resistant tumors: The evolution of therapeutic resistance in melanoma.** Willy Hugo, Los Angeles, CA

2:30 p.m. **Title to be announced.** Douglas T. Fearon, Cold Spring Harbor, NY

Room B312-314, Georgia World Congress Center

**Single-Cell and Spatial Genomics**

**Chair:** Andrew Adey, Portland, OR

1:00 p.m. **Title to be announced.** Andrew Adey, Portland, OR

1:30 p.m. **Title to be announced.** Long Cai, Pasadena, CA

2:00 p.m. **Title to be announced.** Andrew Adey, Portland, OR

2:30 p.m. **Title to be announced.** Speaker to be announced

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

76  AACR ANNUAL MEETING 2019
Room B302-303, Georgia World Congress Center

Update on Young Women’s Breast Cancer

Chair: Pepper Jo Schedin, Portland, OR

1:00 p.m. Common perceptions, misconceptions of young women’s breast cancer. Pepper Jo Schedin, Portland, OR

1:30 p.m. Risk factors for early-onset BrCa: An epidemiologic perspective. Traci N. Bethea, Boston, MA

2:00 p.m. Defining the impact of a postpartum diagnosis on metastasis and the clinical features underlying risk: A young women’s breast cancer cohort study. Virginia F. Borges, Aurora, CO

2:30 p.m. Power of mouse models to decipher underlying biology of YWBC. Doris Germain, New York, NY

METHODS WORKSHOPS • 1:00 p.m.–3:00 p.m.

Room B206, Georgia World Congress Center

Clinical Trial Design: Part 3: Biomarker-Directed Clinical Trials

Cochairs: Patricia M. LoRusso, New Haven, CT; Mithat Gonen, New York, NY

1:00 p.m. Title to be announced. Lisa H. Butterfield, Pittsburgh, PA

1:30 p.m. Title to be announced. Timothy A. Yap, Houston, TX

2:00 p.m. Title to be announced. Lindsay A. Renfro, Los Angeles, CA

Georgia Ballroom 3, Building C, Georgia World Congress Center

Deciphering and Targeting Lysosomes in Cancer

Chair: Rushika M. Perera, San Francisco, CA

1:00 p.m. Development of novel targeted lysosomal inhibitors. Ravi Amaravardi, Philadelphia, PA

1:30 p.m. Monitoring and maintaining lysosomal integrity. Phyllis I. Hanson, Ann Arbor, MI

2:00 p.m. Reconstituting mTORC1 signaling at the lysosomes. Roberto Zoncu, Berkeley, CA

2:30 p.m. Proteomics-based approaches to studying cancer lysosomes. Rushika M. Perera, San Francisco, CA
SATURDAY, MARCH 30**

Room B304-305, Georgia World Congress Center

Methods for Utilizing the Microbiome in Cancer Epidemiology Research

**Chair:** Dominique S. Michaud, Boston, MA

1:00 p.m.  **Introduction.** Dominique S. Michaud, Boston, MA

1:00 p.m.  **Moving microbiome research into population studies: Need for standardization.** Rashmi Sinha, Bethesda, MD

1:30 p.m.  **Microbiome data science and reproducibility with QIIME 2.** Joslynn S. Lee, Chevy Chase, MA

2:00 p.m.  **Statistical analysis of microbiome data: Challenges and solutions.** Jun Chen, Rochester, MN

2:30 p.m.  **Guild-based analysis for ecological understanding of the causative role of gut microbiota in human health and diseases.** Liping Zhao, New Brunswick, NJ

EDUCATIONAL SESSIONS • 3:15 p.m.–5:15 p.m.

Room A402-403, Georgia World Congress Center

Regulatory Science and Policy Session

Cancer Genomic Reference Samples: MDIC Somatic Reference Sample Collaborative Initiative

**Chair:** Zivana Tezak, Silver Spring, MD

**Speakers:** J.D. Alvarez, Spring House, PA
Chris A. Karlovich, Frederick, MD
Diana M. Merino, Washington, DC
Wenming Xiao, Silver Spring, MD
Barbara A. Zehnbauer, Atlanta, GA

Room B312-314, Georgia World Congress Center

ctDNA for Cancer Stratification, Monitoring, Clonal Tracking, MRD Detection, and Early Diagnosis

**Chair:** Carlos M. Caldas, Cambridge, United Kingdom

3:15 p.m.  **ctDNA and cfDNA in body fluids as cancer biomarkers.** Nickolas Papadopoulos, Baltimore, MD

3:45 p.m.  **ctDNA monitoring in hematologic malignancies.** Sarah-Jane Dawson, East Melbourne, Australia

4:45 p.m.  **ctDNA applications in both early and metastatic breast cancer.** Carlos M. Caldas, Cambridge, United Kingdom

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

**AACR ANNUAL MEETING 2019**
Room B304-305, Georgia World Congress Center

**Functional Follow-Up of Microbiome Associations for Cancer Epidemiology Studies**

**Chair:** Wendy Cozen, Los Angeles, CA

- **3:15 p.m.** Metabolomic profiling: Biochemicals as a vector for host microbiome interactions. Jason Kinchen, Durham, NC  
  (not eligible for CME credit)
- **3:45 p.m.** Defining function beyond -omics in studies of the microbiome. William R. DePaolo, Seattle, WA
- **4:15 p.m.** Title to be announced. Scott Bultman, Chapel Hill, NC
- **4:45 p.m.** Title to be announced. Ami S. Bhatt, Stanford, CA

Room A411-412, Georgia World Congress Center

**Molecular Regulation of Cancer Inflammation, Progression, and Treatment Resistance**

**Chair:** Lisa M. Coussens, Portland, OR

- **3:15 p.m.** ER stress responses shape the tumor immunoenvironment. Juan R. Cubillos-Ruiz, New York, NY
- **3:45 p.m.** The role of NFkB in endocrine and castration resistance. Nikki A. Delk, Richardson, TX
- **4:15 p.m.** The dark side of cGAS-STING signaling in cancer. Eileen E. Parkes, Belfast, United Kingdom
- **4:45 p.m.** Antitumor antibodies control tumors depending on innate and adaptive immune sensing. Yang-Xin Fu, Dallas, TX

Room A313-314, Georgia World Congress Center

**Ordering Genomic Changes as Actionable Targets in Pediatric Cancers**

- **3:15 p.m.** Introduction to pediatric cancer somatic genomics and the UCSF experience in clinical genomics of pediatric cancer. Alejandro Sweet-Cordero, San Francisco, CA
- **3:45 p.m.** Precision medicine in the pediatric oncology clinic: Moving from feasibility to clinical impact. Katherine A. Janeway, Boston, MA
- **4:15 p.m.** From extensive molecular characterization to molecular guided therapies: The challenges of defining molecular targets in pediatric cancer. Gudrun Schleiermacher, Paris, France
- **4:45 p.m.** Actionable alterations across 700 high-risk pediatric tumors: Insights from the international INFORM personalized medicine study. David T. W. Jones, Heidelberg, Germany
SATURDAY, MARCH 30**

Organoids as Model Systems in Cancer

Chair: David A. Tuveson, Cold Spring Harbor, NY

3:15 p.m. Organoid models to study pancreatic cancer. David A. Tuveson, Cold Spring Harbor, NY

3:45 p.m. Potentials and pitfalls of organoid technology to study prostate cancer. Yu Chen, New York, NY

4:15 p.m. Patient-derived organoid models of bladder cancer. Michael M. Shen, New York, NY

4:45 p.m. Organoid modeling of tumor immunotherapy. Calvin J. Kuo, Stanford, CA

Systems Biology Approaches to Cancer

Chair: Laura M. Heiser, Portland, OR

3:15 p.m. Modeling cancer cell signaling pathways. Melissa L. Kemp, Atlanta, GA

3:45 p.m. Studying the influence of the tumor microenvironment. Gurinder Atwal, Cold Spring Harbor, NY

4:15 p.m. Understanding the role of cancer heterogeneity. Laura M. Heiser, Portland, OR

4:45 p.m. Predicting therapeutic sensitivity and resistance. James C. Costello, Aurora, CO

Regulatory Science and Policy Session

West Looks East: Western Pharma Explores the China Mainland

Chair: Ke Liu, Silver Spring, MD

Speakers: George Chen, Shanghai, China
          Xiaoyuan Chen, Beijing, China
          Fangning Zhang, Beijing, China

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
METHODS WORKSHOPS • 3:15 p.m.–5:15 p.m.

Georgia Ballroom 3, Building C, Georgia World Congress Center

**BRCA1 Variants of Unknown Significance (VUS): New Vistas in the Assessment of Cancer Risk**

**Chair:** Roy A. Jensen, Kansas City, KS

- **3:15 p.m.**  **BRCA1: We have come a long way, baby.** Roy A. Jensen, Kansas City, KS
- **3:45 p.m.**  **Risk assessment for carriers of BRCA variants of uncertain significance (VUS).** Fergus J. Couch, Rochester, MN
- **4:05 p.m.**  **High-throughput analysis of BRCA1 variants for function in DNA repair.** Jeffrey D. Parvin, Columbus, OH
- **4:25 p.m.**  **VUS: Why they matter.** Susan M. Domchek, Philadelphia, PA
- **4:45 p.m.**  **Panel discussion**

Room B302-303, Georgia World Congress Center

**Modeling Tumor Dormancy**

**Cochairs:** Maria S. Sosa, New York, NY; James V. Alvarez, Durham, NC

- **3:15 p.m.**  **Animal models to study tumor cell dormancy and their clinical relevance.** Maria S. Sosa, New York, NY
- **3:45 p.m.**  **Using intravital imaging to investigate tumor cell dissemination, dormancy, and metastasis in living animals, in situ, and with single-cell resolution.** David Entenberg, Bronx, NY
- **4:15 p.m.**  **Title to be announced.** Shelly R. Peyton, Amherst, MA
- **4:45 p.m.**  **Title to be announced.** James V. Alvarez, Durham, NC
SATURDAY, MARCH 30**

Georgia Ballroom 2, Building C, Georgia World Congress Center

**Novel Imaging Strategies in the Metastatic Niche**

**Chair:** Vicki Plaks, San Francisco, CA

**Georgia Ballroom 2, Building C, Georgia World Congress Center**

**3:15 p.m.**  Ex vivo live imaging of the lung metastatic niche in mice to enable immunoncology drug discovery. Vicki Plaks, San Francisco, CA

**3:45 p.m.**  Intravital microscopy insights in niche-dependent and niche-independent metastatic growth. Jacco Van Rheenen, Utrecht, Netherlands

**4:15 p.m.**  Multimodal imaging and therapeutic delivery in cancer. Katherine W. Ferrara, Palo Alto, CA

**4:45 p.m.**  Imaging tumor metabolism using hyperpolarized 13C-magnetic resonance spectroscopy. Pavithra Viswanath, San Francisco, CA

**Georgia Ballroom 1, Building C, Georgia World Congress Center**

**Sample Size and Power Workshop for Basic, Translational, and Clinical Studies**

**Chair:** Jessica Minnier, Portland, OR

**3:15 p.m.**  Is n=3 enough? How to approach sample size and power calculations. Jessica Minnier, Portland, OR

**3:45 p.m.**  Integrated platform for designing clinical trials. Ying Yuan, Houston, TX

**4:15 p.m.**  Power in multiple testing: Sample size calculations for differential expression analysis of RNA-seq data. Yu Shyr, Nashville, TN

**4:45 p.m.**  Power and sample size for multilevel and longitudinal study designs. Deborah Glueck, Aurora, CO

**AWARDS AND LECTURES • 4:15 p.m.–4:30 p.m.**

Room A311-312, Georgia World Congress Center

**Special WICR Presentation Honoring Dr. Charlotte Friend**

(not eligible for CME credit)

**Chair:** Lucile L. Adams-Campbell, Washington, DC

---

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.
Room A311-312, Georgia World Congress Center
AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship
Leveraging biologic insights to prevent and treat head and neck cancer. Jennifer Rubin Grandis, San Francisco, CA

SPECIAL SESSION • 5:15 p.m.–6:15 p.m.
Room A311-312, Georgia World Congress Center
AACR-WICR: 20th Anniversary: Celebrating Women in Cancer Research
(not eligible for CME credit)
Chair: Lucile L. Adams-Campbell, Washington, DC

PROFESSIONAL ADVANCEMENT SESSION • 5:30 p.m.–7:30 p.m.
Atrium Ballroom A - Marriott
Careers in Clinical and Translational Cancer Research Roundtable
(not eligible for CME credit)
Mentors: Alex A. Adjei, Rochester, MN
Nilofer S. Azad, Baltimore, MD
Edward J. Benz, Boston, MA
Susan E. Critchlow, Macclesfield, United Kingdom
William S. Dalton, Tampa, FL
Ethan Dmitrovsky, Frederick, MD
James H. Doroshow, Bethesda, MD
William N. Hait, Raritan, NJ
S. Percy Ivy, Bethesda, MD
Douglas R. Lowy, Bethesda, MD
David Malkin, Toronto, ON, Canada
Jeffrey A. Moscow, Bethesda, MD
Edith A. Perez, Jacksonville, FL
Sudhir Srivastava, Rockville, MD
SUNDAY, MARCH 31**

MEET-THE-EXPERT SESSIONS • 7:00 a.m.–8:00 a.m.

Room B206, Georgia World Congress Center
Automated Identification of Induced Germline Mutations that Cause Phenotype in Mice
Bruce Beutler, Dallas, TX

Room A302, Georgia World Congress Center
Basic Immunology
Adrian Hayday, London, United Kingdom

Room A315-316, Georgia World Congress Center
Chemical Methods to Decipher the Role of Individual Kinases and Their Cellular Signaling Networks
Kevan M. Shokat, San Francisco, CA

Georgia Ballroom 3, Building C, Georgia World Congress Center
Combination Immunotherapies
Eric H. Rubin, North Wales, PA
(not eligible for CME credit)

Room A313-314, Georgia World Congress Center
Computationally Assessing the Origins of Tumor Aggressivity
Paul C. Boutros, Los Angeles, CA

Room C302, Georgia World Congress Center
DNA Damage Responses: Canonical to Noncanonical
Michael B. Kastan, Durham, NC

Room B401, Georgia World Congress Center
Drug Development
William Pao, Basel, Switzerland

Room A404, Georgia World Congress Center
Genomic Configurations in Cancer: Implications for Diagnosis and Therapy
Edison T. Liu, Bar Harbor, ME

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B304-305, Georgia World Congress Center
**High-Dimensional Single-Cell Mass Cytometry in Translational Cancer Research**
Kara L. Davis, Stanford, CA

Room A305, Georgia World Congress Center
**Lung Cancer: Trials**
Alice T. Shaw, Boston, MA

Room A311-312, Georgia World Congress Center
**Title to Be Announced**
Pier Paolo Pandolfi, Boston, MA

Room A404-405, Georgia World Congress Center
**Title to Be Announced**
Scott A. Armstrong, Boston, MA

Room B302-303, Georgia World Congress Center
**Universal Cancer Biomarker: Are We There Yet?**
Matt Trau, Brisbane, Australia

---

**NCI/NIH-SPONSORED SESSION • 7:00 a.m.–8:00 a.m.**

Room A406-407, Georgia World Congress Center

**NIH Grants Session: Changes in Review, Funding, and Funding Opportunities at the NCI**
*(not eligible for CME credit)*

**Chair:** Daniel L. Gallahan, Bethesda, MD

- **7:00 a.m.** NIH grants session: Changes in review, funding, and funding opportunities at the NCI. Amy L. Rubenstein, Bethesda, MD
- **7:20 a.m.** NIH grants session: Changes in review, funding, and funding opportunities at the NCI. Daniel L. Gallahan, Bethesda, MD
- **7:40 a.m.** Discussion
SUNDAY, MARCH 31**

OPENING CEREMONY • 8:00 a.m.–9:15 a.m.

Hall A, Georgia World Congress Center
(not eligible for CME credit)

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.

Highlights of the Opening Ceremony include:

• Remarks from AACR CEO Margaret Foti and AACR President Elizabeth M. Jaffee
• AACR Team Science Award
• Recognition of the newly inducted Fellows of the AACR Academy
• AACR June L. Biedler Prize for Cancer Journalism
• 2019 Distinguished Public Service Awards
• AACR Award for Lifetime Achievement in Cancer Research
• AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research

Don't miss this exciting event, which leads directly into the Opening Plenary Session!
See you there!

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
REMARKS FROM NCI DIRECTOR NORMAN E. SHARPLESS
9:15 a.m.–9:45 a.m.
Hall A, Georgia World Congress Center

OPENING PLENARY SESSION • 9:45 a.m.–12:15 p.m.
Hall A, Georgia World Congress Center
Opening Plenary: Achieving Equitable Patient Care through Precision and Convergent Cancer Science

Chair: John D. Carpten, Los Angeles, CA

9:45 a.m. Introductory remarks. John D. Carpten, Los Angeles, CA

9:50 a.m. Physicist vs. physician: Digitizing clinical assessment and using it for evidence-based prediction of outcomes. Peter Kuhn, Los Angeles, CA [PL01-01*]

10:05 a.m. Physicist vs. physician: Digitizing clinical assessment and using it for evidence-based prediction of outcomes. Jorge J. Nieva, Los Angeles, CA [PL01-01*]

10:20 a.m. Therapeutic implications of DNA repair defects in cancer. Alan Ashworth, San Francisco, CA

10:45 a.m. Precision oncology: Defining the actionable genome. David B. Solit, New York, NY

11:05 a.m. Precision oncology: The path forward. Levi A. Garraway, Indianapolis, IN

11:15 a.m. Next-generation CAR T cells designed to overcome tumor resistance. Crystal L. Mackall, Stanford, CA [PL01-05*]

11:40 a.m. Role of immune profiling and T-cell exhaustion in the response to immunotherapy in cancer. E. John Wherry, Philadelphia, PA

12:05 p.m. Wrap-up and opportunities for the future. John D. Carpten, Los Angeles, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
SUNDAY, MARCH 31**

AWARDS AND LECTURES • 12:15 p.m.–1:00 p.m.
Room A411-412, Georgia World Congress Center
Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

12:15 p.m.  Macrophages, inflammation, and cancer: Double-edged swords. Alberto Mantovani, Rozzano, Italy

The prestigious Pezcoller Foundation–AACR International Award for Extraordinary Achievement in Cancer Research was established in 1997 to annually recognize a scientist of international renown who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research; who continues to be active in cancer research and has a record of recent, noteworthy publications; and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer. For more information regarding the 2019 award recipient, visit aacr.org/awards.

NCI/NIH-SPONSORED SESSION • 12:15 p.m.–1:45 p.m.
Room A406-407, Georgia World Congress Center
The Cancer Moonshot: Rapid Launching of New Research Programs (not eligible for CME credit)

Chair: Dinah S. Singer, Bethesda, MD

12:15 p.m.  Title to be announced. Dinah S. Singer, Bethesda, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
CLINICAL TRIALS PLENARY SESSION 1 • 12:45 p.m.–3:00 p.m.

Marcus Auditorium, Building A, Georgia World Congress Center

Predictive Biomarkers for Immunotherapy

Chair: Louis M. Weiner, Washington, DC

CT001 Biomarkers of systemic inflammation associated to reduced clinical activity of atezolizumab monotherapy in patients with metastatic triple-negative breast cancer. Yijin Li, South San Francisco, CA

Discussant: Pamela N. Munster, San Francisco, CA

CT002 A strong HPV-specific T-cell response after chemoimmunotherapy for advanced cervical cancer is associated with prolonged survival. Cornelis J. M. Melief, Leiden, Netherlands

Discussant: Amit M. Oza, Toronto, ON, Canada

CT003 Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL. Michael J. Campbell, San Francisco, CA

Discussant: To be announced

CT004 A phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Mark H. O’Hara, Philadelphia, PA

Discussant: To be announced

MAJOR SYMPOSIUM • 1:00 p.m.–2:30 p.m.

Room A311-312, Georgia World Congress Center

Presidential Select Symposium: Engaging Cancer Patients as Partners in the Research Process

Chair: Elizabeth M. Jaffee, Baltimore, MD

Speakers: Vernal Branch, Mooresville, NC
Paul G. Kluetz, Silver Spring, MD
Louis M. Staudt, Bethesda, MD
Nikhil Wagle, Boston, MA
SUNDAY, MARCH 31**

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
1:00 p.m.–2:45 p.m.
Room A411-412, Georgia World Congress Center
**Innate Immunity and Complement in Solid Tumors**

Chair: Eric Vivier, Marseille, France

1:00 p.m.  Targeting innate immunity in next-generation cancer immunotherapies. Eric Vivier, Marseille, France

1:30 p.m.  Mechanistic basis of cancer immunotherapy. Ira Mellman, South San Francisco, CA

2:00 p.m.  The complement system: A novel target for cancer immunotherapy. Ruben Pio, Pamplona, Spain

Room A302, Georgia World Congress Center
**Recent Progress in Boron Neutron Capture Therapy**

Chair: Leena Kankaanranta, Helsinki, Finland

1:00 p.m.  Where things stand today: A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Rolf F. Barth, Columbus, OH

1:30 p.m.  Title to be announced. Hanna Koivunoro, Helsinki, Finland

2:00 p.m.  Experience of BNCT for glioblastoma and current status of accelerator-based BNCT. Akira Matsumura, Tsukuba, Japan

ADVANCES IN ORGAN SITE RESEARCH • 1:00 p.m.–2:45 p.m.
Georgia Ballroom 3, Building C, Georgia World Congress Center
**Advances in Gastric Cancer**

Chair: Keith T. Wilson, Nashville, TN

1:00 p.m.  Advances in *H. pylori*-induced immune dysregulation and gastric carcinogenesis: EGFR and polyamines. Keith T. Wilson, Nashville, TN

1:30 p.m.  Advances in gastric cancer: Metaplasia, paligenosis, and initiating events. Jason C. Mills, St. Louis, MO

2:00 p.m.  Advances in genomics and biology of diffuse gastric cancer. Adam J. Bass, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

90  AACR ANNUAL MEETING 2019
Room B206, Georgia World Congress Center
The Changing Face of Ovarian Cancer

Chair: Gordon B. Mills, Portland, OR

1:00 p.m.  The journey of PARP inhibitors to the front line of ovarian cancer.  
           Shannon N. Westin, Houston, TX

1:30 p.m.  From pathogenesis to targets in ovarian cancer.  Ronny I. Drapkin, 
           Philadelphia, PA

2:00 p.m.  Title to be announced.  Gordon B. Mills, Portland, OR

ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES
1:00 p.m.–2:45 p.m.

Room B401-402, Georgia World Congress Center
The Science of Cancer Health Disparities

Chair: John M. Carethers, Ann Arbor, MI

1:00 p.m.  Breast cancer health disparities: Past, present, and future.  
           Laura Fejerman, San Francisco, CA

1:25 p.m.  Prostate cancer risk factors and genomic characterization in West African 
           black men using epidemiology and NGS: Findings from the CaPTC.  
           Faruk Mohammed, Zaria, Nigeria

1:45 p.m.  Advances in prostate cancer health disparities.  Clayton C. Yates, Tuskegee, 
           AL

2:10 p.m.  Community partnerships close knowledge gaps about genetic ancestry and 
           cancer trajectory.  Olufunmilayo I. Olopade, Chicago, IL
SUNDAY, MARCH 31**

MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.

Hall A, Georgia World Congress Center  
Biomarkers of Response and Toxicity to Cancer Therapy

Chair: Jennifer A. Wargo, Houston, TX

1:05 p.m.  Biomarkers of response and toxicity to cancer therapy: The whole is greater than the sum of its parts. Jennifer A. Wargo, Houston, TX

1:35 p.m.  TME and myeloid microenvironment and the importance of single-cell technologies. Miram Merad, New York, NY

2:05 p.m.  Genetic foundations of immunotherapy efficacy. Timothy A. Chan, New York, NY

Room B312-314, Georgia World Congress Center  
Characterizing and Managing Cancer as a Complex Adaptive System

Chair: Anna D. Barker, Scottsdale, AZ

1:05 p.m.  Decoding the biochemical, regulatory, and clinical impact of genomic mutations. Olga Troyanskaya, New York, NY [SY36-01*]

1:35 p.m.  Exploiting evolutionary dynamics in optimizing cancer treatment. Robert A. Gatenby, Tampa, FL [SY36-02*]

2:05 p.m.  Viewing cancer as a complex adaptive system and managing immunotherapy as “homeostatic reset.” Anna D. Barker, Scottsdale, AZ [SY36-03*]

Georgia Ballroom 2, Building C, Georgia World Congress Center  
Dharma Master Jiantai Advances in Lung Cancer Session: Earlier Detection of Cancer—Who to Screen, Where to Screen, and What to Screen?

Chair: Caroline Dive, Manchester, United Kingdom

1:05 p.m.  Volume CT screening for lung cancer works. Harry J. de Koning, Rotterdam, Netherlands

1:35 p.m.  Liquid biopsies for earlier detection of lung cancer: Are we getting closer?  
Caroline Dive, Manchester, United Kingdom

2:05 p.m.  Do we need to understand tumor biology to tackle early cancer detection?  
Sylvia K. Plevritis, Stanford, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings  
(the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B405, Georgia World Congress Center

The Evolving Tumor Microenvironment in Tumor Progression and Therapy Responses

Chair: Sheila A. Stewart, St. Louis, MO

1:05 p.m. Targeting the metastatic tumor microenvironment to limit cancer progression. Sheila A. Stewart, St. Louis, MO

1:35 p.m. Pancreatic cancer fibroblast subtypes. David A. Tuveson, Cold Spring Harbor, NY

2:05 p.m. The osteogenic niche confers unexpected therapeutic resistance and vulnerability on bone micrometastases. Xiang Zhang, Houston, TX

Room A402-403, Georgia World Congress Center

Regulatory Science and Policy Session

Hyperprogression and Immuno-oncology: Scientific, Clinical, and Regulatory Challenges

Cochairs: Victoria L. Chiou, Silver Spring, MD; Elad Sharon, Bethesda, MD

Speakers: Marina C. Garassino, Milan, Italy
Razelle Kurzrock, La Jolla, CA
Lawrence H. Schwartz, New York, NY
Jean-Charles Soria, Gaithersburg, MD

Panelist: Susan Leighton, Huntsville, AL

Georgia Ballroom 1, Building C, Georgia World Congress Center

Obesity and Cancer: When Systemic Metabolism Meets Cell Metabolism

Chair: Stephen D. Hursting, Chapel Hill, NC

1:05 p.m. Linking systemic energy homeostasis to cancer metabolism. Stephan Herzig, Heidelberg, Germany

1:30 p.m. Hyperinsulinemia mediates the effect of obesity to promote tumor growth in murine breast and colon cancer. Rachel J. Perry, New Haven, CT [SY28-02*]

1:55 p.m. Obesity-associated leptin signaling promotes chemotherapy resistance in triple-negative breast cancer: The role of tumor-initiating cell enrichment. Laura W. Bowers, West Lafayette, IN

2:15 p.m. Extending the paradigm of hormonal dependency of cancer to account for effects of lifestyle on risk and prognosis. Michael N. Pollak, Montréal, QC, Canada [SY28-03*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
SUNDAY, MARCH 31**

Thomas Murphy Ballroom, Building B, Georgia World Congress Center

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

Systems Biology and Cancer Immunology

**Chair:** Catherine J. Wu, Boston, MA

1:05 p.m.  **Systematic approaches to improving personal cancer vaccines.** Catherine J. Wu, Boston, MA

1:35 p.m.  **Antigen-independent de novo prediction of cancer-associated immune repertoire.** Bo Li, Dallas, TX [SY11-02*]

2:05 p.m.  **Comprehensive enumeration of immune cell populations in solid human tissue using MIBI.** Michael Angelo, Palo Alto, CA

Room B302-303, Georgia World Congress Center

Transcriptional and Gene-Regulatory States: How They Relate to Lineage Origin and Plasticity in Pediatric Cancer

**Chair:** Charles Lin, Houston, TX

1:05 p.m.  **Targeting master transcription factor dependency in pediatric cancer.** Charles Lin, Houston, TX [SY24-01*]

1:35 p.m.  **Neuroblastoma: A developmental twist.** Rogier Versteeg, Amsterdam, Netherlands [SY24-02*]

2:05 p.m.  **Core regulatory circuitries and dependencies in pediatric cancer.** Kimberly Stegmaier, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

AACR ANNUAL MEETING 2019
SPECIAL SESSION • 1:00 p.m.–3:00 p.m.
Room A305, Georgia World Congress Center

New Drugs on the Horizon: Part 1

Co-chairs: Julian Blagg, Cambridge, United Kingdom; Sara Buhrlage, Boston, MA

1:01 p.m. BI 905677: A first-in-class LRP5/6 antagonist targeting Wnt-driven proliferation and immune escape. Vittoria Zinzalla, Vienna, Austria (not eligible for CME credit)

1:24 p.m. Discovery and first structural disclosure of AZD7648: A potent and selective DNA-PK inhibitor. Frederick W. Goldberg, Cambridge, United Kingdom [DDT01-02*] (not eligible for CME credit)

1:48 p.m. A first-in-class therapeutic CD80-Fc fusion protein that augments T cell costimulation. Susannah D. Barbee, South San Francisco, CA


2:36 p.m. TAK-981: A first-in-class SUMOylation inhibitor in phase 1 clinical trials promotes a Type I interferon response and antitumor immunity in preclinical models. Dennis Huszar, Cambridge, MA

MAJOR SYMPOSIUM • 1:00 p.m.–3:00 p.m.
Room A313-314, Georgia World Congress Center

Li-Fraumeni Syndrome and p53: Celebrating Gold and Ruby Anniversaries of Paradigm Models of Cancer Predisposition and Tumor Suppression

Co-chairs: David Malkin, Toronto, ON, Canada; Judy E. Garber, Boston, MA

1:00 p.m. What controls the level of mutant p53 proteins and why it matters. David P. Lane, Singapore, Singapore

1:24 p.m. Why tumor suppressor gene mutations that are inherited give rise to different tumors than spontaneous mutations in the same gene: Order matters. Arnold J. Levine, Princeton, NJ

1:48 p.m. Is there a way to prevent the unclenching of the oncogenic mutant p53 in the LFS patients? Varda Rotter, Rehovot, Israel

2:12 p.m. Is early detection and prevention of cancer feasible in Li-Fraumeni syndrome? David Malkin, Toronto, ON, Canada

2:36 p.m. Challenges in estimating TP53-associated cancer risks. Judy E. Garber, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
SUNDAY, MARCH 31**

POSTER SESSION • 1:00 p.m.–5:00 p.m.
Hall B, Georgia World Congress Center
(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print Guide to Poster Sessions and Exhibits. A limited number of copies of the Guide are available in the Exhibit Hall.

Cancer Chemistry
Section 1  Novel Small Molecules for Cancer Therapy
Section 2  3D Models
Section 3  Cell-Cell and Cell Matrix Interactions
Section 4  Developmental Phenotypes and Molecular Imaging
Section 5  Drug Targets in the Microenvironment
Section 6  Gene Expression in the Tumor Microenvironment
Section 7  Genes that Regulate Migration and Invasion
Section 8  Targeting Tumor-Host Interactions

Experimental and Molecular Therapeutics
Section 9  Antibody-Drug Conjugates: New Agents and Technologies
Section 10  Brain Cancers and Neuroblastoma
Section 11  Cell Death and DNA Repair Pathways
Section 12  Combination Approaches to Novel Therapies
Section 13  Drug Resistance 1
Section 14  New Anticancer Agents
Section 15  New Molecular Targets

Clinical Trials
Section 16  Phase I Clinical Trials: Part 1

Clinical Research
Section 17  Circulating and Cell-Free Biomarkers for Diagnosis and Monitoring of Cancer 1
Section 18  Current Developments in Noninvasive Biomarkers for Assessment of Cancer 1
Section 19  Precision Medicine

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
**Immunology**
Section 20  Imaging the Tumor Microenvironment
Section 21  Metabolic Mechanisms that Modulate the Immune Response to Cancer
Section 22  Radiation-Induced Immunomodulation
Section 23  Therapeutic Antibodies 1
Section 24  Tumor Antigens and Neoantigens

**Epidemiology**
Section 26  Biomarkers in Risk and Outcomes
Section 27  Lifestyle Factors and Cancer Risk

**Prevention Research**
Section 28  Experimental Models and Biomarkers in Cancer Prevention Research

**Advocates Poster Session (Scientist↔Survivor Program)**
Section 29  Advocates Poster Session 1

**Bioinformatics and Systems Biology**
Section 30  Convergence Science for Therapeutics and Precision Medicine

**Molecular and Cellular Biology/Genetics**
Section 32  Apoptosis
Section 33  Cancer Genomics 1
Section 34  miRNA Regulation of Cancer Biology
Section 35  Mitochondrial Function and Metabolism in Cancer
Section 36  New Trends in DNA Methylation
Section 37  Oncogenic Gene Dysregulation and Carcinogenesis
Section 38  Targeting Oxidative Stress and Senescence
SUNDAY, MARCH 31**

SPECIAL SESSION • 1:15 p.m.–2:00 p.m.
AACR Central Theater - Hall B
Molecular Epidemiology Working Group (MEG) Networking Session with Early-Career Researchers
(not eligible for CME credit)
Moderator: Ellen L. Goode, Rochester, MN
Speakers: Brooke L. Fridley, Tampa, FL
Tracy A. O’Mara, Herston, Australia
Mark E. Sherman, Jacksonville, FL

MEET AND GREET • 2:00 p.m.–3:00 p.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the Editor-in-Chief of Clinical Cancer Research: Keith T. Flaherty, MD
(not eligible for CME credit)
Keith T. Flaherty, Boston, MA

MICR Networking and Resource Center, AACR Central, Hall B, Georgia World Congress Center
Minorities in Cancer Research Council Meet and Greet
(not eligible for CME credit)
Brian M. Rivers, Atlanta, GA

WICR Networking and Resource Center, AACR Central, Hall B, Georgia World Congress Center
Women in Cancer Research Council Meet and Greet
(not eligible for CME credit)
Lucile L. Adams-Campbell, Washington, DC

NCI/NIH-SPONSORED SESSION • 2:00 p.m.–3:30 p.m.
Room A406-407, Georgia World Congress Center
Towards the Generation of Spatial Human Tumor Maps
(not eligible for CME credit)
Chair: Philipp Oberdoerffer, Bethesda, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
2:00 p.m.  **Human Tumor Atlas Network: A central need for spatial imaging.** Philipp Oberdoerffer, Bethesda, MD

2:05 p.m.  **Lessons from the NIH 4D Nucleome Project.** Sean E. Hanlon, Bethesda, MD

2:10 p.m.  **Molecular and spatial characterization of human tumors: Multiplexed protein imaging in intact tissue sections using CycIF.** Peter K. Sorger, Boston, MA

2:25 p.m.  **Molecular and spatial characterization of human tumors: Spatial transcriptomics using MERFISH.** Xiaowei Zhuang, Cambridge, MA

2:40 p.m.  **Molecular and spatial characterization of human tumors: Microscale3D electron microscopy imaging.** Joe W. Gray, Portland, OR

2:55 p.m.  Discussion

3:05 p.m.  **Establishing a searchable Imaging Data Commons: Mining digital pathology and tumor imaging.** David Gutman, Atlanta, GA

3:15 p.m.  **Establishing a searchable Imaging Data Commons: Construction of an Image Data Commons.** Tanja M. Davidsen, Bethesda, MD

3:25 p.m.  Discussion

**SPECIAL SESSION • 3:00 p.m.-4:15 p.m.**

Room A311, Georgia World Congress Center

**Using Real-World Data to Generate Potential Synthetic Control Arms: The AACR Project GENIE Experience**

**Chair:** Raji Sridhara, Rockville, MD

3:05 p.m.  **AACR Project GENIE: Recent advances.** Charles L. Sawyers, New York, NY

3:20 p.m.  **Use of AACR Project GENIE, a clinicogenomic registry, to define the natural history of AKT1 E17Kmutant ER+/HER2- metastatic breast cancer (MBC).** David Hyman, New York, NY

3:35 p.m.  **Natural history and clinical characteristics of ERBB2 mutant hormone receptor-positive breast cancers: Results from the AACR Project GENIE Registry.** Monica Arnedos, Villejuif, France

3:50 p.m.  **Title to be announced.** Raji Sridhara, Rockville, MD
SUNDAY, MARCH 31**

SPECIAL SESSION • 3:00 p.m.–4:30 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center
NextGen Stars Spotlight 1: Genetics and Immunology
Chair: Riccardo Dalla-Favera, New York, NY

3:00 p.m.  Long noncoding RNA-directed antigenicity loss suppresses
           immunosurveillance. Liuqing Yang, Houston, TX

3:20 p.m.  The role of EZH2 gain-of-function mutations in lymphomagenesis. Wendy
           Béguelin, New York, NY

3:40 p.m.  Revealing the molecular landscape and associated prognostic implications
           in patients with acute myeloid leukemia. Ann-Kathrin Eisfeld, Columbus, OH

4:00 p.m.  Expanding the immunopeptidome with ribosome profiling. Tamara
           Ouspenskaia, Cambridge, MA

CLINICAL TRIALS MINISYMPOSIUM • 3:00 p.m.–5:00 p.m.
Room A411, Georgia World Congress Center
Advances in Novel Immunotherapeutics
Chair: To be announced

CT036   A phase I clinical trial of malignant pleural disease treated with regionally
delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Prasad S.
Adusumilli, New York, NY

CT037   Genomic analyses and immunotherapy in advanced melanoma. F. Stephen Hodi,
Boston, MA

CT042   Fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 therapy in
refractory metastatic melanoma patients—preliminary results from a phase I clinical trial
(NCT03353402). Erez N. Baruch, Ramat Gan, Israel

CT038   Results of a phase Ib trial of an autologous cell vaccine for newly diagnosed
glioblastoma. David W. Andrews, Philadelphia, PA

CT039   A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
(DART) S1609: The neuroendocrine cohort. Sandip Pravin Patel, La Jolla, CA

CT040   A phase I trial of talimogene laherparepvec combined with neoadjuvant
chemotherapy for nonmetastatic triple-negative breast cancer. Hatem Soliman, Tampa, FL

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

100  AACR ANNUAL MEETING 2019
CT041 Identification of gene signatures associated with response in a phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy. Peter Ordentlich, Waltham, MA

CT043 Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study. Marina C. Garassino, Milan, Italy

LATE-BREAKING MINISYMPOSIUM • 3:00 p.m.-5:00 p.m.

Room B402, Georgia World Congress Center
Minisymposium: Late-Breaking Research 1

Chair: Todd R. Golub, Cambridge, MA

LB-048 WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Edmond M. Chan, Boston, MA

LB-049 Targeting the ubiquitin-proteasome system by small molecule inhibition of the DUBome. Xavier Jacq, Belfast, United Kingdom

LB-050 Memory sequencing reveals heritable single-cell gene expression programs associated with therapy resistance. Sydney Shaffer, Philadelphia, PA

LB-051 Integrative, targeted deep sequencing of bladder tumors reveals novel associations between cancer gene mutations and mutational signatures with major risk factors. Stella Koutros, Bethesda, MD

LB-052 Detection of rare, deleterious clonal mutations during unrelated allogeneic hematopoietic stem cell transplants using an error correction pipeline for NGS. Wing Hing Wong, Saint Louis, MO

LB-053 Familial studies identify variants in the E2A transcription factor as putative risk factors for lung cancer. Claudio W. Pikielny, Lebanon, NH

LB-054 Discovery and profiling of M3258, a potent and selective LMP7 inhibitor demonstrating high efficacy in multiple myeloma models. Markus Klein, Darmstadt, Germany

(not eligible for CME credit)
CLINICAL TRIALS PLENARY SESSION 2 • 3:00 p.m.–5:15 p.m.
Marcus Auditorium, Building A, Georgia World Congress Center
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Chair: Timothy A. Yap, Houston, TX

CT031 Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Shun Lu, Shanghai, China

Discussant: To be announced

CT032 TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lecia Sequist, Boston, MA

CT033 TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lecia Sequist, Boston, MA

CT034 Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study. Suresh S. Ramalingam, Atlanta, GA

Discussant: Roy S. Herbst, New Haven, CT

MINISYMPOSIA • 3:00 p.m.–5:00 p.m.
Room B206, Georgia World Congress Center
Bioninformatics and Systems Biology
Tools for Cancer Genome Analysis
Chair: Trevor J. Pugh, Toronto, ON, Canada

3:00 p.m. Introduction

3:05 p.m. 905 Comprehensive immunogenomic profiling of anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms. Charles W. Abbott, Menlo Park, CA (not eligible for CME credit)

3:20 p.m. 906 COSMIC: Describing the world’s knowledge of somatic mutations in cancer. Simon Andrew Forbes, Cambridge, United Kingdom

3:35 p.m. 907 Bioinformatic method to define epigenetically regulated enhancer elements associated with cancer. Thais S. Sабедот, Detroit, MI

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

AACR ANNUAL MEETING 2019
3:50 p.m.  908 Comprehensive analysis of alternative polyadenylation across cancer phenotypes. Luigi Marchionni, Baltimore, MD


4:20 p.m.  910 The cBioPortal for cancer genomics. Jianjiong Gao, New York, NY

4:35 p.m.  911 UCSC Xena for cancer genomics visualization and interpretation. Mary Goldman, Santa Cruz, CA

Room B302-303, Georgia World Congress Center
Clinical Research
Biomarkers for Early Detection and Biologic Assessment of Cancer

Cochairs: Avrum E. Spira, Boston, MA; Luis A. Diaz, New York, NY

3:00 p.m.  Introduction

3:05 p.m.  912 Macrophage inhibitory factor (MIF), osteopontin (OPN) and anti-interleukin-8 (IL-8) autoantibodies (AAb) complement CA125 for detection of early-stage ovarian cancer. Jing Guo, Houston, TX

3:20 p.m.  913 Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. Emil Christensen, Aarhus N, Denmark

3:35 p.m.  914 Development of a whole-urine, next-generation sequencing-based assay for early detection of aggressive prostate cancer. Andi K. Cani, Ann Arbor, MI

3:50 p.m.  915 Pseudogene-associated recurrent gene fusion in prostate cancer. Nallasivam Palanisamy, Detroit, MI

4:05 p.m.  916 Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). Victoria M. Raymond, San Diego, CA

4:20 p.m.  917 Circulating tumor cells accurately detect and characterize lung cancers in high-risk subjects undergoing low-dose CT screening. Yariswamy Manjunath, Columbia, MO

4:35 p.m.  918 Using machine learning to predict the risk of either having an aggressive form of prostate cancer (PCA) or lower-grade PCA/benign prostatic hyperplasia (BPH) based upon the flow cytometry immunophenotyping of myeloid-derived suppressor cells (MDSCs) and lymphocyte cell populations. George A. Dominguez, San Jose, CA
Room C302, Georgia World Congress Center

Endocrinology

Endocrine-Related Cancer Research

Cochairs: Isabel R. Schlaepfer, Aurora, CO; Nicholas Mitsiades, Aurora, CO

3:00 p.m. Introduction

3:05 p.m. 919 Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium. Simon Kreutzfeldt, Heidelberg, Germany

3:20 p.m. 920 p97/VCP: A novel interactor of the sodium iodide symporter, which can be pharmacologically targeted to increase radiiodine uptake in thyroid and breast cancer cells. Alice Fletcher, Birmingham, United Kingdom

3:35 p.m. 921 Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer. Derek Dustin, Houston, TX

3:50 p.m. 922 Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER. Tinya J. Abrams, Cambridge, MA

(not eligible for CME credit)

4:05 p.m. 923 FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells. Changmeng Cai, Boston, MA

4:20 p.m. 924 The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models. Bernard Haendler, Berlin, Germany

(not eligible for CME credit)

4:35 p.m. 925 PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target. Elisabetta Marangoni, Paris, France

Room B304-305, Georgia World Congress Center

Experimental and Molecular Therapeutics

Drug Resistance

Cochairs: Rizwan Hag, Boston, MA; Douglas B. Johnson, Nashville, TN

3:00 p.m. Introduction

3:05 p.m. 926 Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia. Sunil K. Joshi, Portland, OR

3:20 p.m. 927 Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity. Pedram Razavi, New York, NY

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
3:35 p.m. 928 Preventing melanoma from healing itself after therapy-induced immune attack through IPRES blockade. Willy Hugo, Los Angeles, CA

3:50 p.m. 929 Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT “Basket” Trial. Helen H. Won, New York, NY

4:05 p.m. 930 On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation. Yunkai Zhang, Nashville, TN

4:20 p.m. 931 The T790M mutation is acquired through 5-methylcytosine deamination after EGFR TKI treatment in lung cancer. Khaled A. Hassan, Ann Arbor, MI

4:35 p.m. 932 Reversing PARP inhibitor resistance by targeting the replication stress response. Mark J. O’Connor, Cambridge, United Kingdom

Room B405-407, Georgia World Congress Center

Immunology

Adoptive Cell Therapy

Cochairs: Marcela V. Maus, Charlestown, MA; Chantale Bernatchez, Houston, TX

3:00 p.m. Introduction

3:05 p.m. 933 Surface-tethered IL-12 improves tumor-specific T-cell therapy and enhances inflammatory activity in tumors without inducing systemic toxicities. De-Kuan Chang, Cambridge, MA

3:20 p.m. 934 γδ CAR T-cell therapy significantly mitigates bone metastatic castrate-resistant prostate cancer. Jeremy Steven Frieling, Tampa, FL

3:35 p.m. 935 Genetic modification potentiates the antitumor activity of human placental CD34+ cells-derived NK cells. James Li, Warren, NJ (not eligible for CME credit)

3:50 p.m. 936 Regulation of CD8+ T-cell function and antitumor activity by DGKα and DGKζ. Matthew Riese, Milwaukee, WI

4:05 p.m. 937 Nr4a transcription factors limit CAR T-cell function in solid tumors. Joyce Chen, La Jolla, CA

4:20 p.m. 938 Disruption of TOX overcomes CAR T-cell dysfunction function in solid tumor. Hyungseok Seo, San Diego, CA

4:35 p.m. 939 A novel first-in-class common-gamma chain cytokine facilitates expansion of CD8+ T cells and offers a superior cellular source for adoptive T-cell therapy. Anirban Banerjee, Charlottesville, VA
SUNDAY, MARCH 31**

Georgia Ballroom 3, Building C, Georgia World Congress Center

Immunology

Cancer Vaccines and Intratumoral Immunomodulation

Chair: Adi Diab, Houston, TX; Catherine J. Wu, Boston, MA

3:00 p.m.  Introduction

3:05 p.m.  940 Development of ONCR-177, an miR-attenuated oncolytic HSV-1 designed to potently activate systemic antitumor immunity. Brian B. Haines, Cambridge, MA

(Not eligible for CME credit)

3:20 p.m.  941 B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment. Manisha Singh, Houston, TX

3:35 p.m.  942 The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes. Lakshmi Srinivasan, Cambridge, MA

(Not eligible for CME credit)

3:50 p.m.  943 Filtering out self-like neoantigens improves immune response to cancer vaccines. Guilhem Richard, Providence, RI

4:05 p.m.  944 exoSTING: An engineered exosome therapeutic that selectively delivers STING agonist to the tumor resident antigen-presenting cells resulting in improved tumor antigen-specific adaptive immune response. Kyriakos D. Economides, Cambridge, MA

4:20 p.m.  945 PBRM1 loss reduces IFN\(_\gamma\)-STAT1 activity and promotes resistance to immunotherapy and antiangiogenic therapy in renal cell carcinoma. Xiande Liu, Houston, TX

4:35 p.m.  946 Early signs of activity of Tedopi OSE2101, a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors ATALANTE-1. Santiago Viteri, Barcelona, Spain

Room A302, Georgia World Congress Center

Molecular and Cellular Biology/Genetics

Emerging Targets in Cancer Epigenetics

Chair: Scott Bultman, Chapel Hill, NC; Bodour Salhia, Los Angeles, CA

3:00 p.m.  Introduction

3:05 p.m.  947 Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and tumorigenicity. Xiangqian Kong, Baltimore, MD

3:20 p.m.  948 Epigenomic correlates of checkpoint blockade immunotherapy resistance. Alvin H. Shi, Cambridge, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
3:35 p.m.  949  ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer. Eneda Toska, New York, NY

3:50 p.m.  950  In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models. Hillary J. Millar, Spring House, PA (not eligible for CME credit)

4:05 p.m.  951  Setdb1 deletion protects against formation of pancreatic ductal adenocarcinoma through inducing apoptosis and upregulating p53 expression. Satoshi Ogawa, Kyoto, Japan

4:20 p.m.  952  Determining the contribution of cystathionine beta synthase to lung cancer lineage fate. Mojtaba Bakhtiari, Lexington, KY

4:35 p.m.  953  JARID1 family inhibitor reduces generation of drug-resistant EGFR mutation-positive lung cancer cells. Shin Ariga, Sapporo, Japan

Room A315-316, Georgia World Congress Center
Molecular and Cellular Biology/Genetics
Receptor Tyrosine Kinase and GTPase Signaling in Cancer
Cochairs: Joseph N. Contessa, New Haven, CT; Kevin M. Haigis, Boston, MA

3:00 p.m.  Introduction

3:05 p.m.  954  SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors. Hengyu Lu, Cambridge, MA (not eligible for CME credit)

3:20 p.m.  955  Musashi-2 regulates EGFR expression in NSCLC, cell proliferation and survival, response to EGFR inhibitors in EGFR-mutant NSCLC. Alexander Kudinov, Albuquerque, NM

3:35 p.m.  956  An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. Ronald F. Siebenaler, Ann Arbor, MI

3:50 p.m.  957  An essential role for Argonaute 2 in mouse models of KRAS-driven cancers. Sunita Shankar, Ann Arbor, MI

4:05 p.m.  958  Tumor-vascular interactions promote STING-driven inflammation in the tumor microenvironment. Marco Campisi, Turin, Italy

4:20 p.m.  959  Proteomic and genetic interaction mapping of the Ras pathway reveals new effectors and vulnerabilities. Marcus R. Kelly, Stanford, CA

4:35 p.m.  960  Structures of oncogenic KRAS mutants in the active state and complexed with RasGAP provide new insights into targeting RAS-driven cancer. Dhirendra K. Simanshu, Frederick, MD
Room B401-402, Georgia World Congress Center

**Prevention Research**

**Nutrition, Physical Activity, and Cancer Prevention: Current Status and Emerging Strategies**

**Cochairs:** Stephen D. Hursting, Chapel Hill, NC; Steven K. Clinton, Columbus, OH

3:00 p.m.  Lessons from the third AICR/WCRF Expert Report on Diet, Nutrition, Physical Activity, and the Prevention of Cancer. Steven K. Clinton, Columbus, OH

3:20 p.m.  **961** Joint associations of physical activity and body mass index and the risk of excess body fatness-related cancer. Maret L. Maliniak, Atlanta, GA

3:35 p.m.  **962** Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries. Parichoy Pal Choudhury, Baltimore, MD

3:50 p.m.  **963** The interplay between lifestyle-related factors and genetics with risk of invasive breast cancer among postmenopausal women from the UK Biobank. Rhonda S. Arthur, Bronx, NY

4:05 p.m.  **964** The association of meat intake, meat cooking methods, and meat-derived mutagen exposure with the risk of sessile serrated polyps. Dominique A. Mosley, Atlanta, GA

4:20 p.m.  **965** Effects of replacing dietary animal protein with plant-based protein on the formation of intestinal N-nitroso compounds (NOCs) and biomarkers of colon cancer in healthy adults—a 12-week intervention study. Anne-Maria Pajari, Helsinki, Finland

4:35 p.m.  **966** Coffee consumption and invasive breast cancer incidence among postmenopausal women in the Cancer Prevention Study II Nutrition Cohort. Susan M. Gapstur, Atlanta, GA

Room A404-405, Georgia World Congress Center

**Tumor Biology**

**Novel Approaches to Understand Cancer Stem Cells**

**Cochairs:** Andrew S. Goldstein, Los Angeles, CA; Brigitte N. Gomperts, Los Angeles, CA

3:00 p.m.  Introduction

3:05 p.m.  **967** Single-cell transcriptomics uncovers clonal heterogeneity linked to drug response and cellular phenotype in adult brain tumor stem cells. Laura M. Richards, Toronto, ON, Canada

3:20 p.m.  **968** Targeting intratumoral heterogeneity in TNBC with novel combinations of FDA-approved drugs. Nathan A. Truchan, Ann Arbor, MI

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
3:35 p.m.  969 Characterization of murine mammary epithelial populations throughout development and in premalignant tissue via mass cytometry. Gary K. Gray, Boston, MA

3:50 p.m.  970 The mutational landscape of normal human endometrial epithelium. Luiza Moore, Cambridge, United Kingdom

4:05 p.m.  971 PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells. Darren Qiancheng Tan, Cambridge, United Kingdom

4:20 p.m.  972 Direct observation in living tumors shows macrophage-dependent induction and dissemination of cancer stem cells in breast cancer. Ved P. Sharma, Bronx, NY

4:35 p.m.  973 The mitochondrial deoxyguanosine kinase regulates lung adenocarcinoma cancer stem-like cells through AMPK/YAP1 signaling. Shengchen Lin, Hershey, PA

Room B312-314, Georgia World Congress Center
Tumor Biology
The Immune Microenvironment in Cancer

Cochairs: Amanda Lund, Portland, OR; Dmitry I. Gabrilovich, Philadelphia, PA

3:00 p.m.  Introduction

3:05 p.m.  974 The molecular and genomic drivers of immunologically cold tumors: Novel discoveries from pan-cancer analysis. Guangchun Han, Houston, TX

3:20 p.m.  975 Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. Ines Silva, Sydney, Australia

3:35 p.m.  976 Regulation of breast tumor metastasis by the dynamic interaction between the TMEM macrophage, tumor, and endothelial cells. Chinmay R. Surve, Bronx, NY

3:50 p.m.  977 Nano immunotherapeutics crossing blood-brain barrier to activate local brain tumor immune system. Julia Y. Ljubimova, Los Angeles, CA

4:05 p.m.  978 Tim-4+ tissue-resident macrophages impair antitumor T-cell immunity. Andrew Chow, New York, NY

4:20 p.m.  979 Programmed death-ligand 1 expression and tumor-infiltrating immune cells in cancers associated with Li-Fraumeni syndrome. Emilie Saucier, Villejuif Cedex, France

4:35 p.m.  980 Clinical impact of T-cell exhaustion in patients with diffuse large B-cell lymphoma. Suvi-Katri Leivonen, Helsinki, Finland
SUNDAY, MARCH 31**

MEET AND GREET • 3:15 p.m.–4:15 p.m.
AACR Central Theater - Hall B
Meet the Mentor: Undergraduate Focus
(not eligible for CME credit)
Kathleen W. Scotto, New Brunswick, NJ

SPECIAL SESSION • 3:15 p.m.–5:15 p.m.
Room A305, Georgia World Congress Center
New Drugs on the Horizon: Part 2
Cochairs: Andrew C. Phillips, North Chicago, IL; Philip Jones, Houston, TX

3:16 p.m.  First-time disclosure of M3258: A selective inhibitor of the
immunoproteasome subunit LMP7 with potential for improved therapeutic
utility in multiple myeloma compared to pan-proteasome inhibitors. Michael
Sanderson, Darmstadt, Germany
(not eligible for CME credit)

3:40 p.m.  LY3295668: An exquisitely selective Aurora-A inhibitor for the treatment
of cancers with aberrations in RB1 and other cell cycle genes. Sean G.
Buchanan, Indianapolis, IN
(not eligible for CME credit)

4:04 p.m.  Development of GPRC5D/CD3 bispecific antibody for the treatment of
multiple myeloma. Francois Gaudet, Spring House, PA

4:28 p.m.  Discovery of AMG 510: A novel covalent inhibitor of KRASG12C, now in a
phase 1 clinical trial for patients with solid tumors harboring the KRASp.
G12C allele. J. Russell Lipford, Thousand Oaks, CA
(not eligible for CME credit)

4:52 p.m.  ABBV-155: A first-in-class BCL-XL inhibitor antibody drug conjugate.
Andrew C. Phillips, North Chicago, IL
(not eligible for CME credit)

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
NCI/NIH-SPONSORED SESSION • 3:45 p.m.–5:15 p.m.
Room A406-407, Georgia World Congress Center
NCI-Supported Point-of-Care Technology Research for Global Oncology:
Driving Cutting-Edge Technological Advances while Opening
New Possibilities for Patient Care Globally and in Domestic
Cancer Health Disparities Populations
(not eligible for CME credit)
Chair: Lisa M. Stevens, Bethesda, MD
3:50 p.m.  Paul C. Pearman, Rockville, MD
4:00 p.m.  Sonia Gomez Parra, Houston, TX
4:15 p.m.  Cesar M. Castro, Boston, MA
4:30 p.m.  Marc D. Porter, Salt Lake City, UT
4:45 p.m.  Nimmi Ramanujam, Durham, NC
5:00 p.m.  Discussion

AWARDS AND LECTURES • 4:00 p.m.–4:45 p.m.
Thomas Murphy Ballroom, Building B, Georgia World Congress Center
AACR-Irving Weinstein Foundation Distinguished Lecture
T cell-mediated immune tolerance in health and disease. Jeffrey A. Bluestone,
San Francisco, CA

MEET AND GREET • 4:00 p.m.–5:00 p.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the Editor-in-Chief of Cancer Research: Chi Van Dang, MD, PhD
(not eligible for CME credit)
Chi Van Dang, New York, NY
SUNDAY, MARCH 31**

**AWARDS AND LECTURES • 4:15 p.m.–4:30 p.m.**
Room A313-314, Georgia World Congress Center
Special MICR Presentation Honoring Dr. Jane Cooke Wright
Brian M. Rivers, Atlanta, GA

**AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.**
Room A313-314, Georgia World Congress Center
AACR-Minorities in Cancer Research Jane Cooke Wright Memorial Lectureship
A role for inflammation-induced DNA mismatch repair deficits in racial outcomes from advanced colorectal cancer. John M. Carethers, Ann Arbor, MI

**SPECIAL SESSION • 5:00 p.m.–6:30 p.m.**
Georgia Ballroom 3, Georgia World Congress Center
AACR-ONS: The Evolving Landscape of Survivorship Research
Co-chairs: Anna D. Barker, Scottsdale, AZ; Lisa Kennedy Sheldon, Pittsburgh, PA
Panelists: Gregory J. Aune, San Antonio, TX
Laura J. Esserman, San Francisco, CA
Linda Jacobs, Philadelphia, PA

**PROFESSIONAL ADVANCEMENT SESSION • 5:00 p.m.–7:00 p.m.**
International Ballroom North, Hyatt Regency Atlanta
Personalized Career Conversations
(not eligible for CME credit)
Regency Ballroom VII, Hyatt Regency Atlanta
The Critical Role of Physician-Scientists in Advancing Cancer Science—Suggestions for Continued Success
(not eligible for CME credit)
Panelists: Sarki A. Abdulkadir, Chicago, IL
Sanya A. Springfield, Bethesda, MD
Jonathan S. Wiest, Bethesda, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
AWARDS AND LECTURES • 5:30 p.m.–6:15 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center

Presidential Address

Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic microenvironment. Elizabeth M. Jaffee, Baltimore, MD

NCI/NIH-SPONSORED SESSION • 5:30 p.m.–6:30 p.m.
Room A406-407, Georgia World Congress Center

NCI’s Translational Research Programs: Development and Use of Next-Generation Cancer Models for Precision Oncology (not eligible for CME credit)

Cochairs: Eva Tonsing-Carter, Bethesda, MD; Subhashini Jagu, Bethesda, MD

5:30 p.m. Overview of the Human Cancer Models Initiative. Lauren Hurd, Bethesda, MD
5:45 p.m. Developing next-generation cancer models. Eva Tonsing-Carter, Bethesda, MD
6:00 p.m. HCMi data at the NCI Genomic Data Commons. Sharon Gaheen, Bethesda, MD
6:15 p.m. Downstream applications of cancer models by CTD2 Network. Subhashini Jagu, Bethesda, MD

TOWN MEETING • 5:30 p.m.–7:00 p.m.
Room A315-316, Georgia World Congress Center

Chemistry in Cancer Research Working Group (CICR) Town Hall Meeting and Networking Reception (not eligible for CME credit)

5:30 p.m. CICR Chair: Opening remarks. Julian Blagg, Cambridge, United Kingdom
5:40 p.m. CICR Editor: Update on CICR Quarterly Newsletter. Alex G. Waterson, Nashville, TN
5:45 p.m. CICR Chair-Elect: Remarks. Andrew J. Phillips, Cambridge, MA
5:55 p.m. Discussion of member issues; closing remarks. Andrew J. Phillips, Cambridge, MA
TOWN MEETING • 6:00 p.m.–8:00 p.m.
Room A311-312, Georgia World Congress Center
Cancer Immunology Working Group (CIMM)
Town Hall Meeting and Networking Reception
(not eligible for CME credit)

6:00 p.m. Opening remarks: CIMM Chair. Dmitry I. Gabrilovich, Philadelphia, PA
6:15 p.m. CIMM Chair-Elect: Remarks. Weiping Zou, Ann Arbor, MI
6:30 p.m. Cancer Immunology Research: Update from the Editors-in-Chief. Robert D. Schreiber, St. Louis, MO; Philip D. Greenberg, Seattle, WA
6:35 p.m. Program opening remarks. Dmitry I. Gabrilovich, Philadelphia, PA
6:40 p.m. Integrative modeling of immunotherapy response biomarkers. X. Shirley Liu, Boston, MA
7:00 p.m. Evolving landscape of immunotherapy biomarkers and mechanisms. Timothy A. Chan, New York, NY
7:20 p.m. Closing remarks. Weiping Zou, Ann Arbor, MI

SPECIAL SESSION • 6:30 p.m.–8:00 p.m.
International Ballroom EF, Omni Hotel
Networking Hubs
(not eligible for CME credit)

Networking Hub: Technology and Convergence
Regina Barzilay, Cambridge, MA
Laura M. Heiser, Portland, OR
Nicholas E. Navin, Bellaire, TX
Sridhar Nimmagadda, Baltimore, MD
Dana Pe’er, New York, NY

Networking Hub: Personalized Medicine
Antonio Iavarone, New York, NY
Katherine A. Janeway, Boston, MA
Peter Kuhn, Los Angeles, CA
Elaine R. Mardis, Columbus, OH
Jorge J. Nieva, Los Angeles, CA
E. John Wherry, Philadelphia, PA

Networking Hub: Metabolism
Susan L. Bells, Birmingham, AL
Stephen D. Hursting, Chapel Hill, NC

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Katja Lamia, La Jolla, CA
Rachel J. Perry, New Haven, CT
Michael N. Pollak, Montreal, QC, Canada
M. Celeste Simon, Philadelphia, PA

**Networking Hub: Biomarkers and Single-Cell Analysis**
Bernd Bodenmiller, Zurich, Switzerland
Kara L. Davis, Stanford, CA
Miriam Merad, New York, NY
Klaus Pantel, Hamburg, Germany
Shannon L. Stott, Charlestown, MA
Harriet Wikman, Hamburg, Germany
Catherine J. Wu, Boston, MA


**TOWN MEETING • 6:30 p.m.–8:30 p.m.**
Imperial Ballroom AB, Marquis Level, Atlanta Marriott Marquis
**Pediatric Cancer Working Group (PCWG)**
**Town Hall Meeting and Networking Reception**
(not eligible for CME credit)

**Cochairs:** Crystal L. Mackall, Stanford, CA; Kimberly Stegmaier, Boston, MA

**Panelists:** Peter C. Adamson, Philadelphia, PA
Patricia Blanc, Fourqueux, France
Mark W. Kieran, Boston, MA
Andrew Pearson, Sutton, England
Gregory H. Reaman, Silver Springs, MD
Gilles Vassal, Villejuif, France

**MEET AND GREET • 8:30 p.m.–9:30 p.m.**
Room A601, Atlanta Marriott Marquis
**Associate Member Council Meet and Greet**
(not eligible for CME credit)

Allison S. Betof, Durham, NC
MONDAY, APRIL 1**

AWARDS AND LECTURES • 7:00 a.m.–8:00 a.m.
Room A305, Georgia World Congress Center
AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
Inflammation and inflammatory mediators as potential targets for cancer prevention or interception. Raymond N. DuBois, Charleston, SC

Room A311-312, Georgia World Congress Center
Distinguished Public Service Award Lecture
Training sensei. Daniel D. Von Hoff, Phoenix, AZ

MEET-THE-EXPERT SESSIONS • 7:00 a.m.–8:00 a.m.
Room B408, Georgia World Congress Center
Amyloidosis
Suzanne Lentzsch, New York, NY

Room B302-303, Georgia World Congress Center
Approaches to Combination Therapy
Peter K. Sorger, Boston, MA

Room B304-305, Georgia World Congress Center
Breast Cancer Stem Cells: Translating Biology to the Clinic
Max S. Wicha, Ann Arbor, MI

Room C302, Georgia World Congress Center
Drugging the Undruggable: The Myc Oncogene as a Case Study
Louis Chesler, Sutton, United Kingdom

Room A302, Georgia World Congress Center
High Mobility Group A1 (HMGA1) Chromatin Regulators: Revving Up Inflammation and Developmental Networks to Drive Tumor Progression
Linda M.S. Resar, Baltimore, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B401-402, Georgia World Congress Center
**Impacting Cancer Research and Patient Care through Circulating Biomarkers**
Johann S. de Bono, Sutton, United Kingdom

Room A315-316, Georgia World Congress Center
**In Vivo Systems Biology Approaches in Cancer Biology and Therapeutics**
Douglas A. Lauffenburger, Cambridge, MA

Georgia Ballroom 3, Building C, Georgia World Congress Center
**Integrating Genomics into Precision Cancer Medicine**
Elaine R. Mardis, Columbus, OH

Room B206, Georgia World Congress Center
**Metabolism: PI3K**
Lewis C. Cantley, New York, NY

Room A313-314, Georgia World Congress Center
**Next Steps in the Epidemiology of Diet, the Gut Microbiome, and Colorectal Cancer**
Andrew T. Chan, Boston, MA

Room A404-405, Georgia World Congress Center
**Targeting ALK in Neuroblastoma: From Discovery to Phase 3 and Back to the Lab**
Yael P. Mosse, Philadelphia, PA
MONDAY, APRIL 1**

POSTER SESSION • 8:00 a.m.-12:00 p.m.
Hall B, Georgia World Congress Center
(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print Guide to Poster Sessions and Exhibits. A limited number of copies of the Guide are available in the Exhibit Hall.

Cancer Chemistry
Section 1 Innovative Concepts for Drug Discovery

Endocrinology
Section 2 Endocrine-Related Cancers

Tumor Biology
Section 3 Epithelial/Mesenchymal Transition (EMT and MET) 1/Actin Cytoskeleton
Section 4 Human in Mouse
Section 5 Immune Cells in the Tumor Microenvironment 1
Section 6 Metastasis Promoter and Suppressor Genes
Section 7 Novel Imaging Targets
Section 8 Regulation of Cancer Stem Cell Stemness, Epithelial-Mesenchymal Transition, and the Microenvironment
Section 9 Tumor-Immune Interactions

Experimental and Molecular Therapeutics
Section 10 Cancer Immunotherapy
Section 11 Cellular Responses to Anticancer Agents 1: The Microenvironment and Metastasis
Section 12 Credentialing of Molecular Targets
Section 13 Drug Resistance 2
Section 14 Novel Targets and Pathways
Section 15 Tyrosine Kinase and Phosphatase Inhibitors 1

Science Education
Section 16 2019 AACR Margaret Foti Undergraduate Prizes in Cancer Research
[8:00 a.m.—10:00 a.m.]

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Clinical Trials
Section 17  Phase I Clinical Trials: Part 2

Clinical Research
Section 18  Circulating and Cell-Free Biomarkers for Diagnosis and Monitoring of Cancer 2
Section 19  Current Developments in Noninvasive Biomarkers for Assessment of Cancer 2
Section 20  Deep Learning

Immunology
Section 21  Adoptive Cell Therapy 1
Section 22  Cancer Vaccines and Intratumoral Immunomodulation
Section 23  Cellular Interactions in the Tumor Microenvironment
Section 24  Suppressive Myeloid Cells
Section 25  Therapeutic Antibodies 2

Epidemiology
Section 26  Genetics and Genomics 1: Outcomes
Section 27  Genetics and Genomics 2: Risk

Prevention Research
Section 28  Nutrition, Screening, and Early Detection for Cancer Prevention

Advocates Poster Session (Scientist↔Survivor Program)
Section 29  Advocates Poster Session 2 [8:00 a.m.—10:00 a.m.]

Bioinformatics and Systems Biology
Section 30  Convergence Science for Biomarkers, Early Detection, and Diagnosis
Section 31  Laboratory and Computational Methods for Cancer Analysis
**MONDAY, APRIL 1**

**Molecular and Cellular Biology/Genetics**

Section 33  Cancer Genomics 2  
Section 34  Deregulated Cell Processes and Carcinogenesis  
Section 35  DNA Damage and Repair 1  
Section 36  Kinases, GTPases, and Phosphatases  
Section 37  miRNA Profiling in Cancer  
Section 38  Noncoding RNAs 1  
Section 39  Signaling Pathways in Cancer Metabolism

**PLENARY SESSION • 8:15 a.m.–10:15 a.m.**

Hall A, Georgia World Congress Center

**Clinical and Translational Research in Diverse Populations**

*Chair:* Lisa A. Newman, New York, NY

8:15 a.m.  **Colorectal cancer in Nigeria: High-tech and low-tech approaches to improving patient outcomes.** Olusegun I. Alatise, Ile-Ife, Osun, Nigeria

8:45 a.m.  **Spliceomics: Alternative RNA splicing as a source of ancestry-related molecular targets in precision oncology and cancer disparities.** Steven R. Patierno, Durham, NC [PL02-02*]

9:15 a.m.  **The DARC side of breast cancer disparities: Links to African ancestry and immunologic tumor responses.** Melissa B. Davis, New York, NY [PL02-03*]

9:45 a.m.  **Genomic and epigenomic studies of cholangiocarcinoma in diverse populations.** Bin Tean Teh, Singapore, Singapore [PL02-04*]

**MEET THE RESEARCH ICON • 10:00 a.m.–10:45 a.m.**

AACR Central Amphitheater, Hall B, Georgia World Congress Center

**Meet the Research Icon: Speaker 1**  
(not eligible for CME credit)

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

120  
AACR ANNUAL MEETING 2019
MEET AND GREET • 10:00 a.m.–11:00 a.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the New Editor-in-Chief of Cancer Epidemiology, Biomarkers & Prevention: Elizabeth A. Platz, ScD, MPH
(not eligible for CME credit)
Elizabeth A. Platz, Baltimore, MD

NCI/NIH-SPONSORED SESSION • 10:30 a.m.–12:00 p.m.
Room A406-407, Georgia World Congress Center
NCI-Sponsored Training Awards and Opportunities
(not eligible for CME credit)
Chair: Michele McGuirl, Bethesda, MD
10:30 a.m.  NCI individual awards for trainees. Michele McGuirl, Rockville, MD
10:50 a.m.  Tips for preparing NCI NRSA Fellowship applications. Mark Damico, Rockville, MD
11:10 a.m.  Tips for preparing NCI Career Development Award applications. Michael K. Schmidt, Rockville, MD
11:30 a.m.  Training opportunities in NCI Intramural Programs. Jonathan S. Wiest, Rockville, MD
11:50 a.m.  Discussion

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
10:30 a.m.–12:15 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center
Liquid Biopsy in Brain Tumors and Metastases
Chair: Harriet Wikman, Hamburg, Germany
10:30 a.m.  Utility of liquid biopsy in brain metastasis research. Harriet Wikman, Hamburg, Germany
11:00 a.m.  Enhancing detection of ctDNA to study the biology of brain tumors and cell-free DNA. Nitzan Rosenfeld, Cambridge, United Kingdom
11:30 a.m.  Microfluidics for the isolation of circulating biomarkers from glioblastoma patients. Shannon L. Stott, Charlestown, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
MONDAY, APRIL 1**

Thomas Murphy Ballroom, Building B, Georgia World Congress Center

Nonpharmacologic Approaches to Improving Survival and Patient-Reported Outcomes

Chair: Jennifer Ligibel, Boston, MA

10:30 a.m.  Putting breast cancer on a diet: Weight loss interventions for cancer prevention and control. Jennifer Ligibel, Boston, MA

11:00 a.m.  Dietary interventions and cancer: Have we moved beyond a low-fat diet? Dorothy D. Sears, La Jolla, CA

11:30 a.m.  Exercise interventions to improve efficacy of cancer treatments: Are we there? Lee W. Jones, New York, NY

Room A311-312, Georgia World Congress Center

Cancer Detection with Proximate Biologic Specimens

Chair: Mark E. Sherman, Jacksonville, FL

10:30 a.m.  Detection of endometrial cancer in lower genital tract specimens. Mark E. Sherman, Jacksonville, FL

11:00 a.m.  Intercepting lung cancer via the airway field of injury. Avrum E. Spira, Boston, MA

11:30 a.m.  Lessons from studying molecular markers in stool for CRC screening. David F. Ransohoff, Chapel Hill, NC

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

ADVANCES IN ORGAN SITE RESEARCH • 10:30 a.m.–12:15 p.m.

Georgia Ballroom 3, Building C, Georgia World Congress Center

Advances in Pancreatic Cancer

Chair: Alec C. Kimmelman, New York, NY

10:30 a.m.  Identifying metabolic dependencies in pancreatic cancer. Alec C. Kimmelman, New York, NY

10:55 a.m.  Pancreatic cancer biology and medicine. David A. Tuveson, Cold Spring Harbor, NY


11:40 a.m.  Immune vulnerabilities in pancreatic cancer. Robert H. Vonderheide, Philadelphia, PA
Small-Cell Lung Cancer: A Glimmer of Light at the End of the Tunnel

Chair: Trudy G. Oliver, Salt Lake City, UT

10:30 a.m. Epigenetic drivers and vulnerabilities in small cell lung cancer. David Macpherson, Seattle, WA

11:00 a.m. Metabolic vulnerabilities in MYC-driven small cell lung cancer. Trudy G. Oliver, Salt Lake City, UT

11:30 a.m. A tuft cell variant of small-cell lung cancer. Christopher R. Vakoc, Cold Spring Harbor, NY

CLINICAL TRIALS PLENARY SESSION 3 • 10:30 a.m.–12:45 p.m.

Sydney Marcus Auditorium, Building A, Georgia World Congress Center

Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong

Chair: Nilofer S. Azad, Baltimore, MD

CT072 Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy. Ryan J. Sullivan, Boston, MA

Discussant: To be announced

CT074 Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. Solange Peters, Lausanne, Switzerland

Discussant: To be announced

CT075 Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies. James Gulley, Bethesda, MD

Discussant: Maura L. Gillison, Houston, TX

CT073 Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. Hyun Cheol Chung, Seoul, Korea

Discussant: To be announced
MONDAY, APRIL 1**

MAJOR SYMPOSIA • 10:30 a.m.–12:15 p.m.

Room A402-403, Georgia World Congress Center

Regulatory Science and Policy Session

Artificial Intelligence and Machine Learning for Regulatory Science and Drug Development Applications

Chair: Sean Khozin, Silver Spring, MD

Speakers: Metin N. Gurcan, Winston-Salem, NC
Lawrence H. Schwartz, New York, NY
Pratik Shah, Cambridge, MA

Room B401-402, Georgia World Congress Center

Circadian Rhythms and Cancer

Chair: Joseph Bass, Chicago, IL

10:30 a.m. Introduction

10:35 a.m. MYC, clock function, and metabolic vulnerabilities of cancer. Chi Van Dang, New York, NY

11:05 a.m. How does circadian disruption impact c-MYC expression and tumorigenesis? Katja Lamia, La Jolla, CA

11:35 a.m. Clock-HIF signaling in the epigenetic control of glucose metabolism. Clara Bien Peek, Chicago, IL [SY37-03*]

Room A411-412, Georgia World Congress Center

Molecular Determinants and Dynamics of Metastasis

Chair: Christina Curtis, Stanford, CA

10:30 a.m. Introduction

10:35 a.m. Evolutionary constraints, timing and routes of metastasis. Christina Curtis, Stanford, CA

11:05 a.m. Multimodal evolutionary dynamics in pancreatic cancer. Christine A. Iacobuzio-Donahue, New York, NY

11:35 a.m. Immune resistant latent pancreatic cancer metastases. Douglas T. Fearon, Cold Spring Harbor, NY

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B206, Georgia World Congress Center

**Multilevel Consideration of Cancer Health Disparities: Contextual Factors to Molecular Features**

*Chair:* Jennifer A. Doherty, Salt Lake City, UT

**10:30 a.m. Introduction**

**10:35 a.m. Building infrastructures to address multilevel determinants of cancer health disparities.** Scarlett L. Gomez, San Francisco, CA

**11:05 a.m. Environmental, behavioral, social, and genomic factors underlying cancer health disparities in Hispanic and American Indian populations of the American Southwest.** Cheryl L. Willman, Albuquerque, NM

**11:35 a.m. Do molecular features of ovarian cancer contribute to disparities in survival?** Jennifer A. Doherty, Salt Lake City, UT

Georgia Ballroom 2, Building C, Georgia World Congress Center

**Organ-Specific Immunity**

*Chair:* Donna L. Farber, New York, NY

**10:30 a.m. Introduction**

**10:35 a.m. High-resolution analysis of tissue T cells in health and disease.** Donna L. Farber, New York, NY

**11:05 a.m. Human skin-resident T cells: The ups and downs of on-site immunity.** Rachael A. Clark, Boston, MA

**11:35 a.m. Deconstructing tumor-infiltrating T-cell heterogeneity through analysis of antigen specificity.** Evan Newell, Seattle, WA

Room B302-303, Georgia World Congress Center

**Prediagnostic Exposures and Tumor Mutational Signatures in Population Studies**

*Chair:* Peter Kraft, Boston, MA

**10:30 a.m. Introduction**

**10:35 a.m. Mutational signatures in liver cancer identify viral infection and exposure to genotoxic.** Jessica Zucman-Rossi, Paris, France

**11:05 a.m. Sherlock-Lung: Tracing lung cancer mutational processes in never smokers.** Maria Teresa Landi, Bethesda, MD [SY26-02*]

**11:35 a.m. The impact of genomic ancestry on the mechanisms of mutational signatures.** Paz Polak, New York, NY

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
MONDAY, APRIL 1**

Room B304-305, Georgia World Congress Center

**Regulation and Function of TP53**

**Chair:** Carol L. Prives, New York, NY

10:30 a.m. **Introduction**

10:35 a.m. **Deconstructing p53 tumor suppression programs.** Laura D. Attardi, Stanford, CA

11:05 a.m. **Modulation of wild-type p53 activity in cancer cells and in the tumor microenvironment.** Moshe Oren, Rehovot, Israel [SY32-02*]

11:35 a.m. **Regulation of lipids by the p53 network is associated with tumor suppression.** Carol L. Prives, New York, NY

Room B405-407, Georgia World Congress Center

**Systems Epigenetics in Hormone-Driven Cancers**

**Chair:** Tim Hui-Ming Huang, San Antonio, TX

10:30 a.m. **Introduction**

10:35 a.m. **Epigenomic approaches to identify transcriptional dependencies in prostate cancer.** Qianben Wang, Durham, NC

11:05 a.m. **Cistrome mining for new therapeutic targets in hormone-dependent cancers.** Myles A. Brown, Boston, MA

11:35 a.m. **Long-range epigenetic control of estrogen-responsive transcription.** Tim Hui-Ming Huang, San Antonio, TX [SY43-03*]

Hall A, Georgia World Congress Center

**The Microbiome as an Orchestrator of Immunity and Cancer Immunotherapy**

**Chair:** Giorgio Trinchieri, Bethesda, MD

10:30 a.m. **Introduction**

10:35 a.m. **Immunologic orchestrators of intestinal homeostasis.** Gregory Sonnenberg, New York, NY

11:05 a.m. **The microbiome in cancer therapy.** Giorgio Trinchieri, Bethesda, MD

11:35 a.m. **Diet, lifestyle, and the microbiome: Burgeoning targets in immunotherapy.** Carrie R. Daniel-MacDougall, Houston, TX

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
MEET AND GREET • 11:00 a.m.–12:00 p.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the Editor-in-Chief of Cancer Discovery: Lewis C. Cantley, PhD
(not eligible for CME credit)
Lewis C. Cantley, New York, NY

SPECIAL SESSION • 12:00 p.m.–1:00 p.m.
Room B408, Georgia World Congress Center
Annual Business Meeting of Members
(not eligible for CME credit)
AACR Chief Executive Officer: Margaret Foti, Philadelphia, PA
AACR President: Elizabeth M. Jaffee, Baltimore, MD
AACR President-Elect: Elaine R. Mardis, Columbus, OH
AACR Past President: Michael A. Caligiuri, Duarte, CA
AACR Treasurer: William N. Hait, Raritan, NJ

NCI/NIH-SPONSORED SESSION • 12:15 p.m.–1:45 p.m.
Room A406-407, Georgia World Congress Center
The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research
(not eligible for CME credit)
Chair: Sarah S. Hook, Bethesda, MD
12:15 p.m. Overview and RAS inhibitors. Frank McCormick, San Francisco, CA
12:25 p.m. Structural biology. Dhirendra K. Simanshu, Frederick, MD
12:45 p.m. Modeling RAS membrane interactions. Andrew G. Stephen, Frederick, MD
1:05 p.m. KRAS metabolic vulnerability. Kanika Sharma, Frederick, MD
1:25 p.m. RAS interaction with calmodulin. Constance Agamasu, Frederick, MD

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
MONDAY, APRIL 1**

SPECIAL SESSION • 12:30 p.m.–2:30 p.m.
Room A311-312, Georgia World Congress Center
Prediction of Risk and Response: Stand Up To Cancer Open Scientific Session
(not eligible for CME credit)
Moderator: Phillip A. Sharp, Cambridge, MA

12:30 p.m. Immunogenomic contexture of colorectal cancer. Marios Giannakis, Boston, MA
12:54 p.m. Improving access to genetic testing and cancer prevention strategies for families of pancreatic cancer patients: The GENERATE study. Sapna Syngal, Boston, MA
1:18 p.m. Integrated biomarkers for lung cancer interception and early detection. Avrum E. Spira, Boston, MA
1:42 p.m. Identifying determinants of response to PD-1 inhibitors in non-small cell lung cancer. Justin F. Gainor, Boston, MA
2:06 p.m. Single-cell metabolic response to treatment in pancreas cancer organoids. Melissa C. Skala, Madison, WI

SPECIAL SESSION • 1:00 p.m.-2:00 p.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
AACR-Cancer Research UK Transatlantic Postdoctoral Fellowships Information Session
(not eligible for CME credit)

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
1:00 p.m.–2:45 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center
Clonal Cooperation in Cancer
Chair: Joan S. Brugge, Boston, MA

1:00 p.m. Transient commensalism drives solid peritoneal metastasis in a model of ovarian clear cell carcinoma. Joan S. Brugge, Boston, MA
1:30 p.m. Cancer evolution and immune evasion: insights from TRACERx. Charles Swanton, London, United Kingdom
2:00 p.m. Cooperation, multicellularity and cancer: How cancer cells evolve to cheat and cooperate in the multicellular milieu. Athena Aktipis, San Francisco, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Hall A, Georgia World Congress Center

**T-Cell Bispecifics: What Have We Learned about T-Cell Engagers in the Clinic?**

Chair: Gregory R. Friberg, Thousand Oaks, CA

1:00 p.m. Lessons learned from blinatumomab and the bispecific T-cell engagers (BiTEs). Gregory R. Friberg, Thousand Oaks, CA
(not eligible for CME credit)

1:30 p.m. Lessons learned with DARTs and other bispecifics. Ian McCaffery, Thousand Oaks, CA

2:00 p.m. T cell bispecific antibodies (TCB) in clinical development: Lessons learned. Dominik Ruettinger, Penzberg, Germany

**ADVANCES IN ORGAN SITE RESEARCH • 1:00 p.m.–2:45 p.m.**

Georgia Ballroom 3, Building C, Georgia World Congress Center

**Emerging Immunotherapies for Childhood Cancer**

Chair: Crystal L. Mackall, Stanford, CA

1:00 p.m. Title to be announced. Uri Y. Tabori, Toronto, ON, Canada

1:30 p.m. The evolving landscape of CAR T-cell based immunotherapy in hematologic malignancies. Nirali Shah, Bethesda, MD

2:00 p.m. Unleashing the innate and adoptive immune systems for the treatment of pediatric solid tumors. Robbie G. Majzner, Palo Alto, CA

2:30 p.m. Discussion

Room B401-402, Georgia World Congress Center

**Genetic Predisposition in Hematologic Malignancies**

Chair: Charles G. Mullighan, Memphis, TN

1:00 p.m. Diagnosis and management of patients with germline predisposition to hematopoietic malignancies. Lucy A. Godley, Chicago, IL

1:30 p.m. SAMD9 and SAMD9L germline mutations in pediatric MDS and familial monosomy 7. Jeffery Kico, Memphis, TN

2:00 p.m. Germline determinants of susceptibility and drug response in acute lymphoblastic leukemia. Charles G. Mullighan, Memphis, TN
MONDAY, APRIL 1**

MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.
Georgia Ballroom 2, Building C, Georgia World Congress Center

Defining Systemic Tumor-Host Communication in Cancer Progression and Therapy Responses

Chair: Mikala Egeblad, Cold Spring Harbor, NY

1:05 p.m. Tumor-bone communications: Immune-suppressive effects of Dkk1. Roberta Faccio, St. Louis, MO

1:30 p.m. Neutrophils activated during inflammation drive metastasis and awakening of dormant disseminated cancer cells. Mikala Egeblad, Cold Spring Harbor, NY

1:55 p.m. Reprogramming tumor microenvironment metabolism to improve immunotherapy. Greg M. Delgoffe, Pittsburgh, PA

2:15 p.m. Improving immunotherapy efficacy by understanding mechanisms of resistance. Thomas F. Gajewski, Chicago, IL

Room B302-303, Georgia World Congress Center

Deregulation of Histone Modifiers in Cancer

Chair: Sharon Y. R. Dent, Smithville, TX

1:05 p.m. SAGA functions in development and disease. Sharon Y. R. Dent, Smithville, TX

1:35 p.m. Aberrant polycomb repression in midline and hindbrain tumors. Peter W. Lewis, Madison, WI [SY44-02*]

2:05 p.m. Principles of epigenetics and chromatin in development and human disease. Ali Shilatifard, Chicago, IL

Room B405-407, Georgia World Congress Center

Dharma Master Jiantai Symposium in Targeted Therapy: Systematic Elucidation of Nononcogene Targets

Chair: William C. Hahn, Boston, MA

1:05 p.m. Chemical biology-based approach to understanding and overcoming resistance of cancers to therapies. Stuart L. Schreiber, Cambridge, MA [SY42-01*]

1:30 p.m. Inactivating STK11/LKB1 genomic alterations are a major driver of primary resistance to PD-1 axis blockade in nonsquamous non-small cell lung cancer. Ferdinados Skoulidis, Houston, TX

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
1:50 p.m. Strategies to overcome resistance to targeted therapy of lymphoma based on functional genomic and chemical screens. Louis M. Staudt, Bethesda, MD

2:15 p.m. Systematic interrogation of cancer dependencies and synthetic lethal interactions. William C. Hahn, Boston, MA [SY42-03*]

Room A402-403, Georgia World Congress Center
Regulatory Science and Policy Session
Differentiation Syndrome in Acute Myeloid Leukemia: Challenges for Drug Development and Regulation

Cochairs: Kelly J. Norsworthy, Silver Spring, MD; E. Dianne Pulte, Silver Spring, MD
Speakers: Jessica K. Altman, Chicago, IL
Mark J. Levis, Baltimore, MD
B. Douglas Smith, Baltimore, MD
Feng Wang, Houston, TX

Thomas Murphy Ballroom, Building B, Georgia World Congress Center
Evolution and Development of Resistance to Therapy

Chair: Carlo C. Maley, Tempe, AZ
1:05 p.m. Lessons from agriculture for how to manage therapeutic resistance. Carlo C. Maley, Tempe, AZ

1:35 p.m. Personalized adaptive therapy for metastatic cancer: An integrated approach. Alexander R. A. Anderson, Tampa, FL [SY38-02*]

2:05 p.m. From evolutionary mathematical modeling to clinical validation in glioblastoma patients: Lessons learned. Franziska Michor, Boston, MA

Room B312-314, Georgia World Congress Center
Liquid Biopsies: From Validation to Clinical Utility

Chair: Howard I. Scher, New York, NY
1:05 p.m. Development and validation of a clinical-grade cell-free DNA profiling assay: MSK-ACCESS. Dana Wai Yi Tsui, New York, NY [SY31-01*]

1:35 p.m. Clinical utility trials for CTC and ctDNA in ER+ advanced breast cancer. Francois-Clement Bidard, Paris, France [SY31-02*]

2:05 p.m. Predictive biomarkers in circulating tumor cells to direct management of metastatic castration-resistant prostate cancer (mCRPC). Howard I. Scher, New York, NY [SY31-03*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
MONDAY, APRIL 1**

Room A411-412, Georgia World Congress Center
**Metabolism: The New Kids on the Block in Cancer Care**

**Chair:** Eyal Gottlieb, Haifa, Israel

1:05 p.m.  **Metabolic consequences and liabilities of TCA cycle truncation in cancer.** Eyal Gottlieb, Haifa, Israel [SY19-01*]

1:35 p.m.  **Metabolic tumor suppressors and disease progression.** M. Celeste Simon, Philadelphia, PA [SY19-02*]

2:05 p.m.  **Integrating single-cell RNA-seq and metabolic network analysis in the context of tumor response to checkpoint therapy.** Maxim Artyomov, St. Louis, MO

Room B206, Georgia World Congress Center
**Minimal Residual Disease: From Bench to Bedside**

**Chair:** Janine T. Erler, Copenhagen, Denmark

1:05 p.m.  **Elucidating the prometastatic niche.** Janine T. Erler, Copenhagen, Denmark

1:35 p.m.  **Solid tumor cancer stem cells: From bench to bedside.** Michael F. Clarke, Stanford, CA [SY17-02*]

2:05 p.m.  **Detection of BRAFV600E mutation in lymphatic drainage-derived extracellular vesicles as prognosis factor and residual disease indicator in melanoma.** Laura Nogues, Madrid, Spain

Room B304-305, Georgia World Congress Center
**Multilevel Consideration of Cancer Health Disparities: Contextual Factors to Molecular Features**

**Chair:** Melissa B. Davis, New York, NY

1:05 p.m.  **Esophageal GSTT2 and racial differences in esophageal adenocarcinoma.** David G. Beer, Ann Arbor, MI

1:35 p.m.  **Evaluating the role of tumor biology in cancer health disparity.** Jennie L. Williams, Stony Brook, NY

2:05 p.m.  **Lessons from studying colorectal cancer in Nigeria.** T. Peter Kingham, New York, NY

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Sydney Marcus Auditorium, Building A, Georgia World Congress Center

**The Next Generation of Precision Cancer Medicine: Recognizing and Exploiting the Complexity**

**Chair:** Antonio Iavarone, New York, NY

**1:05 p.m.** Biologic pathway-based tumor classification to inform pharmacologic vulnerability. Antonio Iavarone, New York, NY

**1:30 p.m.** Harnessing genetic interactions to advance whole-exome precision cancer treatment. Eytan Ruppin, College Park, MD [SY45-02*]

**1:55 p.m.** Development of therapeutic strategies by resolving the tumor ecosystem. Benjamin Izar, Boston, MA

**2:15 p.m.** Capturing the therapeutic response heterogeneity at the functional level. Cyril Benes, Charlestown, MA [SY45-03*]

Room A313, Georgia World Congress Center

**Women in Cancer Research Scientific Symposium: Advances in Genetics, Diagnosis, and Therapeutics among Common Cancers in Women**

**Chair:** Lucile L. Adams-Campbell, Washington, DC

**1:05 p.m.** Title to be announced. Nancy E. Davidson, Seattle, WA

**1:30 p.m.** Title to be announced. Edith A. Perez, Jacksonville, FL

**1:55 p.m.** Title to be announced. Marcia R. Cruz-Correa, San Juan, PR

**2:20 p.m.** Title to be announced. Olufunmilayo I. Olopade, Chicago, IL

**POSTER SESSION • 1:00 p.m.–5:00 p.m.**

Hall B, Georgia World Congress Center

*(not eligible for CME credit)*

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print **Guide to Poster Sessions and Exhibits**. A limited number of copies of the **Guide** are available in the Exhibit Hall.

**Cancer Chemistry**

Section 1 Anticancer Agents from Natural Sources

*An extended abstract for this presentation is available in the Invited Abstracts section of the **Proceedings** (the abstract number is listed in brackets above).*
MONDAY, APRIL 1**

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

**Tumor Biology**
Section 2 Epithelial/Mesenchymal Transition (EMT and MET) 2/Premetastatic Niche
Section 3 Extracellular Matrix and Mechanotransduction
Section 4 Models and Drug Discovery
Section 5 Novel Imaging Techniques
Section 6 Secreted Changes in the Tumor Microenvironment: Exosomes and Chemokines
Section 7 Therapeutic Metastasis Prevention
Section 8 Tumor-Stroma Interactions

**Experimental and Molecular Therapeutics**
Section 9 Apoptosis, Necrosis, and Cancer Cell Survival
Section 10 Cellular Responses to Anticancer Agents 2/Overcoming Resistance
Section 11 Drug Resistance 3
Section 12 Molecular Classification of Tumors
Section 13 Novel Screening and Delivery Technologies
Section 14 Novel Therapeutics and Pathways
Section 15 Tyrosine Kinase and Phosphatase Inhibitors 2

**Clinical Trials**
Section 16 Phase I Clinical Trials: Part 3
Section 17 Phase I-III Trials in Progress: Part 1

**Clinical Research**
Section 18 Circulating and Cell-Free Biomarkers for Diagnosis and Monitoring of Cancer 3
Section 19 Combination Immunotherapies 1
Section 20 Current Developments in Noninvasive Biomarkers for Assessment of Cancer 3

**Immunology**
Section 22 Adoptive Cell Therapy 2
Section 23 Cancer and Inflammation
Section 24 Molecular Mechanisms in the Immune Response to Cancer
Section 25 Therapeutic Antibodies 3

**Epidemiology**
Section 26 Early Detection and Risk Prediction

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
**Prevention Research**
Section 27  Behavioral Science and Cancer Control

**Bioinformatics and Systems Biology**
Section 30  Convergence Science for Tumor Biology, Molecular Biology, and Microenvironment
Section 31  Databases and Computational Tools for Cancer Discovery

**Molecular and Cellular Biology/Genetics**
Section 32  BCL-2 Family Proteins
Section 33  Cancer Genomics 3
Section 34  Cell Cycle Biology and Signaling
Section 35  DNA Damage and Repair 2
Section 36  miRNA-Based Diagnostics and Therapeutics
Section 37  Oncogenic Transcription Factor Function
Section 38  Receptors and Growth Factors
Section 39  Targeting Hypoxia and Endoplasmic Reticulum Stress

**NCI/NIH-SPONSORED SESSION • 1:45 p.m.–2:45 p.m.**
Room A406-407, Georgia World Congress Center
New NCI Collaborative Initiatives on Rare Tumors and RASopathies (not eligible for CME credit)

**Chair:** Abby Sandler, Bethesda, MD

**Panelists:** Shivaani Kummar, Palo Alto, CA
Frank McCormick, San Francisco, CA
Lisa Schroyer, Altadena, CA
Brigitte C. Widemann, Bethesda, MD

1:45 p.m.  **MyPART: Engaging rare tumor patients and their families in rare tumor research.** Karlyne M. Reilly, Bethesda, MD

2:00 p.m.  **RASopathies: Natural history study and plans for interventional clinical trials.** Marielle Yohe, Bethesda, MD

2:15 p.m.  **Clinical, genetic, and epidemiologic approaches to cancer etiology.** Sharon A. Savage, Rockville, MD

2:30 p.m.  Panel discussion
MONDAY, APRIL 1**

CAREER DISCUSSION • 2:30 p.m.–3:15 p.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
Career Discussions: Distinguishing Yourself from Your Mentor
Organized by the Associate Member Council (AMC)
(not eligible for CME credit)

MEET AND GREET • 3:00 p.m.–3:30 p.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the Editors-in-Chief of Cancer Immunology Research:
Robert D. Schreiber, PhD, and Philip D. Greenberg, MD
Robert D. Schreiber, St. Louis, MO
Philip D. Greenberg, Seattle, WA

SPECIAL SESSION • 3:00 p.m.–4:30 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center
NextGen Stars Spotlight 2: Site-Specific Cancers
3:00 p.m.  Divergent resistance mechanisms to HER2-targeted therapies in breast cancer. Michalina Janiszewska, Jupiter, FL
3:20 p.m.  Functional analysis of 5' UTR mutations in prostate cancer reveals dynamic regulation of clinically relevant gene networks. Yiting Lim, Seattle, WA
3:40 p.m.  Multi-omics analysis reveals a distinct molecular phenotype in patients with young-onset colorectal cancer. Andreana N. Holowatyj, Salt Lake City, UT
4:00 p.m.  Regulation of nutrient stress-induced macropinocytosis in pancreatic cancer. Cosimo Commisso, La Jolla, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
MAJOR SYMPOSIUM • 3:00 p.m.-4:45 p.m.
Room A402-403, Georgia World Congress Center

Science Policy Session
A Discussion of the U.S. Youth E-cigarette Epidemic:
Using Science to Inform Policy to Prevent Another Generation
from the Dangers of Nicotine Addiction

Chair: Roy S. Herbst, New Haven, CT
Panelists: Michele Bloch, Rockville, MD
Alison Cox, London, United Kingdom
D’Jilisser Kelly, Atlanta, GA
Brian A. King, Atlanta, GA
Mitch Zeller, Silver Spring, MD

CLINICAL TRIALS MINISYMPOSIUM 2 • 3:00 p.m.-5:00 p.m.
Marcus Auditorium, Building A, Georgia World Congress Center

The Next Generation of Clinical Trials in Molecularly Driven Therapy

Chair: Colin D. Weekes, Aurora, CO

CT127  Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective
next-generation TRK inhibitor (TRKi). David Hyman, New York, NY

CT128  Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone
receptor positive metastatic breast cancer with prior chemotherapy for advanced disease
(TBRC 035): A phase II study with pharmacodynamic markers. Hope S. Rugo,
San Francisco, CA

CT129  Identifying molecular determinants of response to apalutamide (APA) in patients
(pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN
study. Felix Feng, San Francisco, CA

CT130  Molecular-biologic tumor profiling for drug treatment selection in patients with
advanced and refractory carcinoma: A prospective, two-stage phase II individualized
cancer treatment study. Samantha O. Perakis, Graz, Austria

CT131  Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer
(NSCLC): Integrated analysis of patients enrolled in three trials (STARTRKR-2, STARTRKR-1
and ALKA-372-001). Robert Doebele, Aurora, CO

CT132  Umbralisib monotherapy demonstrates efficacy and safety in patients with
relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration-
directed phase II study. Nathan H. Fowler, Houston, TX

CT133  Interim results of a phase I/II trial of intratumoral CpG, local low-dose radiation,
and oral ibrutinib in patients with low-grade B-cell lymphoma. Tanaya Shree, Stanford, CA
MONDAY, APRIL 1**

LATE-BREAKING MINISYMPOSIUM • 3:00 p.m.-5:00 p.m.
Room B408, Georgia World Congress Center
Minisymposium: Late-Breaking Research 2
Chair: Patrick Hwu, Houston, TX

LB-144  Deletion of Map4k4 enhances CD8 T cell function. Emel Esen, South San Francisco, CA
LB-145  Investigation of T cell dynamic changes in tumor progression by using single-cell data. Hongyi Zhang, Sr., Dallas, TX
LB-146  Phase I CD22 CAR T-cell trial updates. Nirali N. Shah, Bethesda, MD
LB-147  Administration of HER2-CAR T cells after lymphodepletion safely improves T-cell expansion and induces clinical responses in patients with advanced sarcomas. Shoba A. Navai, Houston, TX
LB-148  Combination treatment of the CHK1 inhibitor, SRA737, and low-dose gemcitabine demonstrates profound synergy with anti-PDL1 inducing durable tumor regressions and modulating the immune microenvironment in small-cell lung cancer. Triparna Sen, Houston, TX
LB-149  Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Joo Sang Lee, Bethesda, MD
LB-150  Risk of de novo hepatocellular carcinoma development following use of direct-acting antiviral medications for treatment of chronic hepatitis C virus infection. Samuel O. Antwi, Jacksonville, FL

MAJOR SYMPOSIA • 3:00 p.m.–5:00 p.m.
Room B304, Georgia World Congress Center
AACR/JCA Joint Session: Exosomes in Diagnosis and Treatment of Cancer
Cochairs: Raghu Kalluri, Houston, TX; Takahiro Ochiya, Tokyo, Japan

3:00 p.m.  Basic biology and therapeutic development of engineered exosomes for the treatment of cancer. Raghu Kalluri, Houston, TX
3:25 p.m.  Discussion
3:30 p.m.  Exosomes as a novel therapeutic agent for cancer and regenerative medicine. Takahiro Ochiya, Tokyo, Japan
3:55 p.m.  Discussion
4:00 p.m.  Development of a robust translational pipeline for tumor and immune EV analysis. Jennifer Jones, Bethesda, MD
4:25 p.m.  Discussion
4:30 p.m.  The biologic function of exosomes secreted from senescent cells in the cancer microenvironment. Akiko Takahashi, Tokyo, Japan
4:55 p.m.  Discussion

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Georgia Ballroom 2, Georgia World Congress Center

**Regulatory Science and Policy Session**

**PD-1 Pandemonium: FDA Speaks with Industry on the Past, Present, and Future of PD-1 Drugs**

**Moderators:** Richard Pazdur, Silver Spring, MD
Marc Theoret, Silver Spring, MD

**Panelists:**
Hesham A. Abdullah, Rockville, MD
Kevin Chin, Billerica, MA
Scot Ebbinghuas, Lansdale, PA
Israel Lowy, Tarrytown, NY
Fouad Namouni, Lawrenceville, NJ
Alan B. Sandler, South San Francisco, CA

**MINISYMPOSIA • 3:00 p.m.–5:00 p.m.**

Room B312-314, Georgia World Congress Center

**Clinical Research**

**Present and Future of Biomarkers for Anticancer Immunotherapy**

**Cochairs:** Kurt A. Schalper, New Haven, CT; Vamsidhar Velcheti, New York, NY

3:00 p.m. **Introduction**

3:05 p.m. **2673** Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). Ming Lei, Princeton, NJ (not eligible for CME credit)

3:20 p.m. **2674** Immune profiling in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients. Yuting Liu, New Haven, CT

3:35 p.m. **2675** Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040. Ignacio Melero, Pamplona, Spain

3:50 p.m. **2676** Associations of peripheral biomarkers to outcomes to anti-PD-L1 immune checkpoint blockade in metastatic urothelial cancer. Kobe C. Yuen, South San Francisco, CA (not eligible for CME credit)

4:05 p.m. **2677** MSIClass—identification and classification of microsatellite unstable using cell-free DNA from ultra-low pass sequencing. Yosef E. Maruvka, Cambridge, MA
4:20 p.m.  2678   A clonal expression biomarker improves prognostic accuracy: TRACERx lung. Dhruva Biswas, London, United Kingdom

4:35 p.m.  2679   Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial. Denise M. Wolf, San Francisco, CA

Room C302, Georgia World Congress Center

Epidemiology

Exposures and Genetics in Cancer Risk

Cochairs: Mia M. Gaudet, Atlanta, GA; Mariana C. Stern, Los Angeles, CA

3:00 p.m.   Introduction

3:05 p.m.  2680   Intake of whole grain and dietary fiber and risk of hepatocellular carcinoma among U.S. adults. Wanshui Yang, Boston, MA

3:20 p.m.  2681   Prediagnostic levels of urinary 8-epi-prostaglandin F_2α and prostaglandin E_2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Jian-Min Yuan, Pittsburgh, PA

3:35 p.m.  2682   Analysis of polygenic risk score interaction with coal use and risk of lung adenocarcinoma among never-smoking women in Asia. Batel Blechter, Baltimore, MD

3:50 p.m.  2683   Biomarkers of glucose homeostasis and inflammation and risk of prostate cancer: A case-cohort study. Ying Wang, Atlanta, GA

4:05 p.m.  2684   Identification of 14 novel genetic loci for testicular germ cell tumor susceptibility. Louise C. Pyle, Philadelphia, PA

4:20 p.m.  2685   Identification of circulating protein biomarkers for colorectal cancer risk: A genetic instrument analysis. Xiang Shu, Nashville, TN

4:35 p.m.  2686   Associations between a polygenic risk score and risk of multiple myeloma and its precursor. Alyssa I. Clay-Gilmour, Rochester, MN

Room B401-402, Georgia World Congress Center

Experimental and Molecular Therapeutics

Novel Therapeutic Agents and Screening Approaches

Cochairs: Peter Scott Dragovich, South San Francisco, CA; Melissa M. Vasbinder, Lexington, MA

3:00 p.m.   Introduction

3:05 p.m.  2687   Dolasynthen—a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform. Dorin Toader, Cambridge, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
3:20 p.m. 2688  SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors. Sharsti L. Sandall, Bothell, WA

3:35 p.m. 2689  High-content imaging and single-cell analysis of drug response ex vivo is predictive of clinical outcome for hematologic cancer patients. Gregory I. Vladimer, Vienna, Austria

3:50 p.m. 2690  Massively parallel multiplexed methods to screen hundreds of barcoded cancer cell line models with small molecules or genetic perturbations using next-generation sequencing. Samantha Bender, Cambridge, MA

4:05 p.m. 2691  4D printing of programmable smart material for drug screening in patient-derived organoids. Hatem E. Sabaawy, New Brunswick, NJ

4:20 p.m. 2692  Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies. Zoe Johnson, Geneva, Switzerland

4:35 p.m. 2693  Targeting the Hippo-YAP pathway with novel small-molecule inhibitors of the YAP-TEAD transcription activity. Tracy T. Tang, San Mateo, CA
(not eligible for CME credit)

Room B206, Georgia World Congress Center
Experimental and Molecular Therapeutics
Preclinical Drug Development: Dedicated to the Memory of John Mendelsohn

Chair: William R. Sellers, Cambridge, MA

3:00 p.m. Overview: Preclinical drug development. William R. Sellers, Cambridge, MA

3:20 p.m. 2694  A first-in-class small-molecule modulator of the p300/CBP interactome exhibits broad efficacy in xenograft models of solid tumors and hematologic malignancies. Bernd Hentsch, Waedenswil, Switzerland
(not eligible for CME credit)

3:35 p.m. 2695  Direct targeting of NOTCH transcription complex by a novel small molecule CB-103 circumvents dose-limiting toxicities associated with pan-NOTCH inhibitors. Rajwinder Lehal, Lausanne, Switzerland

3:50 p.m. 2696  Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target. Jennifa Gosling, San Francisco, CA
(not eligible for CME credit)

4:05 p.m. 2697  YPN005, an oral CDK7 inhibitor, exhibits a significant antitumor activity in Myc-driven cancers. Kwang-Ok Lee, Suwon-si, Gyeonggi-do, Republic of Korea
(not eligible for CME credit)
MONDAY, APRIL 1**

4:20 p.m.  2698 eFT226, a potent and selective inhibitor of elf4A, is efficacious in preclinical models of lymphoma. Peggy A. Thompson, San Diego, CA (not eligible for CME credit)

4:35 p.m.  2699 Targeting an ubiquitin-activating enzyme in small-cell lung cancer (SCLC). Safa Majeed, Toronto, ON, Canada

Room B405-407, Georgia World Congress Center

Immunology

Immune Cell Subsets in theSuppressive Tumor Microenvironment

Cochairs: Charles G. Drake, New York, NY; E. John Wherry, Philadelphia, PA

3:00 p.m. Introduction

3:05 p.m.  2700 CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche. Caroline S. Jansen, Decatur, GA

3:20 p.m.  2701 Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade. Brian C. Miller, Brookline, MA

3:35 p.m.  2702 Contribution of effector regulatory T cells to the regulation of antitumor immunity. Jianmei W. Leavenworth, Birmingham, AL

3:50 p.m.  2703 Lymph node colonization promotes distant tumor metastasis through the induction of systemic immune tolerance. Nathan E. Reticker-Flynn, Palo Alto, CA

4:05 p.m.  2704 Immune cell subset composition in ductal carcinoma in situ of the breast. Marie Colombe Agahozo, Rotterdam, Netherlands

4:20 p.m.  2705 Differential stromal macrophagic profiles precede ER+ and ER- breast carcinogenesis. Jodi M. Carter, Rochester, MN

4:35 p.m.  2706 Comprehensive immune profiling of primary tumor-infiltrating lymphocytes isolated from primary non-small cell lung cancer specimens. Johanna K. Kaufmann, Waltham, MA

Room A411-412, Georgia World Congress Center

Immunology

Rational Combinations of Immunotherapy

Cochairs: Naiyer Rizvi, New York, NY; Gregory L. Beatty, Philadelphia, PA

3:00 p.m. Introduction

3:05 p.m.  2707 A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity. Adam B. Keeton, Mobile, AL

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
3:20 p.m.  2708  Potent CAB CTLA4 antibody to reduce immune side effects and toxicities associated with single-agent and combination cancer immunotherapies. William J. Boyle, San Diego, CA (not eligible for CME credit)

3:35 p.m.  2709  Modulation of the tumor-infiltrating lymphocyte population by PARP inhibitor talazoparib in combination with anti-PD1 treatment significantly enhances overall survival in a murine BRCA1-/- breast cancer model. Julia Schüler, Freiburg, Germany

3:50 p.m.  2710  Depletion of CXCR2-dependent myeloid-derived suppressor cells (MDSCs) overcomes anti-PD-1 resistance in a murine model of LKB1-deficient non-small cell lung cancer (NSCLC) with high mutational load. Rui Li, Los Angeles, CA

4:05 p.m.  2711  Rational combination of GITR agonism with PD-1 blockade. Roberta Zappasodi, New York, NY

4:20 p.m.  2712  Effect of combined PD-1 and IL-6 blockade on K-ras mutant lung cancer. Marco A. Ramos-Castaneda, Houston, TX

4:35 p.m.  2713  Development and characterization of AZD8701, a high-affinity antisense oligonucleotide targeting FOXP3 to relieve immunosuppression in cancer. Charles Sinclair, Cambridge, United Kingdom

Room A313-314, Georgia World Congress Center
Molecular and Cellular Biology/Genetics
Exploiting Metabolic Vulnerabilities of Cancer
Cochairs: Dimitrios Anastasiou, London, United Kingdom; Ralph J. DeBerardinis, Dallas, TX

3:00 p.m.  Introduction

3:05 p.m.  2714  Targeting MAT2A in CDKN2A/MTAP-deleted cancers. Kevin Marks, Cambridge, MA

3:20 p.m.  2715  Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma. Richa Bajpai, Atlanta, GA

3:35 p.m.  2716  Autophagy modulates lipid metabolism in liver kinase B1 (LKB1)-deficient Kras-driven lung tumorigenesis. Vrushank D. Bhatt, New Brunswick, NJ

3:50 p.m.  2717  Role of NAD⁺ level by NQO1 enzymatic action in regulation of hair regrowth that prevents chemotherapy induced alopecia. Dipendra Khadka, Iksan, Jeonbuk, Republic of Korea

4:05 p.m.  2718  Insulin-like growth factor-1 signaling promotes mitochondrial turnover and protection in cancer cells. Rosemary O’Connor, Cork, Ireland
MONDAY, APRIL 1**

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

4:20 p.m. **2719 Metabolic product of inositol-trisphosphate 3-kinase B confers chemotherapy resistance by managing redox homeostasis.** Chaoyun Pan, Decatur, GA

4:35 p.m. **2720 Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality.** Jo Ishizawa, Houston, TX

Room A302, Georgia World Congress Center

**Molecular and Cellular Biology/Genetics**

**Structural and Functional Cancer Genomics**

**Cochairs:** Alice Berger, Seattle, WA; Stefan Frohling, Heidelberg, Germany

3:00 p.m. **Introduction**

3:05 p.m. **2721 Establishment of a catalog of somatic genetic alterations of Japanese cancer patients across multiple tumor types at Shizuoka Cancer Center.** Hirotsugu Kenmotsu, Shizuoka, Japan

3:20 p.m. **2722 The genomic landscape of high-grade serous ovarian cancer in long-term survivors.** Dale W. Garsed, Melbourne, Australia

3:35 p.m. **2723 Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.** Stefan Gröschel, Heidelberg, Germany

3:50 p.m. **2724 A combination of short-read and long-read RNA sequencing reveals NOVA1's role in telomere biology.** Andrew T. Ludlow, Ann Arbor, MI

4:05 p.m. **2725 The single-cell atlas of driver mutations in acute myeloid leukemia.** Kiyomi Morita, Houston, TX

4:20 p.m. **2726 Functional multiomic profiling identifies Aurora kinase inhibition as a therapeutic strategy in RIT1-mutant lung adenocarcinoma.** Athea Vichas, Seattle, WA

4:35 p.m. **2727 The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin.** Kirsten Kubler, Cambridge, MA

Room A315-316, Georgia World Congress Center

**Prevention Research**

**Molecular and Cellular Mechanisms in Cancer Prevention Research**

**Chair:** Zvi Livneh, Rehovot, Israel

3:00 p.m. **Introduction**

3:05 p.m. **2728 Cholecystokinin receptor antagonist proglumide reverses nonalcoholic steatohepatitis and prevents hepatocellular carcinoma.** Martha D. Gay, Washington, DC

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
3:20 p.m.  2729 Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer. Deep S. Pandya, Danbury, CT

3:35 p.m.  2730 Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats. Genoveva Murillo, Chicago, IL

3:50 p.m.  2731 A novel PDE10/beta-catenin inhibitor, MCI-048, suppresses lung tumorigenesis to block metastasis. Bing Zhu, Mobile, AL

4:05 p.m.  2732 Frameshift neoantigen vaccination prevents Lynch syndrome mouse model intestinal cancer. Steven M. Lipkin, New York, NY

4:20 p.m.  2733 Novel mouse model carrying APC and PIK3CA mutations in colorectal cancer. Naghma Khan, Madison, WI

4:35 p.m.  2734 Poly-ligand profiling of plasma samples as a potential predictor of prostate biopsy results. Xixi Wei, Phoenix, AZ (not eligible for CME credit)

Room A305, Georgia World Congress Center
Tumor Biology
Invasion and Metastasis 1: Cell-Intrinsic

Cochairs: Andrew E. Aplin, Philadelphia, PA; Ze’ev A. Ronai, La Jolla, CA

3:00 p.m. Introduction

3:05 p.m.  2735 Targeting HDAC prevents smoking-induced pancreatic cancer metastasis. Mouad Edderkaoui, Los Angeles, CA

3:20 p.m.  2736 A molecular and histopathologic map of cancer metastasis. Francisco Sanchez-Vega, New York, NY

3:35 p.m.  2737 PRAME misexpression alters protein ubiquitination and leads to increased invasion and metastasis in uveal melanoma. Margaret I. Sanchez, Miami, FL

3:50 p.m.  2738 Wnt11 regulates migration and invasion in pancreatic ductal adenocarcinoma. Tara Hughes, Houston, TX

4:05 p.m.  2739 EZH2 promotes breast cancer bone metastasis. Jingkun Qu, Houston, TX

4:20 p.m.  2740 MET exon 14 skipping mutation promotes metastasis via activation of the PI3K/Akt-Rac1 pathway in non-small cell lung cancer. Feng Wang, Bronx, NY

4:35 p.m.  2741 Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer. Won-Chul Lee, Houston, TX
MONDAY, APRIL 1**

Room A404-405, Georgia World Congress Center

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

**Tumor Biology**

**Signaling in the Tumor Microenvironment**

**Cochairs:** Amaya Viros Usandizaga, Manchester, United Kingdom; Zvika Granot, Jerusalem, Israel

**3:00 p.m. Introduction**

**3:05 p.m. 2742** Bone marrow-derived stromal cells in the tumor microenvironment might be associated with the progression of gastric cancer. Masakazu Yashiro, Osaka, Japan

**3:20 p.m. 2743** Mesothelioma exosomes as potential new cancer therapy. Phillip B. Munson, Burlington, VT

**3:35 p.m. 2744** Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Ivy X. Chen, Boston, MA

**3:50 p.m. 2745** Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model. Kasey Skinner, Chapel Hill, NC

**4:05 p.m. 2746** Stat3 labels a subpopulation of reactive astrocytes required for brain metastasis. Neibla Priego, Chapel Hill, NC, Spain

**4:20 p.m. 2747** Loss of S100A10 gene suppresses mammary tumor progression in PyMT mouse tumor model. Alamelu Bharadwaj, Halifax, NS, Canada

**4:35 p.m. 2748** The role of TMPRSS2_ERG fusions in modulating tumor microenvironment in prostate cancer. Hubert Pakula, Boston, MA

**Minisymposia (cont’d)**

**10_canprog19_Mon_5.indd** 146

**3/4/19 5:18 PM**
SPECIAL SESSION • 3:00 p.m.–5:00 p.m.

Room A311-312, Georgia World Congress Center

Deploying the Whole Immunotherapy Arsenal: Stand Up To Cancer Open Scientific Session
(not eligible for CME credit)

Moderator: Phillip A. Sharp, Cambridge, MA

3:00 p.m.  Provoking T-cell responses in patients with pancreatic cancer. Robert H. Vonderheide, Philadelphia, PA

3:24 p.m.  Combining TIL adoptive cell therapy with immune checkpoint inhibitor therapy for non-small cell lung cancer. Scott J. Antonia, Durham, NC

3:48 p.m.  Taking next-generation CAR T therapeutics to a broad spectrum of pediatric cancer. Julie R. Park, Seattle, WA


4:36 p.m.  Ecology of the tumor microenvironment in breast cancer. Peter P. Lee, Duarte, CA

AWARDS AND LECTURES • 4:00 p.m.–4:45 p.m.

Georgia Ballroom 3, Building C, Georgia World Congress Center

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

Aspirin and precision prevention of cancer: Who, when, and how? Andrew T. Chan, Boston, MA

MEET AND GREET • 4:00 p.m.–5:00 p.m.

AACR Publications Booth 3226, Hall B, Georgia World Congress Center

Meet the Deputy Editor of Molecular Cancer Research: William C. Hahn, MD, PhD
(not eligible for CME credit)

William C. Hahn, Boston, MA
MONDAY, APRIL 1**

NCI/NIH-SPONSORED SESSION • 4:00 p.m.–5:30 p.m.
Room A406-407, Georgia World Congress Center
Supporting the Translation of Innovative Technologies: Success Stories from the NCI SBIR Program
(not eligible for CME credit)
Chair: Michael Weingarten, Bethesda, MD
Panelists: Katherine Pawelczak, Indianapolis, IN
Anthony J. Capobianco, Miami, FL
Joshua E. Allen, Philadelphia, PA

AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.
Room B302-303, Georgia World Congress Center
AACR G.H.A. Clowes Memorial Award
Stem cells in wound repair, inflammation, and cancer. Elaine Fuchs, New York, NY

TOWN MEETING • 5:00 p.m.–6:15 p.m.
Regency Ballroom VII, Hyatt Regency Atlanta
Minorities in Cancer Research Town Meeting
(not eligible for CME credit)
Chair: Brian M. Rivers, Atlanta, GA

FORUM • 5:00 p.m.–6:30 p.m.
Sydney Marcus Auditorium, Building A, Georgia World Congress Center
Cancer Imaging: Separating the Hype from the Hope in Radiomics and Machine Learning
Moderator: Amber Simpson, New York, NY
Panel: Spyridon Bakas, Philadelphia, PA
Jayashree Kalpathy-Cramer, Charlestown, MA
Chaya Moskowitz, New York, NY

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Thomas Murphy Ballroom, Building B, Georgia World Congress Center
Drugging the Undruggable

Moderator: Moshe Oren, Rehovot, Israel
Panel: Gerard I. Evan, Cambridge, United Kingdom
        Nathanael S. Gray, Boston, MA

Georgia Ballroom 3, Building C, Georgia World Congress Center
Science of Survivorship: The Intersection of Survivorship and Aging

Moderator: Patricia A. Ganz, Los Angeles, CA
Panel: Kirsten K. Ness, Memphis, TN
        Jessica Scott, New York, NY

Room B206, Georgia World Congress Center
The Changing Economics of Cancer

Moderator: William G. Nelson, Baltimore, MD
Panel: Joseph Dimasi, Boston, MA
        Leonard B. Saltz, New York, NY

Georgia Ballroom 1, Building C, Georgia World Congress Center
The Science of Global Community Outreach

Moderators: Brian M. Rivers, Atlanta, GA; Folakemi T. Odedina, Orlando, FL
Panel: Zainab Shinkafi-Bagudu, Abuja, Nigeria
        Lourdes Baezconde-Garbanati, Los Angeles, CA
        Robin Roberts, Nassau, Bahamas

Room B405-407, Georgia World Congress Center
Updates on the Atlas Development

Moderator: Dana Pe’er, New York, NY
Panel: Sean Bendall, Palo Alto, CA
        Mario L. Suvà, Charlestown, MA
MONDAY, APRIL 1**

SPECIAL SESSIONS • 5:00 p.m.–6:30 p.m.
Room B401-402, Georgia World Congress Center
AACR/ASCO Joint Session: Therapeutic Approaches for Breast Cancer Subtypes

Cochairs: Elizabeth M. Jaffee, Baltimore, MD; Sara M. Tolaney, Boston, MA

5:00 p.m.  Treatment strategies for homologous recombination deficient breast cancer: PARP and beyond. Melinda L. Telli, Stanford, CA
5:20 p.m.  Novel strategies for targeting ER. Erika Hamilton, Nashville, TN
5:40 p.m.  Individualizing treatment for early-stage HER2-positive breast cancer. Sara M. Tolaney, Boston, MA
6:00 p.m.  The future of triple-negative breast cancer in the era of biomarkers and immunotherapy. Edith A. Perez, Jacksonville, FL
6:20 p.m.  Discussion

Hall A, Georgia World Congress Center
Making Science Count for Patients: From T-Cell Signaling to CTLA-4 Approval

Chair: Nina Bhardwaj, New York, NY

5:00 p.m.  CTLA-4 blockade in cancer therapy: Historical perspective and new opportunities. James P. Allison, Houston, TX
5:20 p.m.  CTLA-4 and T regulatory cells in autoimmunity and cancer. Jeffrey A. Bluestone, San Francisco, CA
5:40 p.m.  Making ipilimumab. Alan J. Korman, Oakland, CA
6:00 p.m.  The early days of immune checkpoint inhibition: Reducing CTLA-4 blockade to clinical practice. Jedd D. Wolchok, New York, NY

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
AWARDS AND LECTURES • 5:15 p.m.–6:00 p.m.
Georgia Ballroom 2, Building C, Georgia World Congress Center
AACR Princess Takamatsu Memorial Lectureship
Title to be announced. Charles L. Sawyers, New York, NY

SPECIAL SESSION • 5:15 p.m.–6:00 p.m.
Room A307, Georgia World Congress Center
Molecular Epidemiology Working Group (MEG) Networking Session
Roundtables: Stronger Science through Collaborative Research
(not eligible for CME credit)


5:20 p.m. Roundtable discussions
- Cancer Immunology Working Group (CIMM) Representative. Kunle Odunsi, Buffalo, NY
- Chemistry in Cancer Research Working Group (CICR) Representative. Julian Blagg, Cambridge, United Kingdom
- Molecular Epidemiology Working Group (MEG) Representative. Shelley S. Tworoger, Tampa, FL
- Pediatric Cancer Working Group (PCWG) Representative. David Malkin, Toronto, ON, Canada
- Pediatric Cancer Working Group (PCWG) Representative. Smita Bhatia, Birmingham, AL
- Radiation Science and Medicine Working Group (RSM) Representative. Mary Helen Barcellos-Hoff, San Francisco, CA
MONDAY, APRIL 1**

NCI/NIH-SPONSORED SESSION • 5:30 p.m.–6:30 p.m.
Room A406-407, Georgia World Congress Center
**NCI Innovations as a Key Driver of New Company Formation and Early-Stage Technologies**
(not eligible for CME credit)
Chair: Michael L. Salgaller, Rockville, MD

5:30 p.m.  **NCI as your company's technology development partner.** Michael L. Salgaller, Rockville, MD
5:45 p.m.  **NCI activities and programs assisting early-stage companies.** Joseph Conrad, Bethesda, MD
6:00 p.m.  **miReCule, Inc.: Development of a cutting-edge microRNA therapeutics platform in partnership with NIH.** Anthony D. Saleh, Gaithersburg, MD
6:15 p.m.  **From first-in-human to FDA approval in 4 years: The power of partnering with the NCI.** James L. Gulley, Bethesda, MD

TOWN MEETING • 5:30 p.m.–7:30 p.m.
Imperial Ballroom AB, Marquis Level, Atlanta Marriott Marquis
**Radiation Science and Medicine Working Group (RSM) Town Hall Meeting and Reception**
(not eligible for CME credit)
Cochairs: David R. Gius, Chicago, IL; Mary Helen Barcellos-Hoff, San Francisco, CA
Panelists: Constantinos Koumenis, Philadelphia, PA
James M. Larner, Charlottesville, VA
Peter G. Maxim, Indianapolis, IN
Erinn B. Rankin, Stanford, CA

SPECIAL SESSION • 6:00 p.m.–8:00 p.m.
Room A311-312, Georgia World Congress Center
**Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups Evening Scientific Session: Immune Cells in Formation of Metastatic Niche**
(not eligible for CME credit)

6:00 p.m.  **CIMM Chair: Opening remarks.** Dmitry I. Gabrilovich, Philadelphia, PA
6:15 p.m.  **Harnessing immune plasticity in the metastatic niche.** Rosandra Natasha Kaplan, Bethesda, MD

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

152  AACR ANNUAL MEETING 2019
6:45 p.m.  Metastases subvert host tissue stemness program. Ilaria Malanchi, London, United Kingdom

7:15 p.m.  Extracellular matrix-myeloid cells cross-regulation influences the metastatic niche. Mario P. Colombo, Milan, Italy

7:45 p.m.  TME Chair: Closing remarks. Yibin Kang, Princeton, NJ

TOWN MEETING • 6:30 p.m.–8:00 p.m.
Room A315-316, Georgia World Congress Center
Molecular Epidemiology Working Group (MEG)
Town Hall Meeting and Networking Reception
(not eligible for CME credit)

6:30 p.m.  MEG Chair: Opening remarks. Ellen L. Goode, Rochester, MN

6:40 p.m.  MEG Chair-Elect: Remarks. Shelley S. Tworoger, Tampa, FL

6:55 p.m.  Developing transdisciplinary relationships in population studies. Sarah Gehlert, Colombia, SC

7:15 p.m.  Moderator: Discussion. Shelley S. Tworoger, Tampa, FL

7:35 p.m.  Closing remarks. Shelley S. Tworoger, Tampa, FL

PROFESSIONAL ADVANCEMENT SESSION • 6:30 p.m.–8:30 p.m.
Centennial Ballroom III, Hyatt Regency Atlanta
Collaborative Professional Advancement Roundtable
(not eligible for CME credit)

Cochairs: Brian M. Rivers, Atlanta, GA; Kathleen W. Scotto, New Brunswick, NJ; Lucile L. Adams-Campbell, Washington, DC; Allison S. Betof, Durham, NC
TUESDAY, APRIL 2**

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

AWARDS AND LECTURES • 7:00 a.m.–8:00 a.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center
Distinguished Public Service Award Lecture
Overcoming resistance to antibody-targeted cancer immunotherapy
Louis M. Weiner, Washington, DC

MEET-THE-EXPERT SESSIONS • 7:00 a.m.–8:00 a.m.
Room C302, Georgia World Congress Center
A-to-I RNA Editing in Cancer
Erez Y. Levanon, Ramat-Gan, Israel

Room A315-316, Georgia World Congress Center
Defining and Targeting Malignant Brain Tumor Hierarchies
Peter B. Dirks, Toronto, ON, Canada

Room B408, Georgia World Congress Center
Engaging and Involving Patients in Translational Cancer Research
Bodour Salhia, Los Angeles, CA

Room A305, Georgia World Congress Center
A Journey from Phosphotyrosine to Phosphohistidine with Unexpected Links to Pancreatic Cancer and Liver Cancer Along the Way
Tony Hunter, La Jolla, CA

Georgia Ballroom 3, Building C, Georgia World Congress Center
New Single-Cell Methods for Oncology and Immuno-oncology
James R. Heath, Pasadena, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room B302-303, Georgia World Congress Center
Next-Generation Characterization and Functional Mapping of the Cancer Cell Line Encyclopedia: Implications for Targeting Dysregulated Metabolism in Cancer
William R. Sellers, Cambridge, MA

Room A311-312, Georgia World Congress Center
Novel Therapeutic Strategies in Multiple Myeloma
Kenneth C. Anderson, Boston, MA

Room A302, Georgia World Congress Center
Obesity: Changing the Landscape for Cancer Risk in Populations
Elizabeth A. Platz, Baltimore, MD

Room B304-305, Georgia World Congress Center
Prostate Cancer Health Disparity
Timothy R. Rebbeck, Boston, MA

Room A313-314, Georgia World Congress Center
Radiation and Immunotherapy in Breast Cancer
Silvia C. Formenti, New York, NY

Room B206, Georgia World Congress Center
Title to Be Announced
Jeffrey A. Engelman, Cambridge, MA
(not eligible for CME credit)

Room B401-402, Georgia World Congress Center
What Cancer Genomes Tell Us about the Origins of Breast Cancer
Olufunmilayo I. Olopade, Chicago, IL
TUESDAY, APRIL 2**

POSTER SESSION • 8:00 a.m.–12:00 p.m.
Hall B, Georgia World Congress Center
(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print Guide to Poster Sessions and Exhibits. A limited number of copies of the Guide are available in the Exhibit Hall.

Cancer Chemistry
Section 1 Cancer Chemical Biology and Therapeutics Development

Tumor Biology
Section 2 Expression Profiling and Biomarkers of Tumor Progression and Metastasis
Section 3 Immune Cells in the Tumor Microenvironment 2
Section 4 Inflammation and Microbiome
Section 5 Invasion and Migration 1
Section 6 Targets and Therapies in Pediatric Cancer
Section 7 Tumor Evolution and Heterogeneity 1
Section 8 Tumor Radiosensitivity or Resistance

Experimental and Molecular Therapeutics
Section 9 Cellular and Molecular Pharmacology, Pharmacogenomics, Pharmacogenetics, and Therapeutic Response
Section 10 Cellular Responses to Anticancer Agents 3: Novel Targets
Section 11 Diagnostics, Biomarkers, and the Tumor Microenvironment
Section 12 Drug Resistance 4
Section 13 New Target Identification
Section 14 Novel Antitumor Agents 1

Clinical Trials
Section 16 Phase II-III Clinical Trials: Part 1
Section 17 Phase I-III Trials in Progress: Part 2

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Clinical Research
Section 18 Immune Infiltration and Immune Therapy
Section 19 New Discoveries in Childhood Cancer
Section 20 Novel Strategies for Biomarker Identification and Use in Cancer 1
Section 21 Tumor Markers to Assess the Biology and Clinical Course of Cancer 1

Immunology
Section 22 Adoptive Cell Therapy 3
Section 23 Combination Immunotherapies 2
Section 24 Immune Checkpoints 1
Section 25 Novel Immunomodulatory Agents 1

Epidemiology
Section 27 Factors Influencing Cancer Outcomes

Prevention Research
Section 28 Clinical Prevention, Early Detection, and Interception 1

Science and Health Policy/Regulatory Science and Policy
Section 29 Science and Health Policy 1
Section 30 Science and Health Policy 2/Regulatory Science and Policy

Bioinformatics and Systems Biology
Section 31 Applications of Cancer Computational Biology 1

Molecular and Cellular Biology / Genetics
Section 32 Cancer Genomics 4
Section 33 Cell Signaling 1
Section 34 Deregulated Tumor Suppressors and Carcinogenesis
Section 35 DNA Damage and Repair 3
Section 36 High-Throughput Sequencing
Section 37 miRNAs as Tumor Suppressors/Oncogenes
Section 38 Noncoding RNAs 2
Section 39 Targeting Metabolism for Cancer Therapy
PLENARY SESSION • 8:15 a.m.–10:15 a.m.

Hall A, Georgia World Congress Center

Manipulating the Immune System in Cancer Therapy

Chair: Padmanee Sharma, Houston, TX

8:15 a.m.  T-cell therapy targeting unique cancer mutations. Steven A. Rosenberg, Bethesda, MD
8:45 a.m.  Redirecting T cells for cancer immunotherapy using next-generation bispecific antibodies and fusion proteins. Pablo Umana, Zurich, Switzerland
9:15 a.m.  Taming the beast: Strategies to target the immune-suppressive macrophage to enhance cancer immune therapy. Judith A. Varner, La Jolla, CA [PL03-03*]
9:45 a.m.  Mismatch repair deficiency: A connection between the immune system and cancer genetics. Dung T. Le, Baltimore, MD

PROFESSIONAL ADVANCEMENT SESSION • 8:30 a.m.–2:00 p.m.

Grand Ballroom, Omni Atlanta Hotel

AACR Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers (not eligible for CME credit)

Chair: Kathleen W. Scotto, New Brunswick, NJ

9:10 a.m.  Special remarks from AACR President. Elizabeth M. Jaffee, Baltimore, MD
9:30 a.m.  Understanding cancer. Speaker to be announced
9:50 a.m.  Keys to cancer prevention. Speaker to be announced
10:10 a.m. Message from an advocate. Speaker to be announced
10:40 a.m. Why cancer research needs you! Speaker to be announced
MEET THE RESEARCH ICON • 10:00 a.m.–10:45 a.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
Meet the Research Icon: Speaker 2
(not eligible for CME credit)

MEET AND GREET • 10:00 a.m.–11:00 a.m.
AACR Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the New Editor-in-Chief of Molecular Cancer Therapeutics:
Beverly A. Teicher, PhD
(not eligible for CME credit)
Beverly A. Teicher, Bethesda, MD

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
10:30 a.m.–12:15 p.m.
Room A411-412, Georgia World Congress Center
Intratumoral Immunotherapy: Using the Tumor as the Remedy
Chair: Aurelien Marabelle, Villejuif, France

10:30 a.m.  Starting the fight in the tumor: Principles for intratumoral immunotherapy.
Aurelien Marabelle, Villejuif, France

10:55 a.m.  Can all cancers be treated by intratumoral immunotherapy?
Thierry de Baere, Villejuif Cedex, France

11:20 a.m.  Early and late immune analysis post intratumoral TLR 9 agonist in combination with ipilimumab in patients with anti-PD-1 refractory melanoma.
Adi Diab, Houston, TX

11:30 a.m.  If losing Batf3-DC makes anti-PD1 fail, will bringing Batf3-DC to the tumor make anti-PD1 work?
Joshua D. Brody, New York, NY

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
TUESDAY, APRIL 2**

Room B401-402, Georgia World Congress Center
**RNA Editing in Cancer Pathophysiology**

**Chair:** Seishi Ogawa, Kyoto-shi Sakyo-ku, Japan

10:30 a.m.  *Loss of ADAR1 in tumors overcomes resistance to immune checkpoint blockade.* W. Nicholas Haining, Boston, MA

11:00 a.m.  *The role of A-to-I RNA editing in diversifying the cancer genome.* Han Liang, Houston, TX

11:30 a.m.  *RNA editing and small RNA/RBP crosstalk in cancer.* Hiroshi Suzuki, Cambridge, MA

Room B405-407, Georgia World Congress Center
**Vaccines**

**Chair:** Gerald P. Linette, Philadelphia, PA

10:30 a.m.  *Clinical approaches to neoantigen vaccines.* Charles G. Drake, New York, NY

11:00 a.m.  *Exploiting synthetic DNA technology for immunotherapy of cancer.* David Weiner, Philadelphia, PA

11:30 a.m.  *Breast cancer vaccines: Where are we and where are we going?* Elizabeth A. Mittendorf, Boston, MA

**ADVANCES IN ORGAN SITE RESEARCH • 10:30 a.m.–12:15 p.m.**

Room B302-303, Georgia World Congress Center
**Advances in Multiple Myeloma**

**Chair:** Irene M. Ghobrial, Boston, MA

10:30 a.m.  *Immunotherapy and immune regulation in MM.* Madhav V. Dhodapkar, Atlanta, GA

11:00 a.m.  *Genomics in MM and future of precision medicine.* Brian Walker, Little Rock, AR

11:30 a.m.  *Early intervention and clonal evolution in MGUS/SMM.* Irene M. Ghobrial, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Neuroendocrine Tumors: Genomics, Genetics, and Therapy

Chair: Daniel C. Chung, Boston, MA

10:30 a.m. Genomics of multifocal small intestinal neuroendocrine tumors. Matthew L. Meyerson, Boston, MA

11:00 a.m. Systematic identification and pharmacologic targeting of GEP-NET dependencies. Andrea Califano, New York, NY

11:30 a.m. Translational research in neuroendocrine tumors: Implications for clinical trial design. Emily K. Bergsland, San Francisco, CA

ADVANCES IN PREVENTION AND INTERCEPTION
10:30 a.m.–12:15 p.m.

Georgia Ballroom 3, Building C, Georgia World Congress Center

Role of Chronic Stress in the Etiology of Cancer

Chair: Shelley S. Tworoger, Tampa, FL

10:30 a.m. Psychosocial stress as a novel risk factor for cancer: An epidemiologic perspective. Shelley S. Tworoger, Tampa, FL

11:00 a.m. Biologic mechanisms of stress systems on DNA damage and early cancer progression. Melanie S. Flint, Brighton, United Kingdom

11:30 a.m. Psychoneuroimmunology in cancer development and accelerated aging. Janice Kiecolt-Glaser, Columbus, OH

MAJOR SYMPOSIA • 10:30 a.m.–12:15 p.m.

Room A402-403, Georgia World Congress Center

Regulatory Science and Policy Session

ACCELERATE-ing Pediatric Oncology Drug Discovery and Development

Chair: Crystal L. Mackall, Stanford, CA

Speakers: Gregory H. Reaman, Silver Spring, MD
Peter C. Adamson, Philadelphia, PA
Mark W. Kieran, Lawrenceville, NJ
Andrew Pearson, London, United Kingdom
Gilles Vassal, Villejuif, France

Panelists: Patricia Blanc, Fourqueux, France
Nancy Goodman, Washington, DC
Susan Weiner, Brooklyn, NY
TUESDAY, APRIL 2**

Room B304-305, Georgia World Congress Center

**Bone Marrow Sensing of Distant Tumors: From Early Detection to Possible Therapy**

**Chair:** Mario P. Colombo, Milan, Italy

**10:35 a.m.** Tumors talk to bones, bones answer back. Mikael J. Pittet, Boston, MA

**11:05 a.m.** Bone marrow remodeling in response to distant tumor starts early in transformation. Mario P. Colombo, Milan, Italy [SY35-02*]

**11:35 a.m.** Metastatic breast cancer to bone resistance to therapy and dormancy. Jacqueline F. Bromberg, New York, NY

Georgia Ballroom 2, Building C, Georgia World Congress Center

**Convergence of Artificial Intelligence, Big Data, and Prediction in Cancer**

**Chair:** Eliezer M. Van Allen, Brookline, MA

**10:35 a.m.** Convergence of clinical cancer genomics and machine learning for translational discovery. Eliezer M. Van Allen, Brookline, MA

**11:00 a.m.** What is drug resistance and how to predict it. Anna Goldenberg, Toronto, ON, Canada

**11:25 a.m.** Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology. David Liu, Boston, MA

**11:45 a.m.** Rethinking risk models. Regina Barzilay, Cambridge, MA

Hall A, Georgia World Congress Center

**Escape from Immunosurveillance and Therapeutic Opportunities Aimed at Tumor Escape**

**Chair:** Robert D. Schreiber, St. Louis, MO

**10:35 a.m.** The molecular cell biology of cancer immunosurveillance/immunoediting. Robert D. Schreiber, St. Louis, MO

**11:05 a.m.** Evaluating mechanisms of response and resistance to immune checkpoint therapy. Padmanee Sharma, Houston, TX

**11:35 a.m.** Combination therapies to overcome resistance to PD-1 blockade therapy. Antoni Ribas, Los Angeles, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Georgia Ballroom 1, Building C, Georgia World Congress Center

**Germline-Somatic Interactions in Cancer Risk and Tumor Evolution**

**Chair:** Alexander Gusev, Boston, MA

**10:35 a.m.** Identification of enhancer elements at kidney cancer susceptibility loci using genome-wide approaches in which post-GWAS functional studies implicate the SWI/SNF DPF3 gene for the 14q24 risk locus. Stephen J. Chanock, Rockville, MD [SY25-01*]

**11:05 a.m.** Widespread germline-somatic regulatory differences in renal cell carcinoma prioritize risk mechanisms. Alexander Gusev, Boston, MA [SY25-02*]

**11:35 a.m.** Germline MHC-I and -II variation constrains the somatic mutational landscape. Rachel Marty, La Jolia, CA [SY25-03*]

Room B312-314, Georgia World Congress Center

**Metastasis: Evidence and Clinical Implications of Early Dissemination**

**Chair:** Klaus Pantel, Hamburg, Germany

**10:35 a.m.** Blood-borne tumor cell dissemination in cancer patients. Klaus Pantel, Hamburg, Germany [SY23-01*]

**11:05 a.m.** Actions of the EMT Program in fostering malignant progression. Robert A. Weinberg, Cambridge, MA

**11:35 a.m.** Minimal residual disease, tumor dormancy, and cancer recurrence: Therapeutic opportunities. Lewis A. Chodosh, Philadelphia, PA

Room B206, Georgia World Congress Center

**Minorities in Cancer Research Scientific Symposium: Tumor Biology Correlates of Population Differences in Environmental Exposures**

**Cochairs:** Laura Fejerman, San Francisco, CA; Rick A. Kittles, Duarte, CA

**10:40 a.m.** Vitamin D and prostate cancer disparities: From epidemiology to biologic mechanisms. Rick A. Kittles, Duarte, CA

**11:00 a.m.** Colon cancer disparities: Diet, inflammation, and colon cancer biology. Nathan A. Ellis, Tucson, AZ

**11:20 a.m.** Breast cancer disparities: Obesity, inflammation, and breast cancer biology. Victoria L. Seewaldt, Duarte, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above)."
TUESDAY, APRIL 2**

Tumor Metabolism and DNA Damage Response

Chair: Peter M. Glazer, New Haven, CT

10:35 a.m. Analyzing tumor metabolism in patients. Ralph J. DeBerardinis, Dallas, TX [SY21-01*]

11:05 a.m. Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand break. Peter M. Glazer, New Haven, CT [SY21-02*]

11:35 a.m. Shutting off cancer's fountain of youth: Targeting metabolism to block repair and reverse immortality. Stephen J. Kron, Chicago, IL [SY21-03*]

NCI/NIH-SPONSORED SESSION • 10:30 a.m.–12:15 p.m.

Funding Opportunities for Cancer Research at Multiple NIH Institutes and Centers (not eligible for CME credit)

Co-chairs: Julia T. Arnold, Bethesda, MD; Sundar Venkatachalam, Rockville, MD

10:30 a.m. Introduction. Sundar Venkatachalam, Rockville, MD

10:37 a.m. Sailaja Koduri, Bethesda, MD

10:44 a.m. Solita Chiayeng Wang, Bethesda, MD

10:51 a.m. Mukesh Verma, Bethesda, MD

10:58 a.m. Gary J. Murray, Bethesda, MD

11:05 a.m. Abee Boyles, Durham, NC

11:12 a.m. Syed Musaddaq Quadri, Bethesda, MD

11:19 a.m. Wrap-up. Julia T. Arnold, Bethesda, MD

11:26 a.m. Panel discussion

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
**SPECIAL SESSION • 10:30 a.m.–12:30 p.m.**

Room C302, Georgia World Congress Center

**Radiation Science and Medicine Working Group Scientific Session: Biologic Repercussions of Aging and Age-Related Processes on Therapeutic Irradiation**

**Chair:** Mary Helen Barcellos-Hoff, San Francisco, CA

10:35 a.m.  **Reducing age-associated radiation and chemotherapy normal tissue injury.** Bryan G. Allen, Iowa City, IA

11:00 a.m.  **Nonmutational effects of radiation on aging.** Ken Raj, London, United Kingdom

11:45 a.m.  **Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma mode.** Susanna Rosi, San Francisco, CA

**CLINICAL TRIALS PLENARY SESSION 4 • 10:30 a.m.-12:45 p.m.**

Marcus Auditorium, Building A, Georgia World Congress Center

**Novel Rational Checkpoint Inhibitors**

**Chair:** Silvia C. Formenti, New York, NY

CT182  **Neoadjuvant immunoradiotherapy (NIRT) in head and neck cancer: Phase I/II study of combined PD-1/SBRT prior to surgical resection.** Rom Leidner, Portland, OR  
**Discussant:** Christine H. Chung, Tampa, FL

CT183  **Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies.** Giuseppe Curigliano, Milan, Italy  
**Discussant:** To be announced

CT184  **Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial.** Alexander E. Perl, Philadelphia, PA  
**Discussant:** To be announced

CT185  **Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (telomelysin) with radiotherapy in esophageal cancer patients unfit for standard treatments.** Toshiyoshi Fujiwara, Okayama, Japan  
**Discussant:** To be announced
TUESDAY, APRIL 2**

SPECIAL SESSION • 12:00 p.m.-1:00 p.m.
Room B408, Georgia World Congress Center
Conflict of Interest Disclosures: A Dialogue
Opening Remarks: Elizabeth M. Jaffee, Baltimore, MD
Panelists: Anna D. Barker, Scottsdale, AZ
           Victor E. Velculescu, Baltimore, MD

AWARDS AND LECTURES • 12:30 p.m.–1:00 p.m.
Room A315, Georgia World Congress Center
Gertrude B. Elion Cancer Research Award Lecture
A chromatin transregulatory pathway implicated in cancer and developmental overgrowth. Chao Lu, New York, NY

NCI/NIH-SPONSORED SESSION • 12:30 p.m.–2:15 p.m.
Room A406-407, Georgia World Congress Center
Technology Transfer and Intellectual Property: Financial and Career Opportunities for Research Scientists
(not eligible for CME credit)
Co-chairs: Jason V. Cristofaro, Bethesda, MD; Steven M. Ferguson, Rockville, MD; Phuong Kim Pham, Bethesda, MD
12:40 p.m. Title to be announced. Phuong Kim Pham, Bethesda, MD
12:50 p.m. Title to be announced. Kevin Brand, Atlanta, GA
1:00 p.m. Title to be announced. Todd Sherer, Atlanta, GA
1:10 p.m. Title to be announced. Gwen Spratt, Atlanta, GA
1:20 p.m. Discussion

MEET AND GREET • 1:00 p.m.–2:00 p.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
Meet the 2019-2020 AACR President
(not eligible for CME credit)
Elaine R. Mardis, Columbus, OH

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
1:00 p.m.–2:45 p.m.
Room A411-412, Georgia World Congress Center
Molecular Imaging for Cancer Immunotherapy
Chair: Sridhar Nimmagadda, Baltimore, MD

1:00 p.m. Molecular imaging to assess clinical response of immune checkpoint therapies. Joop De Langen, Amsterdam, Netherlands
1:25 p.m. Noninvasive technologies for precision dosing of immune checkpoint therapeutics. Sridhar Nimmagadda, Baltimore, MD
1:50 p.m. Immunotheranostic probes for monitoring cancer immunotherapy response. Ashish A. Kulkarni, Amherst, MA
2:10 p.m. Real-time in vivo imaging of immunotherapy. Mikael J. Pittet, Boston, MA

Tumor Treating Fields: A Fourth Modality in Cancer Treatment
Chair: Roger Stupp, Chicago, IL

1:00 p.m. Identification of a new mechanism for how tumor treating fields affect tumor cells. Sanjiv Sam Gambhir, Stanford, CA
1:30 p.m. Title to be announced. Roger Stupp, Chicago, IL
2:00 p.m. TTFields: From bench to bedside. Eilon D. Kirson, Haifa, Israel

ADVANCES IN ORGAN SITE RESEARCH • 1:00 p.m.–2:45 p.m.
Room B206, Georgia World Congress Center
Genitourinary, Bladder, and Renal Cancers
Chair: Dan Theodorescu, Los Angeles, CA

1:00 p.m. Title to be announced. Dan Theodorescu, Los Angeles, CA
1:30 p.m. Advances in molecular characterization of non-muscle-invasive bladder cancer: Potential for clinical impact? Margaret A. Knowles, Leeds, United Kingdom
2:00 p.m. Targeting the genetic and metabolic basis of renal cell carcinoma. W. Marston Linehan, Bethesda, MD
TUESDAY, APRIL 2**

**ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES**
1:00 p.m.–2:45 p.m.
Georgia Ballroom 1, Building C, Georgia World Congress Center

**Novel Applications of Clinical Trials Research to Studying Disparities**

Chair: Lisa A. Newman, New York, NY

1:00 p.m.  Strategies of community engagement in addressing disparities through clinical trials. Erica Phillips, New York, NY

1:30 p.m.  Role of genomics in studying multiple myeloma disparities. Linda B. Baughn, Rochester, MN

2:00 p.m.  Genomics and population-based cohort studies to address cancer disparities. Melissa L. Bondy, Houston, TX

**MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.**
Sydney Marcus Auditorium, Building A, Georgia World Congress Center

**Advancing Epigenetic Therapies for Solid Tumors**

Chair: Nancy E. Davidson, Seattle, WA

1:00 p.m.  Introduction

1:05 p.m.  Epigenetic therapies in GI cancers: Where do we go next? Nita Ahuja, New Haven, CT

1:35 p.m.  Epigenetic therapies in lung cancer: Early excitement to current approaches. James G. Herman, Pittsburgh, PA

2:05 p.m.  Prospects for epigenetic therapy for breast cancer. Nancy E. Davidson, Seattle, WA

Hall A, Georgia World Congress Center

**Dharma Master Jiantai Symposium in Biomarkers: Blood Biopsy for Response Monitoring**

Chair: George A. Calin, Houston, TX

1:00 p.m.  Introduction

1:05 p.m.  Circulating tumor marker assays: An old tool with new twists. Daniel F. Hayes, Ann Arbor, MI

1:35 p.m.  Circulating tumor cells: Finding rare events for a huge knowledge of cancer dissemination. Catherine Alix-Panabieres, Montpellier, France

*An extended abstract for this presentation is available in the invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

AACR ANNUAL MEETING 2019
2:05 p.m.  Coding and noncoding genome for blood biopsy. George A. Calin, Houston, TX [SY15-03*]

Room B401-402, Georgia World Congress Center
Mammalian Sirtuins, Energy Bioenergetics, Metabolism, and Carcinogenesis
Chair: David R. Gius, Chicago, IL
1:05 p.m. Linking epigenetics, metabolism and cancer: Lessons from SIRT6. Raul Mostoslavsky, Boston, MA [SY20-01*]
1:35 p.m. SIRT1 downstream targets in carcinogenesis. Chuxia Deng, Macau, China
2:05 p.m. The SIRT3-MnSOD-Ac axis in carcinogenesis and tumor resistance. David R. Gius, Chicago, IL [SY20-02*]

Thomas Murphy Ballroom, Building B, Georgia World Congress Center
Overcoming Resistance to T Cell-Based Therapies
Chair: Michel Sadelain, New York, NY
1:00 p.m. Mechanisms of tumor escape from CAR therapy. Michel Sadelain, New York, NY
1:25 p.m. Recognition and evasion: Engineering smarter CAR T cells. Wendell Lim, San Francisco, CA
1:50 p.m. T-cell therapy 2.0: Harder, better, faster, stronger. Christopher A. Klebanoff, New York, NY
2:15 p.m. Discussion

Room A402-403, Georgia World Congress Center
Regulatory Science and Policy Session
Recently Approved Breakthrough Therapies
Chair: Ashley F. Ward, Silver Spring, MD
Speakers: Emily Y. Jen, Silver Spring, MD
Yvette Kasaman, Silver Spring, MD
Roger J. Kurlander, Silver Spring, MD
Leigh Marcus, Silver Spring, MD
David Hyman, New York, NY
Naveen Pemmaraju, Houston, TX
Lauren Pinter-Brown, Irvine, CA

Note: See online program for up-to-date information on therapies to be discussed in this session.

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
TUESDAY, APRIL 2**

Room B405-407, Georgia World Congress Center

The Matrix Reloaded: Influences of the Extracellular Matrix on Tumor Progression

**Chair:** Ashani T. Weeraratna, Philadelphia, PA

1:05 p.m.  **A wrinkle in TiME: How the aging TME drives tumor progression.**  Ashani T. Weeraratna, Philadelphia, PA [SY30-01*]

1:35 p.m.  **How the 3D matrix can induce a switch from cell proliferation to migration.**  Denis Wirtz, Baltimore, MD

2:05 p.m.  **Desmoplastic matrices: Enablers of a synapse-like axis in pancreatic cancer.**  Edna Cukierman, Philadelphia, PA [SY30-03*]

Georgia Ballroom 3, Building C, Georgia World Congress Center

Vascular Regulation of Antitumor Immunity

**Chair:** Rakesh K. Jain, Boston, MA

1:05 p.m.  **Improving immunotherapy of cancer by normalizing tumor vessels.**  Rakesh K. Jain, Boston, MA [SY33-01*]

1:35 p.m.  **Exploiting immune functions of lymphatic vessels for cancer immunotherapy.**  Melody A. Swartz, Chicago, IL

2:05 p.m.  **Endothelial cell diversity and programming in tumor and immune angiogenesis.**  Eugene C. Butcher, Stanford, CA

SPECIAL SESSION • 1:00 p.m.–3:00 p.m.

Room C302, Georgia World Congress Center


**Chair and Moderator:** Kimberly Stegmaier, Boston, MA

1:05 p.m.  **Fusion oncogenes co-opt developmental programs for rhabdomyosarcoma tumorigenesis.**  Genevieve C. Kendall, Dallas, TX

1:25 p.m.  **Implications of T-cell variance in pediatric immunotherapy.**  David M. Barrett, Philadelphia, PA

1:50 p.m.  **Initiation of FN-RMS from endothelial progenitors.**  Catherine J. Drummond, Dunedin, New Zealand; Memphis, TN

2:10 p.m.  **Discovery and development of GPC2 as an immunotherapeutic target in neuroblastoma and other cancers.**  Kristopher R. Bosse, Philadelphia, PA

2:30 p.m.  **Driver oncogenes specify differential requirements for GATOR2-mTORC1 activation in rhabdomyosarcoma.**  Amit J. Sabnis, San Francisco, CA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
POSTER SESSION • 1:00 p.m.–5:00 p.m.
Hall B, Georgia World Congress Center
(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print Guide to Poster Sessions and Exhibits. A limited number of copies of the Guide are available in the Exhibit Hall.

Cancer Chemistry
Section 1 Drug Delivery and Nanoparticles

Tumor Biology
Section 2 Biology and Signaling in Pediatric Cancer
Section 3 Epigenetic Regulation, Plasticity, and DNA Repair of Cancer Stem Cells
Section 4 Novel Model Organisms and Approaches
Section 5 Radiation Tissue Tolerance, Immunity, and in Vivo Effects of Radiation
Section 6 Tumor Dormancy, Metastasis, and the Metastatic Niche
Section 7 Tumor Evolution and Heterogeneity 2
Section 8 Viral and Microbiome-Associated Carcinogenesis

Experimental and Molecular Therapeutics
Section 10 Drug Resistance 5
Section 11 Epigenetic Targets
Section 12 Novel Antitumor Agents 2
Section 13 Pharmacokinetics and Pharmacodynamics/Preclinical Toxicology
Section 14 PI3K/AKT Inhibitors
Section 15 Preclinical Radiotherapeutics

Clinical Trials
Section 16 Phase II-III Clinical Trials: Part 2
Section 17 Phase I-III Trials in Progress: Part 3

Clinical Research
Section 18 Immunomodulation by Chemotherapy and Targeted Agents
Section 19 Novel Strategies for Biomarker Identification and Use in Cancer 2
Section 20 Special Populations/Biostatistics in Clinical Trials
Section 21 Tumor Markers to Assess the Biology and Clinical Course of Cancer 2
TUESDAY, APRIL 2**

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

Immunology
Section 22 Biomarkers and Immune Monitoring
Section 23 Combination Immunotherapies 3
Section 24 Immune Checkpoints 2
Section 25 Novel Immunomodulatory Agents 2

Epidemiology
Section 26 Cancer Predisposition
Section 27 Descriptive Epidemiology: Risk, Outcomes, and Disparities

Prevention Research
Section 28 Clinical Prevention, Early Detection, and Interception 2

Bioinformatics and Systems Biology
Section 29 Applications of Cancer Computational Biology 2

Molecular and Cellular Biology/Genetics
Section 31 Autophagy
Section 32 Cell Signaling 2
Section 33 Epigenetic Changes as Molecular Markers
Section 34 Functional Genomics
Section 35 Metabolic Reprogramming in Cancer
Section 36 Post-transcriptional and Translational Control of Gene Regulation
Section 37 Targeting the Cell Cycle: Development of Preclinical Models and Therapeutic Targets
Section 38 Ubiquitin Ligases

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers. 

172 AACR ANNUAL MEETING 2019
CAREER DISCUSSIONS • 2:30 p.m.–3:15 p.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
Career Discussions: Searching for the Right Postdoctoral Position
Organized by the Associate Member Council (AMC)
(not eligible for CME credit)

NCI/NIH-SPONSORED SESSION • 2:45 p.m.–4:15 p.m.
Room A406-407, Georgia World Congress Center
Liquid Biopsy: A Holy Grail of Early Detection
(not eligible for CME credit)
Chair: Sudhir Srivastava, Rockville, MD
2:45 p.m. Overview of liquid biopsy program. Sudhir Srivastava, Rockville, MD
2:55 p.m. Research directions of the precompetitive collaboration on liquid biopsy for early cancer detection. David T. Wong, Los Angeles, CA
3:15 p.m. Methodologies and challenges in liquid biopsy for low analytes. Bob S. Carter, Boston, MA
3:35 p.m. Potential clinical application of liquid biopsy in early detection. Nickolas Papadopoulos, Baltimore, MD
3:55 p.m. Data integration, analysis, and interpretation: Artificial intelligence approaches. Changhuei Yang, Pasadena, CA

AWARDS AND LECTURES • 3:00 p.m.–3:45 p.m.
Room B304-305, Georgia World Congress Center
AACR Award for Outstanding Achievement in Chemistry in Cancer Research
Drug discovery in academia: Cancer research. Michael E. Jung, Los Angeles, CA
MEET AND GREET • 3:00 p.m.-4:00 p.m.
AACC Publications Booth 3226, Hall B, Georgia World Congress Center
Meet the New Editors-in-Chief of Cancer Prevention Research: Raymond N. DuBois, MD, PhD, and Michael N. Pollak, MD (not eligible for CME credit)
Raymond N. DuBois, Charleston, SC
Michael N. Pollak, Montreal, QC, Canada

CLINICAL TRIALS MINISYMPOSIUM 3 • 3:00 p.m.–5:00 p.m.
Marcus Auditorium, Building A, Georgia World Congress Center
Developmental Therapeutics: Clinical Results of Novel Agents
Chair: Anthony El-Khoudery, Los Angeles, CA

CT232  Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors. Khanh T. Do, Boston, MA

CT233  Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium phase II trial. Amy E. Armstrong, Indianapolis, IN

CT234  A phase II, single-arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2, or PALB2. Kim A. Reiss Binder, Philadelphia, PA

CT235  A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. Kyle C. Cuneo, Ann Arbor, MI

CT236  Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster. Olivera J. Finn, Pittsburgh, PA

CT237  Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel. Rakesh Awasthi, East Hanover, NJ

CT238  TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A phase I study. Funda Meric-Bernstam, Houston, TX

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
MAJOR SYMPOSIUM • 3:00 p.m.–5:00 p.m.
Room A402-403, Georgia World Congress Center

Regulatory Science and Policy Session

Regulatory Considerations for Utilizing Liquid Biopsies in Drug and Diagnostic Development

Cochairs: Gideon Blumenthal, Silver Spring, MD; Reena Philip, Silver Spring, MD

Speakers: Soma Ghosh, Silver Spring, MD
J. Carl Barrett, Waltham, MA
James H. Godsey, South San Francisco, CA
Dana Wai Yi Tsui, New York, NY

MINISYMPOSIA • 3:00 p.m.–5:00 p.m.
Georgia Ballroom 2, Building C, Georgia World Congress Center

Bioinformatics and Systems Biology

Convergence

Chair: Paul T. Spellman, Portland, OR

3:00 p.m. Introduction
3:05 p.m. 4444 Deep learning of the immune synapse. John-William Sidhom, Baltimore, MD
3:20 p.m. 4445 MHC class II antigen identification for cancer immunotherapy by deep learning on tumor HLA peptides. Tommy Boucher, Cambridge, MA
3:35 p.m. 4446 Assessment of tissue composition with digital pathology in colorectal cancer. Enric Domingo, Oxford, United Kingdom
3:50 p.m. 4447 Deep neural network for automatic histopathologic analysis of murine lung tumors. Peter Maxwell Kienitz Westcott, Cambridge, MA
4:05 p.m. 4448 Machine-learning assisted histopathology (HistoMAP) links nuclear membrane instability to disease progression in prostate cancer. Andries Zijlstra, Nashville, TN
4:20 p.m. 4449 Designing precision metabolic therapies by identifying vulnerabilities in metabolic pathways due to genomic loss in cancer patients. Abhinav Achreja, Ann Arbor, MI
4:35 p.m. 4450 Novel transducer array layouts to optimize the treatment of multiple brain metastases with tumor treating fields. Ze’ev Bomzon, Haifa, Israel
Room B206, Georgia World Congress Center
Clinical Research
Next-Generation Small Molecules: From Hits to Leads to Candidates

Co-chairs: Chris de Savi, Cambridge, MA; Sara Buhrlage, Boston, MA

3:00 p.m. Introduction

3:05 p.m. 4451 Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation. Nicolas Floch, Cambridge, United Kingdom

3:20 p.m. 4452 GNE-0011, a novel monovalent BRD4 degrader. Robert A. Blake, South San Francisco, CA

3:35 p.m. 4453 Novel, potent and selective small-molecule inhibitors modulating immuno-oncology targets CD73, A2A/A2B adenosine receptors and CSF1R discovered via DNA-encoded library screening. Andrew J. McRiner, Waltham, MA

3:50 p.m. 4454 Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression. Norbert Schmees, Berlin, Germany (not eligible for CME credit)

4:05 p.m. 4455 Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors. Brian A. Lanman, Thousand Oaks, CA (not eligible for CME credit)

4:20 p.m. 4456 Discovery of E7766: A representative of a novel class of macrocycle-bridged STING agonists (MBSAs) with superior potency and pan-genotypic activity. Dae-Shik Kim, Andover, MA

4:35 p.m. 4457 Open science medicinal chemistry: Towards a treatment for DIPG. Sue Cramp, Harlow, United Kingdom

Room B405-407, Georgia World Congress Center
Clinical Research
Molecular and Cell-Based Circulating Biomarkers to Guide Optimal Anticancer Treatment

Co-chairs: Abhijit Patel, Waterford, CT; Shannon L. Stott, Charlestown, MA

3:00 p.m. Introduction

3:05 p.m. 4458 Clinical significance of PIK3CA and ESRI mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant. Sara M. Tolaney, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
3:20 p.m. 4459 Morphologic and genomic characterization of circulating tumor cells in patients with ERBB2 mutant HER2 nonamplified metastatic breast cancer treated with neratinib. Stephanie Nicole Shishido, Los Angeles, CA

3:35 p.m. 4460 Clinical utility of comprehensive cell-free DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed metastatic non-small cell lung cancer (mNSCLC). Victoria M. Raymond, San Diego, CA

3:50 p.m. 4461 Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC). Cyril Y. Ramathal, North Chicago, IL

4:05 p.m. 4462 Sensitivity and reproducibility of onco-panel sequencing across multiple laboratories and technologies. Joshua Xu, Jefferson, AR

4:20 p.m. 4463 Tumor-derived cell-free DNA from bronchoalveolar lavage fluid (BALF): A potential liquid biopsy analysis in lung cancer patients. Xin Zhang, Jefferson, AR

4:35 p.m. 4464 Tumor-derived extracellular vesicles in blood of metastatic breast, colorectal, prostate and non-small cell lung cancer patients associate with worse survival. Afroditi Nanou, Enschede, Netherlands

Room A404-405, Georgia World Congress Center

**Epidemiology**

**Factors Influencing Cancer Outcomes**

**Cochairs:** Lorelei A. Mucci, Boston, MA; Elizabeth A. Platz, Baltimore, MD

3:00 p.m. Introduction

3:05 p.m. 4465 The effect of insurance status on childhood and adolescent cancer survival using data from the National Cancer Database. Xiaoyan Wang, St. Louis, MO

3:20 p.m. 4466 Somatic mutations within chronic lymphocytic leukemia (CLL) putative driver genes are associated with outcomes beyond the CLL international prognostic index (CLL-IPI). Geffen Kleinstern, Rochester, MN

3:35 p.m. 4467 Survival of patients with microsatellite unstable (MSI) metastatic colorectal cancer (mCRC) upon systemic nonimmunotherapy. G. E. Wensink, Utrecht, Netherlands

3:50 p.m. 4468 Role of statins and PSA nadir after androgen-deprivation therapy in overall survival of patients with metastatic prostate cancer. Paramita M. Ghosh, Sacramento, CA
TUESDAY, APRIL 2**

Minisymposia (cont’d)

4:05 p.m.  **4469**  Clinical outcomes among patients treated with abiraterone acetate for advanced prostate cancer with pre-existing cardiovascular conditions. Grace Lu-Yao, Philadelphia, PA

4:20 p.m.  **4470**  Aneuploidy drives lethal progression in prostate cancer. Konrad H. Stopsack, New York, NY

4:35 p.m.  **4471**  Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk. Jordan H. Creed, Tampa, FL

Room B312, Georgia World Congress Center
Experimental and Molecular Therapeutics
Genomic Correlates of Therapy Response

**Cochairs:** Anthony G. Letai, Boston, MA; Andrew J. Aguirre, Boston, MA

3:00 p.m.  Introduction

3:05 p.m.  **4472**  The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Wen-Hsuan Yang, Durham, NC

3:20 p.m.  **4473**  DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia. Lena J. McLaughlin, Baltimore, MD

3:35 p.m.  **4474**  Novel neoplastic RAD51AP1-DYRK4 fusion transcript in aggressive luminal breast cancers. Chia Chia Liu, Pittsburgh, PA

3:50 p.m.  **4475**  Targeting c-MET and MAPK pathway in metastatic castration-resistant prostate cancer. María Dolores Fenor de la Maza, Madrid, Spain

4:05 p.m.  **4476**  Therapeutic exploitation of passenger amplifications in hepatocellular carcinoma. Christos Patsis, Heidelberg, Germany

4:20 p.m.  **4477**  MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies. Youzhen Wang, Cambridge, MA

(not eligible for CME credit)

4:35 p.m.  **4478**  High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors. Patrick D. Bholia, Boston, MA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Georgia Ballroom 3, Building C, Georgia World Congress Center

**Experimental and Molecular Therapeutics**

**Novel Therapeutics**

**Cochairs:** S. Percy Ivy, Bethesda, MD; Gary K. Schwartz, New York, NY

3:00 p.m. **Introduction**

3:05 p.m. **4479** BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Mike Rigby, Cambridge, United Kingdom
   (not eligible for CME credit)

3:20 p.m. **4480** Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists. Liang-Chuan S. Wang, Wilmington, DE
   (not eligible for CME credit)

3:35 p.m. **4481** BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models. Gavin S. Bennett, Cambridge, United Kingdom
   (not eligible for CME credit)

3:50 p.m. **4482** S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models. Olivier Geneste, Croissy sur Seine, France

4:05 p.m. **4483** Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization. Phillip C. C. Liu, Wilmington, DE
   (not eligible for CME credit)

4:20 p.m. **4484** Discovery and in vitro characterization of AMG 510—a potent and selective covalent small-molecule inhibitor of KRAS<sup>G12C</sup>. Anne Y. Saiki, Thousand Oaks, CA
   (not eligible for CME credit)

4:35 p.m. **4485** Enhancing antitumor immune responses with clinical BET bromodomain inhibitor RG6146. Simon J. Hogg, Melbourne, Australia

Room A411-412, Georgia World Congress Center

**Immunology**

**Tumor Immune Microenvironment**

**Cochairs:** Stefani Spranger, Cambridge, MA; Ryan J. Sullivan, Boston, MA

3:05 p.m. **4486** Androgen-deprivation therapy promotes immune suppression in a murine model of prostate cancer. John J. Krolewski, Buffalo, NY

3:20 p.m. **4487** Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer. Anniina Farkkila, Boston, MA
3:35 p.m. 4488 Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors. Sangeetha M. Reddy, Boston, MA
3:50 p.m. 4489 IL-10 blockade reactivates antitumor immunity in human colorectal cancer liver metastases. Kevin M. Sullivan, Seattle, WA
4:05 p.m. 4490 PARP inhibitor efficacy depends on CD8+ T-cell recruitment via the STING pathway in BRCA-deficient models of triple-negative breast cancer. Constantia Pantelidou, Boston, MA
4:20 p.m. 4491 Association of intratumoral immunologic profile with overall survival in metastatic pancreatic cancer patients treated with combination immunotherapy with or without PD-1 blockade. Annie A. Wu, Baltimore, MD
4:35 p.m. 4492 Humanized anti-EGFR antibody panitumumab inhibits tumor growth of inflammatory breast cancer by inducing antitumor immunity. Xiaoping Wang, Houston, TX

Room A302, Georgia World Congress Center
Molecular and Cellular Biology/Genetics
Deregulated Transcription and RNA Processing in Cancer
Co-chairs: Kamini Singh, New York, NY; Christopher Ott, New York, NY
3:00 p.m. Introduction
3:05 p.m. 4493 SF3B1 mutation promotes c-Myc protein stability through aberrant splicing and downregulation of PP2A B56α subunit in chronic lymphocytic leukemia. Qimei Han, Augusta, GA
3:20 p.m. 4494 HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction. Natasha J. Caplen, Bethesda, MD
3:35 p.m. 4495 Role of base excision repair (BER) pathway in regulation of KRAS expression in pancreatic cancer. Kishor K. Bhakat, Omaha, NE
3:50 p.m. 4496 Cytokine-induced post-translational modifications of FOXA1 affect enhancer selection and estrogen signaling in breast cancer cells. Shen Li, Chapel Hill, NC
4:05 p.m. 4497 Distinct structural classes of activating FOXA1 alterations in prostate cancer progression. Abhijit Parolia, Ann Arbor, MI
4:20 p.m. 4498 O GlcNAcylation of SOX2 regulates its tumor initiation properties in pancreatic cancer. Nikita S. Sharma, Miami, FL
4:35 p.m. 4499 Genomic editing of EWS-FLI1 and its targets, and its therapeutic potential in treatment of Ewing sarcoma. Sheetal A. Mitra, Miami, FL

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room A305, Georgia World Congress Center

**Molecular and Cellular Biology/Genetics**

**Noncoding RNAs in Cancer Biology**

**Cochairs:** Li Ma, Houston, TX; Xiao-Fan Wang, Durham, NC

3:00 p.m.  **Introduction**

3:05 p.m.  4500  **Mechanisms of tumor associated myeloid cells in modulating host immune microenvironment and metastatic progression.** Li Yang, Bethesda, MD

3:20 p.m.  4501  **Loss of miR-21 delays myc-driven prostate cancer progression in the hi-myc transgenic mouse model.** Kenji Zennami, Toyoake, Japan

3:35 p.m.  4502  **The role of A-to-I RNA editing in diversifying the microRNA functions in cancer.** Han Liang, Houston, TX

3:50 p.m.  4503  **Functional CRISPR screen towards identifying novel conserved long noncoding RNAs with oncogenic activity.** Yajia Zhang, Ann Arbor, MI

4:05 p.m.  4504  **MILIP is a pan cancer-associated long noncoding RNA that links MYC to inactivation of p53.** Yuchen Feng, Newcastle, Australia

4:20 p.m.  4505  **miR-122 regulates hepatic glutamine metabolism by directly targeting mitochondrial glutaminase.** Dipanwita Sengupta, Columbus, OH

4:35 p.m.  4506  **MDM2 alternative splicing is regulated by microRNA binding to control p53 activity.** Dawn S. Chandler, Columbus, OH

---

Room A313-314, Georgia World Congress Center

**Molecular and Cellular Biology/Genetics**

**Oncogenes, Tumor Suppressors, and Carcinogenesis**

**Cochairs:** David S. Yu, Atlanta, GA; Fen Xia, Columbus, OH

3:00 p.m.  **Introduction**

3:05 p.m.  4507  **Study of CCCTC-binding factor (CTCF) genetic aberrations and dysregulation in head and neck squamous cell carcinoma (HNSCC).** Sze Man Chan, Columbus, OH

3:20 p.m.  4508  **Cyclophilin A as a molecular switch regulating PRLr-Jak2 complex-mediated signaling, mammary tumorigenesis, and metastasis.** Shawn Hakim, Richmond, VA

3:35 p.m.  4509  **Overexpression of CADM1 enhances malignant features of small-cell lung cancer.** Toko Funaki, Richmond, VA

3:50 p.m.  4510  **Linking growth factors and immune actors: PTEN/PI3K signaling in cancer and the response to cytokines.** Sanjay Chandrasekaran, Atlanta, GA
**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

4:05 p.m.  4511  Prostate cancer-specific enrichment of TP53 missense mutations elicits differential, context-dependent biochemical and biologic outcomes. Irina Vasilevskaya, Philadelphia, PA

4:20 p.m.  4512  Identifying novel mechanisms of p53-mediated tumor suppression. Nathan H. Leisenring, Durham, NC

4:35 p.m.  4513  Targeting the DLC1 Rho-GAP tumor suppressor protein to treat solid tumors. Brajendra K. Tripathi, Bethesda, MD

Room B401-402, Georgia World Congress Center
Tumor Biology
Invasion and Metastasis 2: Tumor Microenvironment

Cochairs: John S. Condeelis, Bronx, NY; Melody A. Swartz, Chicago, IL

3:00 p.m.  Introduction

3:05 p.m.  4514  Intravital imaging at single-cell resolution reveals, for the first time, the mechanism of cancer cell dissemination and metastasis. Lucia Borriello, Bronx, NY

3:20 p.m.  4515  Utilizing nucleic-acid scavengers (NASs) to inhibit proinflammatory and proinvasive signaling in triple-negative breast cancer. Elias O. Eteshola, Durham, NC

3:35 p.m.  4516  Suppression of metastasis by inhibiting nanoscale physical communication of cancer cell and the endothelium. Chinmayee Dash, Cambridge, MA

3:50 p.m.  4517  Tumor-associated macrophages are reprogrammed by pancreatic ductal adenocarcinoma cells through tumor-induced DNA methylation on metabolic genes. Xingyi Pan, Baltimore, MD

4:05 p.m.  4518  IL-4/IL-13 stimulated tumor-associated macrophages enhance breast cancer cell invasion through Rho-GTPase signaling. Andrew C. Little, Ann Arbor, MI

4:20 p.m.  4519  The reciprocal interaction between neutrophil extracellular traps and cancer cells impacts on their malignant potentials. Hiroki Kajioka, Okayama, Japan

4:35 p.m.  4520  Lymphatic vessels regulate exosome trafficking from tumors. Lea Maillat, Chicago, IL

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**
Room A311-312, Georgia World Congress Center

**Tumor Biology**

**Nonclinical Models of Cancer**

**Cochairs:** Phuoc T. Tran, Baltimore, MD; Dean W. Felsher, Stanford, CA

**3:00 p.m.**  
**Introduction**

**3:05 p.m.**  
4521  
*Mutant Kras expression triggers clonal acinar cell expansion as an early step in pancreas cancer.* Steven E. Artandi, Stanford, CA

**3:20 p.m.**  
4522  
*An in vitro 3D immune exclusion tumor model engineered in a layer-by-layer fashion.* Kolin C. Hribar, San Francisco, CA

**3:35 p.m.**  
4523  
*A novel syngeneic mouse model of prostate cancer bone metastasis: Mechanisms of chemotaxis and bone colonization.* Srinivas Nandana, Lubbock, TX

**3:50 p.m.**  
4524  
*Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute's Patient-Derived Models Repository (PDMR).* Yvonne A. Evrard, Frederick, MD

**4:05 p.m.**  
4525  
*Modulating chemoresistance: Uncovering the role of mutant SMAD4**R361H** in colorectal cancer using PDO and PDX models.* Ulrike Pfohl, Berlin, Germany

**4:20 p.m.**  
4526  
*Tumor invasion and escape from an engineered solid-like aggregate of human breast cancer cells into a cavity.* Andreas P. Kourouklis, Princeton, NJ

**4:35 p.m.**  
4527  
*Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer.* Ron Bose, St. Louis, MO

**AWARDS AND LECTURES • 3:30 p.m.–4:15 p.m.**

Georgia Ballroom 1, Building C, Georgia World Congress Center

**AACR-CRI Lloyd J. Old Award in Cancer Immunology**

**Adventures in immunotherapy of cancer.** Cornelis J.M. Melief, Leiden, Netherlands
TUESDAY, APRIL 2**

AWARDS AND LECTURES • 3:45 p.m.–4:30 p.m.
Room B304-305, Georgia World Congress Center
AAPC-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
Diet, physical activity, metabolic health, and cancer prevention. Edward L. Giovannucci, Boston, MA

AWARDS AND LECTURES • 4:00 p.m.–4:45 p.m.
Room B302-303, Georgia World Congress Center
AAPC-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
Advancing treatment through collaboration: A pediatric oncology paradigm. Susan L. Cohn, Chicago, IL

NCI/NIH-SPONSORED SESSION • 4:30 p.m.–6:30 p.m.
Room A406-407, Georgia World Congress Center
Multidisciplinary Approaches for the Study of Macromolecular Interactions (not eligible for CME credit)
Chair: Juli Klemm, Rockville, MD
4:30 p.m. Overview of the Informatics Technology for Cancer Research Program. Juli Klemm, Rockville, MD
4:40 p.m. Overview of the Innovative Molecular Analysis Technologies Program. Anthony Dickherber, Bethesda, MD
4:50 p.m. Overview of the Cancer Systems Biology Consortium. Shannon Hughes, Bethesda, MD
5:00 p.m. Overview of the Physical Sciences in Oncology Network. Nastaran Zahir, Bethesda, MD
5:15 p.m. Mechanical modulation and misregulation of Ras activation at the membrane. Jay T. Groves, Berkeley, CA
5:30 p.m. Toward spatially integrated models for oncogenic signaling through multiplexed and correlative nanoscopy. Xiaolin Nan, Portland, OR
5:45 p.m. Multiscale mapping of cancer-specific protein interactome sheds light on the heterogeneous alteration landscape in cancer. Fan Zheng, La Jolla, CA
6:00 p.m. Protein painting: Using small-molecule dyes to identify druggable contact regions between protein binding partners. Alessandra Luchini, Manassas, VA
6:15 p.m. Discussion

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.

184 AACR ANNUAL MEETING 2019
SPECIAL SESSION • 4:45 p.m.–6:00 p.m.
Room A307, Georgia World Congress Center
Social Interactome Session
(not eligible for CME credit)
Cochairs: Rodrigo Dienstmann, Barcelona, Spain; Justin Guinney, Seattle, WA
4:45 p.m. Introduction. Justin Guinney, Seattle, WA
4:45 p.m. Title to be announced. Rodrigo Dienstmann, Barcelona, Spain

FORUMS • 5:00 p.m.–6:30 p.m.
Room A411-412, Georgia World Congress Center
B Cells in Solid Tumors: Good or Bad
Moderator: Michael Karin, La Jolla, CA
Panel: Joseph D. Rosenblatt, Miami, FL
Qiao Li, Ann Arbor, MI

Room A402-403, Georgia World Congress Center
Science Policy Session
Biden Cancer Initiative

Room B401-402, Georgia World Congress Center
Challenges and Opportunities of International Consortia
Moderator: Folakemi T. Odedina, Orlando, FL
Panel: Camille Ragin, Philadelphia, PA
Marc J. Gunter, London, United Kingdom

Georgia Ballroom 3, Building C, Georgia World Congress Center
Elimination of HPV and Related Cancers
Moderator: Anna R. Giuliano, Tampa, FL
Panel: Margaret A. Stanley, Tampa, FL
Mona Saraiya, Atlanta, GA
Marc Steben, Montreal, QC, Canada
Mark Jit, London, United Kingdom
TUESDAY, APRIL 2**

Hall A, Georgia World Congress Center
Fighting the IL-1 Inflammatory Pathway
Moderator: Alberto Mantovani, Rozzano, Italy
Panel: Razelle Kurzrock, La Jolla, CA
Paul Ridker, Boston, MA

Georgia Ballroom 1, Building C, Georgia World Congress Center
Implementation Science for Evidence-Based Cancer Prevention and Early Detection Practices in Defined Diverse Populations
Moderator: Robert A. Hiatt, San Francisco, CA
Panel: Ernest T. Hawk, Houston, TX
Melissa A. Simon, Chicago, IL

Thomas Murphy Ballroom, Building B, Georgia World Congress Center
Reinforcing the Blockade: New Combination Approaches to Bolster Immune Checkpoint Therapy
Moderator: Tak W. Mak, Toronto, ON, Canada
Panel: Pamela S. Ohashi, Toronto, ON, Canada
Charles G. Drake, New York, NY

SPECIAL SESSION • 5:00 p.m.–6:30 p.m.
Room B312-314, Georgia World Congress Center
Making Science Count for Patients: CDK4/6
Chair: Richard S. Finn, Los Angeles, CA

5:00 p.m. CDK 4/6 inhibitors: Preclinical, approval, and optimization. Richard S. Finn, Los Angeles, CA
5:25 p.m. CDK 46/inhibitors: Beyond efficacy. Benjamin O’Leary, London, United Kingdom
5:50 p.m. CDK 4/6 inhibitors: Evolving data outside of breast cancer. Jessica Teh, Philadelphia, PA

**Program as of March 1, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
TOWN MEETING • 6:00 p.m.–8:00 p.m.
Room A315-316, Georgia World Congress Center
Tumor Microenvironment Working Group (TME) Town Hall Meeting and Networking Reception: Tumor Microenvironment Regulation of Cancer Progression and Therapeutic Response
(not eligible for CME credit)

6:00 p.m.  TME Chair: Opening remarks. Yibin Kang, Princeton, NJ
6:09 p.m.  TME Chair-Elect: Remarks. Sheila A. Stewart, St. Louis, MO
6:14 p.m.  How can TME members contribute to identifying research areas/How do junior investigators get exposure to study sections? Neeraja Sathyamoorthy, Bethesda, MD
6:14 p.m.  How can TME members contribute to identifying research areas/How do junior investigators get exposure to study sections? Candace Kerr, Baltimore, MD
6:29 p.m.  Mechanisms and consequences of pancreatic cancer stromal evolution. Mara H. Sherman, Portland, OR
6:41 p.m.  Immunotherapy fails against adult glioblastoma; understanding the synergy between age, distress, and anatomy, on the immune response to malignant glioma. Derek A. Wainwright, Brookfield, IL
6:53 p.m.  Crosswalk between astrocytes and cancer cells during brain metastasis. Qing Chen, Philadelphia, PA
7:05 p.m.  Engineering precision cancer immunotherapy. Michel J. Dupage, Berkeley, CA
7:17 p.m  Interferon signaling contributes to prostate cancer self-renewal and therapy resistance. Supreet Agarwal, Bethesda, MD
7:25 p.m.  Metastatic colonization in the perivascular niche: A mechanotransduction perspective. Ekrem Emrah Er, New York, NY
7:33 p.m.  Closing remarks. Sheila A. Stewart, St. Louis, MO
WEDNESDAY, APRIL 3**

MEET-THE-EXPERT SESSIONS • 7:00 a.m.–8:00 a.m.
Room A404-405, Georgia World Congress Center
ATAC Sequencing
Andrew Adey, Portland, OR

Room B206, Georgia World Congress Center
Brain Tumor Biology: Malignant Networks in the Brain and How to Target Them
Frank A. Winkler, Heidelberg, Germany

Georgia Ballroom 3, Building C, Georgia World Congress Center
Deconvoluting Tumor Heterogeneity Using Single-Cell Genomics
James B. Hicks, Los Angeles, CA

Room A304-305, Georgia World Congress Center
The Epidemiologic Method: One Hammer; Many Nails
Thomas A. Sellers, Tampa, FL

Room B401-402, Georgia World Congress Center
Mechanisms of Enhanced Efficacy for Radiation Therapy with Chemotherapy or Immunotherapy
David G. Kirsch, Durham, NC

Room A311-312, Georgia World Congress Center
Natural Killer Cells: Players in Immune Defense Against Cancer and Infection
Michael A. Caligiuri, Duarte, CA

Room B312-314, Georgia World Congress Center
PD-1 Blockade in Cancer Therapy: Mechanism-Based Biomarkers and New Frontiers
Suzanne L. Topalian, Baltimore, MD

Georgia Ballroom 1, Building C, Georgia World Congress Center
Uses of CRISPR Technology in Translational Cancer Research
René Bernards, Amsterdam, Netherlands

**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
Room A315-316, Georgia World Congress Center

**Using Zebrafish to Model Pediatric Cancer and Identify New Pathways for Targeted Drug Therapy**

A. Thomas Look, Boston, MA

Room A305, Georgia World Congress Center

**When Will We Be Ready to Deliver Precision Medicine in Melanoma?**

Richard M. Marais, Manchester, United Kingdom

---

**PLENARY SESSION • 8:00 a.m.–10:00 a.m.**

Hall A, Georgia World Congress Center

**Pathogen-Related Cancers: Implications for Populations and Public Health**

Chair: Douglas R. Lowy, Bethesda, MD

8:00 a.m.  Screening for nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA: Technological and clinical insights.  
Yuk Ming Dennis Lo, Shatin, Hong Kong [PL04-01*]

8:30 a.m.  Hepatitis B and C virus-related hepatocellular carcinoma in the era of highly active antiviral therapies.  
Jean-Michel Pawlotsky, Créteil, France

9:00 a.m.  HIV malignancies: From despair to gene therapy.  
Ariela Noy, New York, NY [PL04-02]

9:30 a.m.  Therapeutic vaccination to treat HPV disease: Lessons learned from high-grade intraepithelial lesions.  
Cornelia L. Trimble, Baltimore, MD

---

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

**Wednesday, April 3**

**Poster Session • 8:00 a.m.–10:00 a.m.**

Hall A, Georgia World Congress Center

(Not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2019), and the print Guide to Poster Sessions and Exhibits. A limited number of copies of the Guide are available in the Exhibit Hall.

**Cancer Chemistry**

Section 2 Cancer Proteomics

**Tumor Biology**

Section 3 Immune Cells in the Tumor Microenvironment 3
Section 4 Immunity in the Microenvironment
Section 5 Invasion and Migration 2
Section 6 Mouse Models
Section 7 Mutagenesis, Chemical Carcinogenesis, and Tumor Initiation/Promotion
Section 8 Signaling Cascades in Cancer Stem Cells
Section 9 Tumor Evolution and Heterogeneity 3

**Experimental and Molecular Therapeutics**

Section 10 DNA Repair and Reactive Agents/HDAC/Demethylating Agents
Section 11 Drug Resistance 6
Section 12 Gene- and Vector-Based Therapy
Section 13 Novel Antitumor Agents 3
Section 14 Targeted Therapies
Section 15 Targeted Therapies and Immunologic/Tumor Microenvironment Effects

**Clinical Research**

Section 18 Advances in Radiation Therapy/Surgical Oncology
Section 19 Novel Strategies for Biomarker Identification and Use in Cancer 3
Section 20 Supportive Care and Survivorship Research / Outcome Research
Section 21 Tumor Markers to Assess the Biology and Clinical Course of Cancer 3

**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

190   AACR ANNUAL MEETING 2019


**Immunology**
Section 23  Adaptive Immune Cells in the Tumor Microenvironment
Section 24  Immunomodulators and Response to Therapy
Section 25  Tumor Immune Microenvironment

**Epidemiology**
Section 26  Influences on Cancer Risk and Outcomes

**Prevention Research**
Section 27  Cancer Chemoprevention and Interception: From Mechanism to Translation

**Bioinformatics and Systems Biology**
Section 30  Methods and Tools for Cancer Analysis

**Molecular and Cellular Biology/Genetics**
Section 32  Advanced Omics
Section 33  Cellular and Stromal Interactions of Tumor Cells
Section 34  Changes in Chromatin Structure
Section 35  Deregulation of Histone Modifications
Section 36  Mechanisms and Consequences of Transcriptional Deregulation
Section 37  Regulation of Gene Expression in Cancer
Section 38  Tracking Metabolic Profiles and Subtype-Specific Metabolic Interventions
Section 39  Tumor Suppressors, Carcinogenesis, and Tumor Cell Resistance
WEDNESDAY, APRIL 3**

MEET THE RESEARCH ICON • 10:00 a.m.–10:45 a.m.
AACR Central Amphitheater, Hall B, Georgia World Congress Center
Meet the Research Icon: Speaker 3
(not eligible for CME credit)

NCI/NIH-SPONSORED SESSION • 10:15 a.m.–11:15 a.m.
Room A406-407, Georgia World Congress Center
NCI-Supported Biospecimen Resources Available to the Cancer Research Community
(not eligible for CME credit)

Chair: Irina A. Lubensky, Rockville, MD

10:15 a.m. NCI National Clinical Trials Network Biospecimen Banks (NCTN Banks) and navigator access. Irina A. Lubensky, Rockville, MD


10:39 a.m. Biospecimen resources available through the NCI’s Division of Cancer Prevention. Lori M. Minasian, Rockville, MD

10:51 a.m. SEER-Linked Virtual Tissue Repository (VTR): Pilot program and future plans. Alison L. Van Dyke, Rockville, MD

11:03 a.m. NCI Specimen Resource Locator: Database for human biospecimen resources. Joanne Demchok, Rockville, MD

**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
10:15 a.m.–12:00 p.m.
Room A411-412, Georgia World Congress Center
Proton Therapy

Chair: Alexander Lin, Philadelphia, PA

10:15 a.m. The need for and implementation of biologic treatment optimization in proton therapy. Harald Paganetti, Boston, MA
10:45 a.m. The role of particle therapy in generating an immunogenic tumor death. Ramesh Rengan, Seattle, WA
11:15 a.m. Ultra-high-dose proton radiotherapy: A potential, novel method to further enhance therapeutic ratio. Alexander Lin, Philadelphia, PA

Sydney Marcus Auditorium, Building A, Georgia World Congress Center
Regulation of the Immune Microenvironment by Glycosylation

Chair: Joseph N. Contessa, New Haven, CT

10:15 a.m. Partial inhibition of N-linked glycosylation: Genetics and pharmacology. Joseph N. Contessa, New Haven, CT
10:40 a.m. Critical role of glycosylation of PD-L1. Mien-Chie Hung, Houston, TX
11:05 a.m. Remodeling of the tumor microenvironment in a novel mouse model of pancreatic cancer driven by overexpression of the ST6Gal-I glycosyltransferase. Susan L. Bellis, Birmingham, AL
11:30 a.m. Sialoglycans as targets for cancer immunotherapy. Heinz Laubli, Basel, Switzerland
WEDNESDAY, APRIL 3**

ADVANCES IN ORGAN SITE RESEARCH • 10:15 a.m.–12:00 p.m.
Room B312-314, Georgia World Congress Center

Advances in Brain Metastasis

Chair: Bodour Salhia, Los Angeles, CA

10:15 a.m.  21st century clinical management of brain metastasis. Jann N. Sarkaria, Rochester, MN

10:45 a.m.  Brain metastasis prevention: From novel insights into the early steps of brain colonization to targeted clinical concepts. Frank A. Winkler, Heidelberg, Germany

11:15 a.m.  Advances in preclinical models of brain metastasis. Bodour Salhia, Los Angeles, CA

Georgia Ballroom 1, Building C, Georgia World Congress Center

Esophageal Cancer: Biology to Translational Medicine

Chair: Anil K. Rustgi, Philadelphia, PA

10:15 a.m.  CyclinDI and glutamine dependence in esophageal cancer. J. Alan Diehl, Charleston, SC

10:45 a.m.  Evolution of SOX2 function in esophageal squamous carcinogenesis. Adam J. Bass, Boston, MA

11:15 a.m.  Esophageal cancer 3D organoids equal a platform for insights into pathobiology and precision medicine. Hiroshi Nakagawa, Philadelphia, PA

**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.
MAJOR SYMPOSIA • 10:15 a.m.–12:00 p.m.

Hall A, Georgia World Congress Center
AACR-Bayard D. Clarkson Symposium:
Single-Cell Analysis of Tumor Heterogeneity

Chair: Samuel Aparicio, Vancouver, BC, Canada

10:15 a.m. Introduction

10:20 a.m. Measuring clonal structure and fitness in tumors with single-cell whole-genome sequencing and sgRNA/CRISPR targeting. Samuel Aparicio, Vancouver, BC, Canada

10:50 a.m. A large-scale single-cell atlas of human breast cancer links tumor ecosystems to poor prognosis and immunosuppression. Bernd Bodenmiller, Zurich, Switzerland

11:20 a.m. Single cells and therapy resistance in cancer. Arjun Raj, Philadelphia, PA

Room B206, Georgia World Congress Center
At the Roots of Cancer: Biology and Regulation of the Hippo-YAP Pathway

Chair: Kun-Liang Guan, La Jolla, CA

10:15 a.m. Introduction

10:20 a.m. The Hippo pathway in growth, regeneration, and cancer. Kun-Liang Guan, La Jolla, CA [SY40-01]

10:50 a.m. YAP/TAZ activity as hallmark of cancer: Biologic properties, upstream regulations, and downstream targets. Stefano Piccolo, Padua, Italy [SY40-02]

11:20 a.m. Growth control and Hippo signaling in the Drosophila abdomen. Nicolas Tapon, London, United Kingdom

Room B405-407, Georgia World Congress Center
Genomic Instability

Chair: Angelika Amon, Cambridge, MA

10:15 a.m. Introduction

10:20 a.m. The role of aneuploidy in tumorigenesis. Angelika Amon, Cambridge, MA

10:50 a.m. Characterizing tumor evolution one cell at a time. Tyler Jacks, Cambridge, MA

11:20 a.m. Chromatin loop extrusion is an underlying mechanism for programmed genomic rearrangements in the immune system. Frederick W. Alt, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
WEDNESDAY, APRIL 3**

Thomas Murphy Ballroom, Building B, Georgia World Congress Center

**Immune Exhaustion in Cancer Therapies**

Chair: Andy J. Minn, Philadelphia, PA

10:15 a.m. Introduction

10:20 a.m. The epigenetic landscape of T-cell exhaustion. W. Nicholas Haining, Boston, MA

10:50 a.m. Opposing functions of interferon signaling regulate adaptive and innate immunity against cancer. Andy J. Minn, Philadelphia, PA

11:20 a.m. Chromatin state dynamics defining tumor-specific T-cell dysfunction and therapeutic reprogrammability. Andrea Schietinger, New York, NY

Georgia Ballroom 3, Building C, Georgia World Congress Center

**Novel Insights in the Molecular Pathogenesis and Monitoring of Malignant Lymphomas**

Chair: Kojo Elenitoba-Johnson, Philadelphia, PA

10:15 a.m. Introduction

10:20 a.m. Proteogenomics for identification of novel biomarkers and therapeutic targets in lymphoid neoplasia. Kojo Elenitoba-Johnson, Philadelphia, PA

10:50 a.m. Deconvoluting cellular determinants of antitumor immune recognition. Ash A. Alizadeh, Stanford, CA

11:20 a.m. New insights in signaling and resistance in ALCL. Roberto Chiarle, Boston, MA

Room B401-402, Georgia World Congress Center

**The Changing Etiology of Liver Cancer: Needs for Prevention**

Chair: John D. Groopman, Baltimore, MD

10:15 a.m. Introduction

10:20 a.m. The changing etiology of liver cancer. John D. Groopman, Baltimore, MD [SY27-01*]

10:50 a.m. Prevention of HCC: Big successes but new challenges. Norah Terrault, Los Angeles, CA

11:20 a.m. Functional genomics identify cancer stem cell markers for hepatocellular cancer risk and prevention. Lopa Mishra, Washington, DC

*An extended abstract for this presentation is available in the invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).

**Program as of March 5, 2019. Please check the Annual Meeting app for changes in rooms, times, or speakers.**

AACR ANNUAL MEETING 2019
Room B302-303, Georgia World Congress Center

**The Science of Survivorship: Long-Term Survivorship in Vulnerable Populations**

**Chair:** Deborah K. Mayer, Bethesda, MD

**10:15 a.m. Introduction**

**10:20 a.m.** The Cancer Tsunami: What is it and what does it mean for survivors, clinicians, and researchers? Deborah K. Mayer, Bethesda, MD [SY29-01*]

**10:50 a.m.** A research roadmap for equitably improving outcomes for cancer survivors. Catherine M. Alfano, Washington, DC

**11:20 a.m.** Survivorship interventions in vulnerable populations: Improving patient reported outcomes via technology-based delivery and addressing the sociocultural context. Frank J. Penedo, Chicago, IL

**PLENARY SESSION • 12:15 p.m.–1:45 p.m.**

Hall A, Georgia World Congress Center

**AACR Annual Meeting 2019 Highlights: Vision for the Future**

**Chair:** Elizabeth M. Jaffee, Baltimore, MD

**12:15 p.m. Introduction.** Elizabeth M. Jaffee, Baltimore, MD

**12:20 p.m.** Prevention, early detection, and interception. Marcia R. Cruz-Correa, San Juan, Puerto Rico

**12:45 p.m.** Basic cancer science and translational research. John D. Carpten, Los Angeles, CA

**1:10 p.m.** Clinical research and clinical trials and therapeutics. Patricia M. LoRusso, New Haven, CT

**1:35 p.m.** Wrap-up and vision for the future. Elaine R. Mardis, Columbus, OH

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2019. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 4,600 grants to young investigators and has received support from more than 60 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, 17 organizations or individuals generously provided the funding to support this program.

The names and affiliations of the 2019 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.

2019 AACR Scholar-in-Training Awards

The AACR has received and distributed funds to support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2019.

**Songyeon Ahn, MS,** University of Texas at Austin, Austin, TX. **Abstract 1966.** Obesity and prostate cancer progression: Role of the chemokine CXCL12.

**Zachary S. Buchwald, MD, PhD,** Emory University, Atlanta, GA. **Abstract 526.** Tumor-draining lymph node irradiation reduces tumor-infiltrating stem-like CD8+T cells and abrogates the abscopal effect.

**Ekrem Emrah Er, PhD,** Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 209.** Metastatic colonization in the perivascular niche: A mechanotransduction perspective.

**Charles P. Hinzman, MS,** Georgetown University Medical Center, Washington, DC. **Abstract 1040.** Characterization of extracellular vesicles in pancreatic cancer: Changing the way we think about tumorigenesis.

**Dongya Jia, PhD,** Rice University, Houston, TX. **Abstract 2448.** Elucidating the metabolic plasticity of cancer by coupling gene regulation with metabolic pathways.

**Justyna E. Kanska, PhD,** Cedars-Sinai Medical Center, Los Angeles, CA. **Abstract 1734.** Crispr/Cas9 screening of Brca1 and Brca2 susceptibility genes in breast and ovarian cancer precursor cells can identify phenotypically different mutants with variable penetrance.

**Geffen Kleinstern, PhD,** Mayo Clinic, Rochester, MN. **Abstract 4466.** Somatic mutations within chronic lymphocytic leukemia (CLL) putative driver genes are associated with outcomes beyond the CLL international prognostic index (CLL-IPI).

**Shengchen Lin, PhD,** Penn State University College of Medicine, Hershey, PA. **Abstract 973.** The mitochondrial deoxyguanosine kinase regulates lung adenocarcinoma cancer stem-like cells through AMPK/YAP1 signaling.

**Jian Liu, PhD,** National Institute of Environmental Health Sciences, Durham, NC. **Abstract 5212.** Ablation of SMAD4 repression on Elf3 promotes the progression of lung cancer in vivo.

**Xiande Liu, PhD,** The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 945.** PBRM1 loss reduces IFNγ-STAT1 activity and promotes resistance to immunotherapy and antiangiogenic therapy in renal cell carcinoma.

**Abhijit Parolia, BS,** University of Michigan, Ann Arbor, MI. **Abstract 4497.** Distinct...
structural classes of activating FOXA1 alterations in prostate cancer progression.

Tessa M. Popay, BS, Vanderbilt University, Nashville, TN. Abstract 2600. Interaction of host cell factor-1 with the oncprotein transcription factor MYC.

John R. Prensner, MD, PhD, Boston Children’s Hospital, Boston, MA. Abstract 4344. Integrative functional proteogenomics for unannotated or uncharacterized proteins in cancer.

Hannan Qureshi, MD, Fred Hutchinson Cancer Research Center, Seattle, WA. Abstract 2841. Differential immune responses to HPV-positive and HPV-negative head and neck cancer.

Vaishnavi Sambandam, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 3913. PDK1 drives susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition.

Nikita S. Sharma, MS, University of Miami, Miami, FL. Abstract 4498. O GlcNAcylation of SOX2 regulates its tumor initiation properties in pancreatic cancer.

Nirmish Singla, MD, University of Texas Southwestern Medical Center, Dallas, TX. Abstract 2505. Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.

Preethi Srinivasan, MS, Weill Cornell Graduate School of Medical Sciences, New York, NY. Abstract 4158. Dissecting the role of zyosity and lineage in Lynch Syndrome-associated microsatellite instability.


Emily A. Teslow, BS, Karmanos Cancer Institute at Wayne State University SOM, Detroit, MI. Abstract 3680. SRSF2-dependent MBD2v2 expression is induced by obesity and promotes tumor-initiating triple-negative breast cancer stem cells.


Fan Zhang, PhD, Fred Hutchinson Cancer Research Institute, Seattle, WA. Abstract 4770. Programming tumor-clearing macrophages with targeted in situ gene therapy.

2019 AACR-American Brain Tumor Association Scholar-in-Training Awards

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality abstracts in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2019.

Ahmed Elsehemy, PhD, University of Toronto, University Health Network (UHN), Toronto, ON, Canada. Abstract 4671. Novel biological roles of the atypical WNT ligand, Norrin, on glioblastoma stem cells segregate with ASCL1 expression.

Kazutaka Fukumura, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 3406. Comprehensive genomic analysis of brain metastases from multiple cancer types.
**TRAVEL AWARDS**

**Evan Noch, MD, PhD,** Weill Cornell Medicine, New York, NY. **Abstract 2062.** Evaluating the effect of tumor necrosis on glycolytic flux and cell survival in glioblastoma.

**Tadas K. Rimkus, BS,** Wake Forest University School of Medicine, Winston-Salem, NC. **Abstract 3481.** Roles of tumor suppressor candidate 2 (TUSC2) in glioblastoma progression and gliomagenesis.

**Jack M. Shireman, BS,** Northwestern University, Chicago, IL. **Abstract 81.** ARL13B interacts with IMPDH2 to modulate purine synthesis and temozolomide resistance in glioblastoma.

**Shih-Ying Wu, PhD,** Wake Forest Baptist Health, Winston-Salem, NC. **Abstract 1512.** Nicotine promotes brain metastasis of lung cancer by inducing M1/M2 conversion and suppressing the innate immune response of microglia.

**Chinmayee Dash, MS,** Brigham & Women’s Hospital, Harvard Medical School, Cambridge, MA. **Abstract 4516.** Suppression of metastasis by inhibiting nanoscale physical communication of cancer cell and the endothelium.

**Golnaz Morad, DDS,** Harvard University, Boston, MA. **Abstract 1989.** Breast cancer-derived exosomes modulate the endocytic pathway in brain endothelial cells.

**Jingkun Qu, MD, PhD,** The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2739.** EZH2 promotes breast cancer bone metastasis.

**Tanmoy Saha, PhD,** Harvard Medical School, Brigham and Women’s Hospital, Cambridge, MA. **Abstract 1480.** A novel mechanism of immunosuppression via nanotube-mediated mitochondrial trafficking between cancer cell and immune cell.

**Abhishek Tyagi, PhD,** Wake Forest Baptist Medical Center, Winston-Salem, NC. **Abstract 2025.** Nicotine promotes lung metastasis in triple-negative breast cancer through paracrine signaling in the tumor microenvironment.

---

**2019 AACR-Breast Cancer Research Foundation Scholar-in-Training Awards**

The Breast Cancer Research Foundation has graciously donated funds to support young investigators who will be presenting high-quality abstracts in breast cancer research at the AACR Annual Meeting 2019. This year, additional funding to support three awardees has been given by the Breast Cancer Research Foundation to honor the memory of Dr. Arti Hurria.

**Rania Bassioni, PhD,** University of Southern California, Los Angeles, CA. **Abstract 3488.** Loss of nuclear alpha-catenin is associated with race, aggressive disease, and chemoresistance in triple-negative breast cancer.

**Alamelu G. Bharadwaj, PhD,** Dalhousie University, Halifax, NS, Canada. **Abstract 2747.** Loss of S100A10 gene suppresses mammary tumor progression in PyMT mouse tumor model.

**Ivy Xiaoyu Chen, PhD,** Massachusetts General Hospital, Boston, MA. **Abstract 2744.** Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Gloria V. Echeverria, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 2901. Clonal dynamics and phenotypic evolution during chemoresistance and metastasis revealed by patient-derived xenograft models of triple-negative breast cancer.


Yunkai Zhang, PhD, Vanderbilt University Medical Center, Nashville, TN. Abstract 930. On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation.

2019 AACR-June L. Biedler Scholar-in-Training Awards

These awards are presented to authors of meritorious abstracts in the field of drug resistance to be presented at the AACR Annual Meeting 2019. These awards are made possible through the Estate of Dr. June L. Biedler. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Tyler B. Bland, PhD, Washington State University, Spokane, WA. Abstract 2064. CHRM1-mediated acetylcholine signaling protects prostate cancer cells from the chemotherapy agent docetaxel.

Derek A. Franklin, PhD, Vanderbilt University Medical Center, Nashville, TN. Abstract 1511. MEK activation modulates immunosuppressive MDSCs and metabolic phenotypes in TNBC.

Sunil K. Joshi, BA, Oregon Health & Science University (OHSU), Portland, OR. Abstract 926. Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia.

Casey D. Stefanski, MS, University of Notre Dame, Notre Dame, IN. Abstract 3478. APC loss mediates doxorubicin response in breast cancer via changes in intracellular drug concentration and DNA repair pathways.

Shuhei Asada, PhD, The Institution of Medical Science, The University of Tokyo, Tokyo, Japan. Abstract 4643. Mutant ASXL1 collaborates with HHEX to promote myeloid leukemogenesis.

Vrushank Dharmesh Bhatt, MS, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Abstract 2716. Autophagy modulates lipid metabolism in liver kinase B1 (LKB1)-deficient Kras-driven lung tumorigenesis.

Ryan Carpenter, BS, University of Massachusetts Amherst, Amherst, MA. Abstract 3748. Implantable tumor attracting niche models to study disseminated tumor cell biology.

Cheng Chen, MS, University of Illinois at Urbana Champaign, Urbana, IL. Abstract 1893. Consumption of oil derived from frying bacon increases breast cancer metastasis.

2019 AACR-Bristol-Myers Squibb Oncology Scholar-in-Training Awards

Bristol-Myers Squibb Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2019.

Shuhei Asada, PhD, The Institution of Medical Science, The University of Tokyo, Tokyo, Japan. Abstract 4643. Mutant ASXL1 collaborates with HHEX to promote myeloid leukemogenesis.
TRAVEL AWARDS

Tat Wei Lionel Chia, MSc, Johns Hopkins University, Baltimore, MD. Abstract 2595. HMGA1 induces the HOXB13 developmental gene to drive tumor progression in androgen receptor negative, castrate-resistant prostate cancer.

Patricia Cho, MSc, Harvard Medical School, Boston, MA. Abstract 884. Interplay between NRF2 and GPX4 is critical for cancer cell survival in 3D spheroids.

Dilanka Fernando, MSc, Monash University, Clayton, VIC, Australia. Abstract 790. STAT3 control of mitochondrial RNA stability and translation is a vulnerability in tumors.

Arnab Ghosh, MBBS, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 4843. TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models.

G. Kenneth Gray, MS, Harvard Medical School, Boston, MA. Abstract 969. Characterization of murine mammary epithelial populations throughout development and in premalignant tissue via mass cytometry.

Sarah J. Hill, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 368A. Functional assessment of DNA damage repair defects and the antitumor immune response in high-grade serous ovarian cancers using patient-derived organoids.

Caroline S. Jansen, BS, Emory University, Atlanta, GA. Abstract 2700. CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche.

Masanori Kawakami, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 4407. Next-generation CDK2/9 inhibitor CYC065 triggers anaphase catastrophe in diverse aneuploid cancers and markedly inhibits growth and metastasis.

Lea Maillat, MS, University of Chicago, Chicago, IL. Abstract 4520. Lymphatic vessels regulate exosome trafficking from tumors.

Brian C. Miller, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 2701. Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade.

Kiyomi Morita, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 2725. The single-cell atlas of driver mutations in acute myeloid leukemia.

Marco A. Ramos, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 2712. Effect of combined PD-1 and IL-6 blockade on K-ras mutant lung cancer.

April A. N. Rose, MD, PhD, University of Toronto, Toronto, ON, Canada. Abstract 3141. The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma.

Xiaoyan Wang, MD, Washington University in St Louis, St Louis, MO. Abstract 4465. The effect of insurance status on childhood and adolescent cancer survival using data from the National Cancer Database.

Yiliang Wei, PhD, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Abstract 5161. Probing leukemia vulnerabilities in vivo using domain-focused CRISPR screening.

Roberta Zappasodi, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 2711. Rational combination of GITR agonism with PD-1 blockade.

Feng Zhu, PhD, National Cancer Institute, National Institutes of Health, Frederick, MD.
**Abstract 2355.** IKKa serves as a molecular switch linking miRNA biogenesis and inflammation in skin tumorigenesis.

**2019 AACR-James V. Buzzitta, MD Family Fund Scholar-in-Training Awards**

Funds have been graciously donated to the AACR by the James V. Buzzitta, MD Family Fund to recognize outstanding young investigators for their meritorious work in cancer research and to support their attendance at the 2019 AACR Annual Meeting.

**Andrew Chow, MD, PhD,** Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 978.** Tim-4⁺ tissue-resident macrophages impair antitumor T-cell immunity.

**Philip Jonsson, PhD,** Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 1752.** BRCA-mediated tumorigenesis is origin and cell-type dependent.

**2019 AACR-Dr. Charles Chalfant Scholar-in-Training Awards**

AACR Member Dr. Charles Chalfant, Professor and Chair of the Department of Cell Biology, Microbiology and Molecular Biology at the University of South Florida College of Medicine, is the generous donor of these awards. Dr. Chalfant made this contribution in honor and support of training for the next generation of scientists.

**Kirsten Kubler, MD, PhD,** Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts General Hospital Cancer Center, Charlestown, MA; Harvard Medical School, Boston, MA. **Abstract 2727.** The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin.

**Benika J. Pinch, MS,** Harvard University, Cambridge, MA. **Abstract 2757.** Discovery and characterization of covalent Pin1 inhibitors targeted to an active site cysteine.

**2019 AACR-Club R-K Scholar-in-Training Award in Support of Breast Cancer Research**

Funds have been graciously donated to the AACR by Club R-K to recognize an outstanding young investigator for meritorious work in breast cancer research being presented at the 2019 AACR Annual Meeting.

**Parichoy Pal Choudhury, PhD,** The Johns Hopkins University, Baltimore, MD. **Abstract 962.** Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries.

**2019 AACR Margaret Foti Scholar-in-Training Awards**

Through a generous gift of the Margaret Foti Foundation, these awards recognize outstanding young investigators for their meritorious work in pediatric, pancreatic, or ovarian cancer research.


**Thomas P. Howard, MS,** Dana-Farber Cancer Institute, Boston, MA. **Abstract 2867.** MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors.

Clare F. Malone, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 2878. CRISPR-Cas9 screens identify the nuclear export factor NXT1 as a novel therapeutic target in MYCN-amplified neuroblastoma.

Naiara Martínez-Velez, PhD, Clinic University of Navarra, Pamplona, Spain. Abstract 3117. Delta-24-RGD/DNX-2401: Oncolytic virotherapy for pediatric high-grade glioma and DIPG.

Ronald F. Siebenaler, BS, University of Michigan Medical School, Ann Arbor, MI. Abstract 956. An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.


Annie A. Wu, BS, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 4491. Association of intratumoral immunologic profile with overall survival in metastatic pancreatic cancer patients treated with combination immunotherapy with or without PD-1 blockade.

2019 AACR-Gerald B. Grindey Memorial Scholar-in-Training Award

This award is presented to the author of a meritorious abstract in the field of preclinical science presented at the AACR Annual Meeting 2019. The late Dr. Grindey was a dedicated member of the AACR and a distinguished scientist at Eli Lilly and Company. The Gerald B. Grindey Memorial Fund was established in his honor and has been entrusted to the AACR to be used toward educational programs for early-career scientists engaged in preclinical cancer research.

Catherine A. Higgins, PhD, Queens University Belfast, Belfast, United Kingdom. Abstract 382. Development and preclinical assessment of a first-in-class small-molecule inhibitor of FLIP.

2019 AACR-Get Your Rear in Gear Philadelphia Scholar-in-Training Awards Supported by the Colon Cancer Coalition

Get Your Rear in Gear Philadelphia has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts on colorectal cancer research at the AACR Annual Meeting 2019.

Erica K. Barnell, BS, Washington University School of Medicine, St. Louis, MO. Abstract 4213. Stool-derived eukaryotic RNA (seRNA) assay for noninvasive detection of colorectal cancer and high-risk adenomas.

Naghma Khan, PhD, University of Wisconsin-Madison, Madison, WI. Abstract 2733. Novel mouse model carrying APC and PIK3CA mutations in colorectal cancer.
Xiangqian Kong, PhD, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Abstract 947. Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and tumorigenicity.

Trine B. Mattesen, MS, Aarhus University Hospital, Aarhus, Denmark. Abstract 466. A novel DNA methylation-based approach for molecular subtyping and improved prognostication of colorectal cancer using formalin-fixed and paraffin-embedded tissue.

Xiaoliang (Wendy) Wang, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. Abstract 630. Smoking is associated with risks of molecular subtypes of colorectal cancer.

Xiang Shu, PhD, Vanderbilt University Medical Center, Nashville, TN. Abstract 2685. Identification of circulating protein biomarkers for colorectal cancer risk: A genetic instrument analysis.


2019 AACR-MEG Scholar-in-Training Awards

These awards are for authors of meritorious abstracts in molecular epidemiology that will be presented at the AACR Annual Meeting 2019, supported by the Molecular Epidemiology Working Group (MEG) of the AACR. The mission of MEG is to increase knowledge about cancer and chronic disease etiology, thereby promoting the prevention and treatment of cancer and the improvement of public health. In addition to travel support, award recipients receive membership to the Working Group.

Audrey Y. Jung, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany. Abstract 620. Evaluating multiple tumor markers in a novel analysis of reproductive factors and breast cancer risk.

Andi K. Cani, MS, University of Michigan, Ann Arbor, MI. Abstract 914. Development of a whole-urine, next-generation sequencing-based assay for early detection of aggressive prostate cancer.


Naveen Ramesh, MS, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 446. Plasma genome sequencing identifies prostate cancer patients that are sensitive to platinum-based therapy.
TRAVEL AWARDS

2019 AACR-Pezcoller Foundation Scholar-in-Training Awards
The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Marco Campisi, MS, Politecnico di Torino, Turin, Italy. Abstract 958. Tumor-vascular interactions promote STING-driven inflammation in the tumor microenvironment.

Maximilian Yuanzhe Deng, MD candidate, German Cancer Research Center (DKFZ), Heidelberg, Germany. Abstract 3646. (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrent PDGFRA amplification and loss of CDKN2A/B following primary acute lymphatic leukemia and medulloblastoma.

Steffen Fuchs, MD, Charité-University Medicine Berlin, Berlin, Germany. Abstract 1820. Circular RNAs contribute to neuroblastoma pathogenesis.

Robert L. Hollis, PhD, University of Edinburgh, Edinburgh, United Kingdom. Abstract 749. Multilayer molecular characterization of high-grade serous ovarian carcinomas.

Disha Malani, MS, Institute for Molecular Medicine Finland, Helsinki, Finland. Abstract 458. Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex vivo drug sensitivity testing and molecular profiling.

Lucas D. Trucco, PhD, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom. Abstract 4653. Melanocyte specific deletion of Map3k1 reveals its role in BRAFV600E-driven melanoma.

2019 AACR-SIC Scholar-in-Training Awards
The AACR-SIC Scholar-in-Training Awards are a partnership between the AACR and the Società Italiana di Cancerologia (SIC, the Italian Cancer Society). The AACR and SIC sponsor these awards to enhance participation by early-career investigators who are members of SIC, and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Valentina Audrito, PhD, University of Turin & Italian Institute for Genomic Medicine, Turin, Italy. Abstract 1845. BRAF-mediated NAMPT overexpression induces a melanoma cell dedifferentiation program leading to metabolic reprogramming and intrinsic resistance to BRAF inhibitors.

Denisa Baci, PhD, University of Milano-Bicocca, Monza, Italy. Abstract 4571. Proinflammatory and proangiogenic properties of tumor associated natural killer cells in prostate cancer.

Francesca Citron, PhD, CRO-Aviano, Aviano, Italy. Abstract 3128. miR-9 expression regulates and predicts the response to EGFR inhibitors in head and neck squamous cell carcinoma.

Martina Di Modica, MSc, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Abstract 4959. The gut microbiota contributes to the effectiveness of HER2-targeted therapy.
Marco Giordano, PhD, European Institute of Oncology (IEO), Milan, Italy. **Abstract 3678.** Ovarian cancer stemness is driven by a novel L1/Stat3/Src axis.

Denise Pinessi, PhD, Mario Negri Institute for Pharmacological Research IRCCS, Bergamo, Italy. **Abstract 198.** The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature.

Carolina Reduzzi, MS, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. **Abstract 1390.** Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management?

Domenico Trombetta, PhD, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. **Abstract 4887.** Recurrent NRG1 rearrangements in Caucasian pulmonary mucinous adenocarcinoma: results from an Italian multi-center cohort.

**2019 AACC-Warner Fund Scholar-in-Training Award**

The Warner Fund has graciously donated funds to the AACR to support an early-career investigator who will be presenting meritorious work relating to cholangiocarcinoma.

Lorena Marcano-Bonilla, BS, Mayo Clinic, Rochester, MN. **Abstract 5049.** Associations of aspirin, non-aspirin NSAIDs, statins, and metformin with risk of biliary tract cancer: A Swedish population-based cohort study.

**2019 AACC Scholar-in-Training Award in Honor of Cathy Whalen**

Gifts made in honor and support of Cathy Whalen have been graciously donated to support a young investigator presenting a high-quality abstract in bile duct cancer at the AACR Annual Meeting 2019.

Bridget P. Keenan, MD, PhD, University of California San Francisco, San Francisco, CA. **Abstract 4063.** Single-cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action.

**2019 GLOBAL SCHOLAR-IN-TRAINING AWARDS**

The AACR is proud to offer Global Scholar-in-Training Awards (GSITA) to support the participation of meritorious early-career scientists from low- and middle-income countries (LMICs) in the Annual Meeting 2019. The GSITA program builds upon the success of the African Cancer Research Travel Award, which over the course of three years (2016-2018) benefited 15 African scientists from seven countries—Egypt, Ghana, Morocco, Nigeria, Senegal, South Africa, and Sudan—and expands the program to eligible investigators from all LMICs. This year, GSITA recipients hail from nine LMICs—Bangladesh, Brazil, China, Colombia, Egypt, India, Nigeria, South Africa, and Turkey.

The names and affiliations of the 2019 GSITA recipients, along with the abstract numbers and titles of their abstracts, are listed below.
Kanchan Chakma, PhD, University of Chittagong, Chittagong, Bangladesh. **Abstract 821.** DNA hypermethylation of IRX4 is a frequent event that may confer growth advantage to pancreatic cancer cells.

Titilope M. Dokunmu, PhD, Covenant University, Ota, Nigeria. **Abstract 5048.** Determination of haptoglobin, hemoglobin genotypes and malaria incidence in Nigerian breast cancer patients.

Carolina C. Gomes, DDS, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. **Abstract 4663.** KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features.


Ozhan Ocal, PhD, Bilkent University, Ankara, Turkey. **Abstract 1790.** Investigation of oncogenic G-protein coupled receptor signaling pathways in Kras dependent pancreatic cancer cell lines.

Ana Karina Oliveira, PhD, Brazilian Center for Research in Energy and Materials-CNPEM, Campinas, Brazil. **Abstract 2800.** Oral cancer cell-derived extracellular vesicles can modulate an immunosuppressive microenvironment through M2 phenotype polarization.

Jeremiah Olorunjuwon Olugbami, PhD, University of Ibadan, Ibadan, Nigeria. **Abstract 1867.** Liver and urinary bladder cancers: The modifying role of aqueous leaf extract of Terminalia glaucescens Planch. ex Benth.

Mohamed H. Osman, Zagazig University, Zagazig City, Egypt. **Abstract 1644.** Pancreatic cancer survival prediction using machine learning and comparing its performance with TNM staging system and prognostic nomograms.

Doğancan Özturan, Koc University, Istanbul, Turkey. **Abstract 5208.** Genomewide AR enhancer activity in prostate cancer.

Saumya Patel, PhD, Gujarat University, Ahmedabad, India. **Abstract 2106.** Role of organic cation transporter-1 (OCT-1) in drug resistance condition of ph+ chronic myeloid leukemia (CML).

Tirzah Braz Petta Lajus, PhD, Universidade Federal do Rio Grande do Norte, Natal, Brazil. **Abstract 4171.** Identification of individuals with colonic polyposis in a highly inbred region.

Guoliang Qiao, MD, PhD, Capital Medical University, Beijing, China. **Abstract 1426.** Expansion of CD8+PD-1+ T cells restored TCR repertoire as a prognostic marker to adoptive T cell immunotherapy of advanced pancreatic cancer.

Silvia J. Serrano-Gómez, PhD, Instituto Nacional de Cancerología, Bogotá, Colombia. **Abstract 460.** Understanding transcriptomic profiles that might explain discordance of the PAM50 and immunohistochemistry classification methods in luminal tumors from Colombian women.

Pauline J. van der Watt, PhD, University of Cape Town, Cape Town, South Africa. **Abstract 1729.** Investigating deregulated circadian clock machinery in cancer cells.

Wu Zhang, PhD, Shanghai Institute of Hematology, Shanghai, China. **Abstract 4406.** TRIB3 stabilizes high TWIST1 expression to promote rapid APL progression & ATRA resistance.
2019 AACR MINORITY AND MINORITY-SERVING INSTITUTION FACULTY SCHOLARS IN CANCER RESEARCH AWARDS

The AACR is very pleased to administer this important program, which provides funds for the participation of full-time minority faculty members and faculty members of Minority-Serving Institutions (MSI) at the AACR Annual Meeting 2019. Recipients of this award are scientists who are working at the level of Assistant Professor or above who are engaged in meritorious basic, clinical, or translational cancer research.

Since its inception in 1997, this award program has been supported by a generous grant provided by the National Cancer Institute’s Center to Reduce Cancer Health Disparities. The Center to Reduce Cancer Health Disparities (CRCHD) works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers. The Board of Directors of the AACR expresses its appreciation to the CRCHD for its long-term and generous support of faculty members and congratulates these outstanding Scholars.

The names and affiliations of the 2019 Minority and Minority-Serving Institution Faculty Scholars are listed below, along with the numbers and titles of their presentations.

**Ernest K. Amankwah, PhD,** Assistant Professor, Johns Hopkins University, Tampa, FL. **Abstract 1576.** Identification of six novel candidate miRNAs associated with early relapse in B-cell pediatric acute lymphoblastic leukemia.

**Claudia A. Benavente, PhD,** Assistant Professor, University of California, Irvine, Irvine, CA. **Abstract 2148.** UHRF1 overexpression is a significant driver of tumor progression in RB-mediated cancers.

**Eileen J. Brantley, PhD,** Assistant Professor, Loma Linda University Health, Redlands, CA. **Abstract 1304.** Aryl hydrocarbon receptor ligands 5F 203 and 3,3′-diindolylmethane disrupt mammospheres derived from MCF-7 cells and induce tumor suppressor miR125b-2 expression. **Abstract 16.** 3,3′-Diindolylmethane induces cytoglobin expression and synergizes with poly ADP ribose polymerase inhibitor PJ34 to inhibit triple negative breast cancer cell growth.

**Chun-Liang Chen, PhD,** Associate Professor, University of Texas Health Science Center at San Antonio, Helotes, TX. **Abstract 2766.** Amplification-associated upregulation of genes involved in oxidative phosphorylation for disseminated prostate cancer cells. **Abstract 173.** Upregulated EPHB2 and SRC pathways modulate spatial EGFR dynamics and malignant phenotypes and predict poor prognosis in prostate cancer.

**Jonine Figueroa, PhD, MPH,** Associate Professor, University of Edinburgh, Edinburgh, Scotland. **Abstract 622.** Reproductive factors and breast cancer risk to women in Ghana, West Africa. **Abstract LB-178.** Performance of breast cancer polygenic risk score (PRS) in a Ghanaian population.

**Kristianna Fredenburg, MD, PhD,** Assistant Professor, University of Florida, Gainesville, FL. **Abstract 3583.** Differential expression of noncoding RNAs in black compared with white laryngeal cancers. **Abstract 5222.** Repression of neuronal genes protects the pancreas from certain injuries and aberrant plasticity.

**Filipa Godoy-Vitorino, PhD,** Associate Professor, University of Puerto Rico, Medical Sciences Campus, School of Medicine,
Caguas, PR. **Abstract 2831.** Detection of methane-producing archaea in the cervix of Hispanics using shotgun metagenomics. **Abstract 4216.** The microbiota associated to cervical and anal HPV infections in a Hispanic population.

**Yared Hailemichael, PhD,** Assistant Professor, The University of Texas MD Anderson Cancer Center, Manvel, TX. **Abstract 5010.** Potentiating immune checkpoint blockade therapeutic efficacy using a small-molecule activator of integrin cell adhesion receptors.

**Dennis Jones, PhD,** Assistant Professor, Boston University School of Medicine, Framingham, MA. **Abstract 1089.** Characterization of the immune response to lymph node metastases.

**Chun-Lin Lin, PhD,** Assistant Professor, University of Texas Health Science Center at San Antonio, Helotes, TX. **Abstract 5150.** Adipose-derived stem cell disruption of gap junction intercellular communication in obesity-associated endometrial cancer. **Abstract 2766.** Amplification-associated upregulation of genes involved in oxidative phosphorylation for disseminated prostate cancer cells. **Abstract SY43-03.** Long-range epigenetic control of estrogen-responsive transcription. **Abstract 2193.** AXL inhibitor TP-0903 attenuates AXL-TGFbeta Hippo signaling axis in lung adenocarcinoma cells.

**Luciana Madeira da Silva, PhD,** Assistant Professor, University of South Alabama, Mobile, AL. **Abstract 3864.** A novel PDE10/β-catenin pathway inhibitor, MCI-030, for the treatment of colorectal cancer. **Abstract 4822.** Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors.

**Jessie Villanueva, PhD,** Assistant Professor, The Wistar Institute, Hilltown, PA. **Abstract 3842.** Co-targeting BET and MEK as salvage therapy for MAPKi and checkpoint inhibitor resistant melanoma.

**Lisa T. Wigfall, PhD,** Assistant Professor, Texas A&M University, College Station, TX. **Abstract 3327.** HPV vaccination among adults at high risk for HIV infection: A public health priority.

**Jovanny Zabaleta, PhD,** Associate Professor, Louisiana State University Health Sciences Center, Metairie, LA. **Abstract 152.** Gene expression and mutational load in colon tumors from African American patients. **Abstract 460.** Understanding transcriptomic profiles that might explain discordance of the PAM50 and immunohistochemistry classification methods in luminal tumors from Colombian women.

**Ana Patricia P. Ortiz-Martinez, PhD,** Professor, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR. **Abstract 2435.** Knowledge and attitudes towards anal cancer and anal cancer screening among Hispanic women at increased risk of anal cancer.

**2019 AACR MINORITY SCHOLAR IN CANCER RESEARCH AWARDS**

The AACR is very pleased to administer this important program, which provides funds for the participation of early-career, meritorious minority scientists at the AACR Annual Meeting 2019. Scholars are chosen from both minority institutions and the larger bodies of universities, colleges, and research institutes. They are selected on the
basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

Since its founding in 1985, the Minority Scholar Awards in Cancer Research program has been supported by a generous grant of the National Cancer Institute’s Center to Reduce Cancer Health Disparities. The Center to Reduce Cancer Health Disparities (CRCHD) works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers.

For 34 years, the AACR has endeavored through this program to reach out to minority predoctoral and postdoctoral students, trainees, and junior investigators as future cancer researchers. The program was created in an attempt to address the serious problem of lack of minority participation in cancer research by offering young minority students and trainees the opportunity to attend and participate in the Annual Meetings and Special Conferences of the AACR.

The names and affiliations of the 2019 Minority Scholar Award recipients are listed below, along with the numbers and titles of their presentations.

**Ky’Era Actkins, BS**, Graduate Student, Meharry Medical College, Nashville, TN. **Abstract 5127.** Association of inactivating calcium sensing receptor exon 7 SNPs with hypercalcemia-related disease phenotypes.

**Nathaniel D. Anderson, BS**, Graduate Student, The Hospital for Sick Children, Toronto, ON, Canada. **Abstract 2506.** Exploring the complex etiology of oncogenic fusions in childhood cancer.

**David Anwanwan, MS**, Medical Student, Morehouse School of Medicine, Atlanta, GA. **Abstract 4412.** Piperine enhances the efficacy of 5 FU against liver cancer.

**Heather K. Beasley, MS**, Graduate Student, Meharry Medical College, Nashville, TN. **Abstract 133.** The role of the calcium-sensing receptor (CaSR) in the adaptation of breast cancer cells in high Ca2+ microenvironments.

**Vincent Bernard, MS**, Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1402.** Single cell transcriptomic profiling of ex vivo tumoroid models reveal therapeutic vulnerabilities of pancreatic ductal adenocarcinoma.

**Aria L. Byrd, MS**, Graduate Student, University of Kentucky, Lexington, KY. **Abstract 5185.** Squamous cell cancers and chronic obstructive pulmonary disease share polycomb repressive complex 2 dysregulation.

**Doratha A. Byrd, PhD, MPH**, Postdoctoral Fellow, Emory University, Atlanta, GA. **Abstract 627.** Associations of novel dietary and lifestyle inflammation scores with incident colorectal cancer in the National Institutes of Health-American Association of Retired Persons Diet and Health study.

**Patrice D. Cagle, PhD**, Postdoctoral Fellow, North Carolina Central University, Durham, NC. **Abstract 3561.** MicroRNA-214 inhibits prostate cancer cell proliferation, migration, invasion and increases drug sensitivity by targeting PTK6.

**Anita M. Chanana, BS**, Medical Student, Stanford University School of Medicine, Stanford, CA. **Abstract 1964.** -C chemokine receptor type 1 is a prognostic indicator in ovarian cancer.

**Claudia B. Colon-Echevarria, MPH**, Graduate Student, Ponce Health Sciences University, Ponce, PR. **Abstract 512.** Adrenergic modulation of inflammatory cytokines in ovarian cancer.
TRAVEL AWARDS

Tiffany A. Coupet, BS, Graduate Student, Geisel School of Medicine, Dartmouth, Lebanon, NH. Abstract 1539. Mechanisms of action of bispecific T cell engager-mediated immune response in a lymphoma tumor model.

Marimar De La Cruz Bonilla, BS, Graduate Student, MD Anderson Cancer Center, Houston, TX. Abstract 3746. Fasting in mice enables abdominal radiation dose escalation in the setting of pancreatic cancer by mitigating small intestinal toxicity.

Guillermo Flores, BS, Graduate Student, Van Andel Institute, Grand Rapids, MI.

Lee D. Gibbs, PhD, Postdoctoral Fellow, University of Southern California, Los Angeles, CA. Abstract 4703. Single-cell CNV end-to-end workflow to uncover tumor heterogeneity in a murine breast cancer model.


Jamaal L. James, PhD, Postdoctoral Fellow, Vanderbilt University Medical Center, Nashville, TN. Abstract 4728. IFNγ signaling drives EZH2 degradation to induce MHC-II expression in melanoma.

Taylor Rae R. Jamieson, BS, Ottawa Hospital Research Institute, Ottawa, ON, Canada. Abstract 2593. A double dose of DNA damage: Overcoming drug resistance using targeted oncolytic viruses.

Jonelle K. Lee, MS, Graduate Student, University of Maryland, Baltimore, Baltimore, MD. Abstract 2056. Combined FLT3 and Pim kinase inhibitor treatment downregulates c-Myc early in apoptosis induction in acute myeloid leukemia with FLT3-ITD.

John A. Ligon, MD, Clinical Fellow, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 4973. The immunosuppressive tumor microenvironment of metastatic osteosarcoma inhibits the cytotoxic effect of tumor-infiltrating lymphocytes.


Greisha L. Ortiz Hernandez, BS, Graduate Student, Loma Linda University, Loma Linda, CA. Abstract 4395. The cMYC-associated transcription factor JPO2 is upregulated in taxane-resistant prostate cancer cells and interacts with the stress oncoprotein LEDGF/p75.


Margaret S. Pichardo, MPH, Graduate Student, Yale University School of Public Health, New Haven, CT. Abstract 625. Association between obesity and prostate cancer disease risk and mortality among African American men.

Sarah Roth, MS, Graduate Student, Georgetown University, Washington D.C. Abstract 2912A. Intratumoral heterogeneity and immune checkpoint inhibitor response in the KPC pancreatic cancer model.

Jean F. Ruiz Calderon, PhD, Postdoctoral Fellow, UPR Medical Science Campus, San Juan, PR. Abstract 2185. Efficacy of Rac/Cdc42 inhibitors in multiple cancer models.

Tino Sanchez, PhD, Postdoctoral Fellow, Loma Linda University, Loma Linda, CA. Abstract 1623. Autoantibodies to human endogenous retrovirus K envelope protein
(HERV-K ENV) are associated with features of prostate cancer aggressiveness in African American men.

Janice M. Santiago-Ofarrill, PhD, Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 4768. PARP inhibitor-induced autophagy provides an adaptive mechanism of drug resistance in preclinical models of ovarian cancer.

Ciera S. Singleton, MS, Graduate Student, LSU Health Sciences Center-New Orleans, New Orleans, LA. Abstract 5250. Notch signaling in ER+ breast cancer in response to endocrine therapy agents.

Sherona R. Sirkisoon, MS, Graduate Student, Wake Forest School of Medicine, Winston-Salem, NC. Abstract 3689. Tumor-specific gain-of-function tGLI1 transcription factor is a novel mediator of breast cancer stem cells and a novel transcriptional activator of cancer stemness genes.

Jeronay A. Thomas, MS, Graduate Student, Morehouse School of Medicine, Atlanta, GA. Abstract 4237. CC chemokines are differentially expressed in breast cancer and are associated with racial disparity.


Yorleny M. Vicioso, BS, Graduate Student, Case Western Reserve University School of Medicine, Cleveland, OH. Abstract 3186. A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia.

Demond Williams, BS, Graduate Student, Vanderbilt University, Nashville, TN. Abstract 1201. IL4 receptor mediated metabolic changes contribute to histone acetylation leading to metastatic progression in breast cancer.

Marquita A. Winters, BS, Graduate Student, Cornell University, Ithaca, NY. Abstract 4611. Identifying drivers of mammary tumorigenesis and elucidating the mechanisms of cancer initiation in DNA replication defective Chaos3 mice.


2019 AACR WOMEN IN CANCER RESEARCH SCHOLAR AWARDS

The AACR is very pleased to administer this important program, which provides funds for the participation of early-career, meritorious scientists at the AACR Annual Meeting 2019. Scholars are selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

The names and affiliations of the 2019 Women in Cancer Research Scholars, along with the numbers and titles of their presentations, are listed below.


Justina Caushi, BS, Graduate Student, Johns Hopkins University, Baltimore, MD. Abstract 4041. Coupling neoantigen-specific T-cell clonotypes and their molecular phenotypes at the single-cell level in resectable anti-PD-1-treated NSCLC.
TRAVEL AWARDS

Shansahn Deng, MD, Graduate Student, UT MD Anderson Cancer Center, Houston, TX. Abstract 2356. Estrogen mediates sex-specific function of epithelial STAT3 in K-ras mutant lung tumorigenesis by reprogramming lung tumor microenvironment.

Fernanda Faiao-Flores, PhD, Graduate Student, Moffitt Cancer Center, Tampa, FL. Abstract 378. HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT, and RTK signaling.

Alice Fletcher, PhD, Postdoctoral Fellow, University of Birmingham, Birmingham, England. Abstract 920. P97/VCP: A novel interactor of the sodium iodide symporter, which can be pharmacologically targeted to increase radiiodine uptake in thyroid and breast cancer cells.

Martha D. Gay, PhD, Postdoctoral Fellow, Georgetown University, Washington, D.C. Abstract 2728. Cholecystokinin receptor antagonist proglumide reverses nonalcoholic steatohepatitis and prevents hepatocellular carcinoma.

Eileen Y. Hu, MD, PhD, Medical Student, The Ohio State University College of Medicine, Columbus, OH. Abstract 1541. Evaluation of ROR1 targeted antibody-drug conjugate in ROR1-positive leukemia.

Stephanie LaHaye, PhD, Postdoctoral Fellow, Nationwide Children’s Hospital, Columbus, OH. Abstract 1651. Utilization of an ensemble approach for identification of driver fusions in pediatric cancer.

Kamira Maharaj, BS, Graduate Student, Moffitt Cancer Center, Tampa, FL. Abstract 4723. Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia.

Ann Taber, MMed, Aarhus University Hospital, Århus, Denmark. Abstract 913. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultradeep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma.

AACR-UNDERGRADUATE SCHOLAR AWARDS

The AACR is pleased to announce the recipients of 2019 AACR-Undergraduate Scholar Awards. The primary purpose of these awards is to inspire young science students at the undergraduate level to enter the field of cancer research. The AACR is committed to promoting the education and training of the next generation of dedicated scientists and to facilitating and nurturing their careers in cancer research or cancer-related biomedical science. In 2019, the AACR, Dr. Kathleen W. Scotto, Dr. Jose G. Treviño, and the California Community Foundation have all generously provided funding for these awards. The Board of Directors of the AACR expresses its deep appreciation to these funders for their generous contributions and support of this program.

The names and affiliations of the 2019 Awardees are listed below, along with the numbers and titles of their abstract presentations, where appropriate. Congratulations are extended to these talented young scholars.
2018-2019


**Samantha M. Bouchal**, Duke University, Durham, NC.

**Laura E. Goo**, University of Michigan, Ann Arbor, MI. *Abstract 4363*. Effects of the small GTPase RhoC on inflammatory breast cancer metabolism.

**Theodore D. Hansel**, Harvey Mudd College, Claremont, CA.

**Malay Mody**, University of Michigan, Ann Arbor, MI. *Abstract 956*. An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.

**Karim B. Nabi**, Johns Hopkins School of Medicine, Baltimore, MD. *Abstract 803*. Identification of compensatory pathway for glutamate production.


**Aman Prasad**, The Ohio State University, Columbus, OH.


**Rachel Gleyzer**, University of Chicago, Chicago, IL.

**Debora K. Kim**, Rice University, Houston, TX.

**Stefan Kovac**, University of Alabama at Birmingham, Birmingham, AL. *Abstract 132*. Direct interactions of oral bacteria and oral squamous cell carcinoma cells.

**Dominique A. Mosley**, Spelman College, Atlanta, GA. *Abstract 964*. The association of meat intake, meat cooking methods, and meat-derived mutagen exposure with the risk of sessile serrated polyps.

**Takahiro Ouchi**, University of Michigan, Ann Arbor, MI. *Abstract 4497*. Distinct structural classes of activating FOXA1 alterations in prostate cancer progression.


**Emma A. Tillison**, Marquette University, Milwaukee, WI. *Abstract 3704*. Colonic adenocarcinoma-associated DNA-binding site mutations in Rad52 perturbs its ssDNA binding polarity and function in homologous recombination.

**Johnathan Tran**, Massachusetts College of Pharmacy and Health Sciences, Boston, MA.

**Wei T. Tse**, University of California San Diego, La Jolla, CA.

2019-2020

**Ryan Brown**, UW Madison, Madison, WI.

**Azim M. Dharani**, Duke University, Durham, NC.
Be Inspired!

At Our Spotlight Theatre Seminar

Attend our educational seminar to be inspired by leaders in cancer genomics and learn about the application of NGS tools in precision cancer treatment.

Case Studies of Biomarker-Assisted Patient Stratification for Oncology Precision Medicine

Sunday, March 31, 2019
3:30-4:30 PM
Spotlight Theatre C on the exhibit floor

Yu-Zhen Liu, Ph.D.
Global Diagnostic Expert, Precision Medicine & Genomics, Global R&D, AstraZeneca
Biomarker testing and companion diagnostic development for precision medicine

Lei Zheng, MD, Ph.D.
Co-Director, the “Precision Medicine” Center of Excellence for Pancreatic Cancer, Johns Hopkins University School of Medicine
Refining the Precision Medicine for Pancreatic Cancer

We Sequence, You Discover.

BGI offers a complete line of NGS services and Drug Discovery solutions to support your academic research or pharmaceutical R&D projects. From single sample to large-scale population studies, we are here to put our genomics experience behind your research!

Visit our booth #1643, to learn how we can assist with superior NGS services and solutions.
As precision oncology advances,

FOCUS ON RET

RET alterations are primary oncogenic drivers across a diverse range of tumor types.\(^5\)
Investigation into selective RET inhibition is actively advancing. Now is the time to consider adding RET as the next actionable biomarker that may be identified through tumor genomic testing, such as next-generation sequencing.

Are You Ready for RET?
Learn more at RETalteredcancers.com and visit our AACR booth #1640.

There is no guarantee that any agents under investigation will receive health authority approval or become commercially available in any country for the uses being investigated.

RET=rearranged during transfection.